10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

-OR-

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-34885

AMYRIS, INC.

(Exact name of registrant as specified in its charter) 

Delaware	55-0856151
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Amyris, Inc.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

(510) 450-0761

(Address and telephone number of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	AMRS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

Shares outstanding of the Registrant's common stock:

Class	Outstanding as of August 4, 2022
Common Stock, $0.0001 par value per share	321,402,149

AMYRIS, INC.

TABLE OF CONTENTS

		Page
	PART I
Item 1.	Financial Statements (unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021	3
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021	5
	Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2022 and 2021	6
	Condensed Consolidated Statements of Stockholders’ Equity (Deficit) and Mezzanine Equity for the Three Months Ended March 31 and June 30, 2022 and 2021	7
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021	9
	Notes to Condensed Consolidated Financial Statements	11
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	41
Item 4.	Controls and Procedures	42
	PART II
Item 1.	Legal Proceedings	43
Item 1A.	Risk Factors	43
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	#SectionPage#
Item 3.	Defaults Upon Senior Securities	44
Item 4.	Mine Safety Disclosures	44
Item 5.	Other Information	44
Item 6.	Exhibits	45
SIGNATURES

2

PART I

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

AMYRIS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except shares and per share amounts)	June 30, 2022		December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	99,820	$	483,462
Restricted cash	1,090		199
Accounts receivable, net of allowance of $1,337 and $945, respectively	41,125		37,074
Accounts receivable - related party, net of allowance of $0 and $0, respectively	5,001		5,667
Contract assets	3,946		4,227
Contract assets - related party	15,265		—
Inventories	99,195		75,070
Prepaid expenses and other current assets	44,667		33,513
Total current assets	310,109		639,212
Property, plant and equipment, net	151,137		72,835
Restricted cash, noncurrent	5,633		4,651
Recoverable taxes from Brazilian government entities	22,038		16,740
Right-of-use assets under financing leases, net	393		7,342
Right-of-use assets under operating leases, net	90,070		32,428
Goodwill	134,164		131,259
Intangible assets, net	57,645		39,265
Other assets	18,251		10,566
Total assets	$	789,440	$	954,298
Liabilities, Mezzanine Equity and Stockholders' (Deficit) Equity
Current liabilities:
Accounts payable	$	102,962	$	79,666
Accrued and other current liabilities	80,689		71,457
Financing lease liabilities	12		140
Operating lease liabilities	1,640		7,689
Contract liabilities	816		2,530
Debt, current portion	955		896
Related party debt, current portion, measured at fair value	—		107,427
Total current liabilities	187,074		269,805
Long-term debt, net of current portion	672,965		309,061
Related party debt, net of current portion, measured at fair value	51,516		—
Financing lease liabilities, net of current portion	54		61
Operating lease liabilities, net of current portion	75,285		19,829
Derivative liabilities	1,649		7,062
Acquisition-related contingent consideration (Note 3 and Note 7)	40,275		64,762
Other noncurrent liabilities	4,210		4,510
Total liabilities	1,033,028		675,090
Commitments and contingencies
Mezzanine equity:
Contingently redeemable common stock	5,000		5,000
Contingently redeemable noncontrolling interest	31,004		28,520
Stockholders’ (deficit) equity:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of June 30, 2022 and December 31, 2021; zero shares issued and outstanding as of June 30, 2022 and December 31, 2021	—		—
Common stock - $0.0001 par value, 550,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 321,111,428 and 308,899,906 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	32		31
Additional paid-in capital	2,357,311		2,656,838
Accumulated other comprehensive loss	(61,351)		(52,769)
Accumulated deficit	(2,568,986)		(2,357,661)
Total Amyris, Inc. stockholders’ (deficit) equity	(272,994)		246,439
Noncontrolling interest	(6,598)		(751)
Total stockholders' (deficit) equity	(279,592)		245,688
Total liabilities, mezzanine equity and stockholders' (deficit) equity	$	789,440	$	954,298

3

See the accompanying notes to the unaudited condensed consolidated financial statements.

4

AMYRIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except shares and per share amounts)	2022		2021		2022		2021
Revenue:
Renewable products (includes related party revenue of $2,965, $4,620, $7,377 and $6,282, respectively)	$	54,390	$	37,172	$	97,855	$	65,351
Licenses and royalties (includes related party revenue of $6,454, $0, $15,270 and $143,612, respectively)	6,454		11,000		15,767		154,800
Collaborations, grants and other (includes related party revenue of $2,000, $2,000, $4,000 and $4,000, respectively)	4,363		4,144		9,294		9,024
Total revenue (includes related party revenue of $11,419, $6,620, $26,647 and $153,894, respectively)	65,207		52,316		122,916		229,175
Cost and operating expenses:
Cost of products sold	55,930		30,421		104,925		53,080
Research and development	26,111		22,424		52,469		45,756
Sales, general and administrative	126,587		54,340		233,503		92,262
Total cost and operating expenses	208,628		107,185		390,897		191,098
(Loss) income from operations	(143,421)		(54,869)		(267,981)		38,077
Other income (expense):
Interest expense	(5,304)		(4,723)		(10,567)		(10,536)
Gain (loss) from change in fair value of derivative instruments	3,598		5,141		5,413		(17,604)
Gain (loss) from change in fair value of debt	35,114		70,132		55,910		(256,653)
Gain (loss) upon extinguishment of debt	—		935		—		(26,378)
Other income (expense), net	780		28		(2,272)		(650)
Total other income (expense), net	34,188		71,513		48,484		(311,821)
(Loss) income before income taxes and loss from investment in affiliate	(109,233)		16,644		(219,497)		(273,744)
Benefit from (provision for) income taxes	685		(57)		1,505		(112)
(Loss) income from investment in affiliate	(4,972)		(1,140)		(5,761)		(748)
Net (loss) income	(113,520)		15,447		(223,753)		(274,604)
Loss (income) attributable to noncontrolling interest	3,507		(66)		6,435		(1,266)
Net (loss) income attributable to Amyris, Inc.	(110,013)		15,381		(217,318)		(275,870)
Less: loss (income) allocated to participating securities	—		(13)		—		1,086
Net (loss) income attributable to Amyris, Inc. common stockholders, basic	$	(110,013)	$	15,368	$	(217,318)	$	(274,784)
Net (loss) income per share attributable to common stockholders, basic	$	(0.34)	$	0.05	$	(0.69)	$	(0.98)
Weighted-average shares of common stock outstanding used in computing net (loss) income per share of common stock, basic	319,916,244		320,088,143		316,425,739		279,819,520
Net loss per share attributable to common stockholders, diluted	$	(0.44)	$	(0.16)	$	(0.80)	$	(0.98)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted	336,642,879		338,807,849		335,798,275		279,819,520

See the accompanying notes to the unaudited condensed consolidated financial statements.

5

AMYRIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Comprehensive income (loss):
Net income (loss)	$	(113,520)	$	15,447	$	(223,753)	$	(274,604)
Foreign currency translation adjustment	(23,868)		4,773		(8,582)		2,735
Total comprehensive income (loss)	(137,388)		20,220		(232,335)		(271,869)
Loss (income) attributable to noncontrolling interest	3,507		(66)		6,435		(1,266)
Comprehensive income (loss) attributable to Amyris, Inc.	$	(133,881)	$	20,154	$	(225,900)	$	(273,135)

See the accompanying notes to the unaudited condensed consolidated financial statements.

6

AMYRIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

AND MEZZANINE EQUITY

(Unaudited)

	Preferred Stock			Common Stock
(In thousands, except number of shares)	Shares	Amount		Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Noncontrolling Interest		Total Stockholders' Deficit		Mezzanine Equity - Contingently Redeemable Common Stock		Mezzanine Equity - Contingently Redeemable Noncontrolling Interest
Balances at December 31, 2021	—	$	—	308,899,906	$	31	$	2,656,838	$	(52,769)	$	(2,357,661)	$	(751)	$	245,688	$	5,000	$	28,520
Cumulative effect of change in accounting principle for ASU 2020-06 (see "Significant Accounting Policies" in Note 1)	—	—		—	—		(367,974)		—		5,993		—		(361,981)		—		—
Acquisitions	—	—		—	—		—		—		—		155		155		—		2,917
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	—	—		528,704	—		(3)		—		—		—		(3)		—		—
Issuance of common stock as purchase consideration in business combinations	—	—		7,121,806	1		33,093		—		—		—		33,094		—		—
Issuance of common stock upon exercise of stock options	—	—		33,250	—		98		—		—		—		98		—		—
Issuance of common stock upon exercise of warrants	—	—		1,391,603	—		3,994		—		—		—		3,994		—		—
Stock-based compensation	—	—		—	—		11,588		—		—		—		11,588		—		—
Foreign currency translation adjustment	—	—		—	—		—		15,286		—		—		15,286		—		—
Net loss attributable to Amyris, Inc.	—	—		—	—		—		—		(107,305)		(2,928)		(110,233)		—		—
Balances at March 31, 2022	—	$	—	317,975,269	$	32	$	2,337,634	$	(37,483)	$	(2,458,973)	$	(3,524)	$	(162,314)	$	5,000	$	31,437
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	—	—		1,087,200	—		(7)		—		—		—		(7)		—		—
Issuance of common stock as purchase consideration in business combinations	—	—		806,757	—		3,485		—		—		—		3,485		—		—
Issuance of common stock in lieu of cash compensation to non-employee directors	—	—					279		—		—		—		279		—		—
Issuance of common stock upon ESPP purchase	—	—		334,699	—		671		—		—		—		671		—		—
Issuance of common stock upon exercise of stock options	—	—		2,771	—		5		—		—		—		5		—		—
Issuance of common stock upon exercise of warrants	—	—		904,732	—		2,597		—		—		—		2,597		—		—
Stock-based compensation	—	—		—	—		12,647		—		—		—		12,647		—		—
Foreign currency translation adjustment	—	—		—	—		—		(23,868)		—		—		(23,868)		—		—
Net income (loss) attributable to Amyris, Inc.	—	—		—	—		—		—		(110,013)		(3,074)		(113,087)		—		(433)
Balance as of June 30, 2022	—	$	—	321,111,428	$	32	$	2,357,311	$	(61,351)	$	(2,568,986)	$	(6,598)	$	(279,592)	$	5,000	$	31,004
Balances at December 31, 2020	8,280	$	—	244,951,446	$	24	1,957,224		$	(47,375)	$	(2,086,692)	$	4,774	$	(172,045)	$	5,000	$	—
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	—	—		496,341	—		(2)		—		—		—		(2)		—		—
Issuance of common stock upon conversion of debt principal, net of 2,600,000 pre-delivery shares returned to Amyris	—	—		5,827,164	1		110,574		—		—		—		110,575		—		—
Issuance of common stock upon exercise of stock options	—	—		377,542	—		1,920		—		—		—		1,920		—		—
Issuance of common stock upon exercise of warrants	—	—		15,557,480	2		32,217		—		—		—		32,219		—		—
Issuance of common stock upon exercise of warrants - related party	—	—		6,056,944	—		—		—		—		—		—		—		—
Stock-based compensation	—	—		—	—		4,281		—		—		—		4,281		—		—
Foreign currency translation adjustment	—	—		—	—				(2,038)		—		—		(2,038)		—		—
Net loss attributable to Amyris, Inc.	—	—		—	—				—		$	(291,251)	$	1,200	(290,051)		—		$	—
Balances at March 31, 2021	8,280	$	—	273,266,917	$	27	$	2,106,214	$	(49,413)	$	(2,377,943)	$	5,974	$	(315,141)	$	5,000	$	—
Issuance of contingently redeemable noncontrolling interest	—	—		—	—		(14,520)		—		—		—		(14,520)		—		28,520
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	—	—		880,603	—		(1,479)		—		—		—		(1,479)		—		—

7

	Preferred Stock			Common Stock
(In thousands, except number of shares)	Shares	Amount		Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Noncontrolling Interest		Total Stockholders' Deficit		Mezzanine Equity - Contingently Redeemable Common Stock		Mezzanine Equity - Contingently Redeemable Noncontrolling Interest
Issuance of common stock as purchase consideration in business combination	—	—		225,784	—		3,167		—		—		—		3,167		—		—
Issuance of common stock in public offering	—	—		8,805,345	1		130,792		—		—		—		130,793		—		—
Issuance of common stock upon conversion of debt principal	—	—		2,862,772	1		38,632		—		—		—		38,633		—		—
Issuance of common stock upon conversion of preferred stock	(8,280)	—		1,943,659	—		—		—		—		—		—		—		—
Issuance of common stock upon ESPP purchase	—	—		145,112	—		321		—		—		—		321		—		—
Issuance of common stock upon exercise of stock options	—	—		145,200	—		860		—		—		—		860		—		—
Issuance of common stock upon exercise of warrants	—	—		1,381,940	—		6,622		—		—		—		6,622		—		—
Issuance of common stock upon exercise of warrants - related party	—	—		8,057,966	1		5,744		—		—		—		5,745		—		—
Stock-based compensation	—	—		—	—		8,747		—		—		—		8,747		—		—
Foreign currency translation adjustment	—	—		—	—		—		4,773		—		—		4,773		—		—
Net income attributable to Amyris, Inc.	—	—					—		—		$	15,381	$	66	15,447		—		$	—
Balances at June 30, 2021	—	$	—	297,715,298	$	30	$	2,285,100	$	(44,640)	$	(2,362,562)	$	6,040	$	(116,032)	$	5,000	$	28,520

See the accompanying notes to the unaudited condensed consolidated financial statements.

8

AMYRIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Months Ended June 30,
(In thousands)	2022		2021
Operating activities
Net loss	$	(223,753)	$	(274,604)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of debt discount	1,923		1,646
Amortization of intangible assets	2,076		135
Amortization of right-of-use assets under operating leases	2,651		1,555
Depreciation and amortization	4,986		4,300
(Gain) loss from change in fair value of debt	(55,910)		256,653
(Gain) loss from change in fair value of derivative instruments	(5,413)		17,604
Loss from investment in affiliate	5,761		748
Gain on foreign currency exchange rates	(1,367)		(102)
Loss upon extinguishment of debt	—		26,378
Other	16		—
Stock-based compensation	24,235		13,028
Changes in assets and liabilities:
Accounts receivable	(3,876)		3,522
Contract assets	(14,984)		988
Inventories	(23,060)		(11,017)
Deferred cost of products sold - related party	—		6,678
Prepaid expenses and other assets	(28,388)		(18,969)
Accounts payable	25,418		6,855
Accrued and other liabilities	2,319		(478)
Lease liabilities	(10,415)		(2,440)
Contract liabilities	(1,702)		(2,275)
Net cash provided by (used in) operating activities	(299,483)		30,205
Investing activities
Purchases of property, plant and equipment	(71,462)		(5,382)
Acquisitions, net of cash acquired	(17,760)		(288)
Net cash used in investing activities	(89,222)		(5,670)
Financing activities
Issuance costs incurred in connection with debt modification	—		(2,500)
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units	(10)		(1,481)
Principal payments on debt	—		(23,396)
Principal payments on financing leases	(135)		(1,865)
Proceeds from exercises of common stock options	103		2,780
Proceeds from exercises of warrants	6,591		38,841
Proceeds from exercises of warrants - related party	—		5,745
Proceeds from issuance of common stock in public offering, net of issuance costs	—		130,793
Proceeds from issuance of common stock upon ESPP purchase	671		321
Proceeds from issuance of contingently redeemable noncontrolling interest in subsidiary	—		10,000
Net cash provided by financing activities	7,220		159,238
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(284)		440
Net increase in cash, cash equivalents and restricted cash	(381,769)		184,213
Cash, cash equivalents and restricted cash at beginning of period	488,312		31,422
Cash, cash equivalents and restricted cash at end of the period	$	106,543	$	215,635
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	99,820	$	214,424
Restricted cash, current	1,090		250
Restricted cash, noncurrent	5,633		961
Total cash, cash equivalents and restricted cash	$	106,543	$	215,635

See the accompanying notes to the unaudited condensed consolidated financial statements.

9

AMYRIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS, Continued

(Unaudited)

	Six Months Ended June 30,
(In thousands)	2022		2021
Supplemental disclosures of cash flow information:
Cash paid for interest	$	5,307	$	4,444
Supplemental disclosures of non-cash investing and financing activities:
Acquisition of intangible assets in connection with business combinations	$	22,944	$	8,107
Acquisition of right-of-use assets under operating leases	$	60,195	$	1,108
Common stock and warrants issued in exchange for debt principal and accrued interest reduction	$	—	$	149,208
Common stock issued as purchase consideration in business combinations	$	36,579	$	3,167
Common stock issued in lieu of cash compensation to non-employee directors	$	279	$	—
Derecognition of derivative liabilities to equity upon extinguishment of debt	$	—	$	59
Goodwill recorded in connection with business combinations	$	13,437	$	4,013
Noncontrolling interest recorded in connection with business combinations	$	3,072	$	—
Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period	$	5,729	$	7,105

See the accompanying notes to the unaudited condensed consolidated financial statements.

10

AMYRIS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

    

Note 1. Basis of Presentation and Summary of Significant Accounting Policies	11
Note 2. Balance Sheet Details	13
Note 3. Fair Value Measurement	17
Note 4. Debt	21
Note 5. Mezzanine Equity	22
Note 6. Stockholders' (Deficit) Equity	23
Note 7. Acquisitions	24
Note 8. Net Loss per Share Attributable to Common Stockholders	26
Note 9. Commitments and Contingencies	26
Note 10. Revenue Recognition, and Contract Assets and Liabilities	28
Note 11. Related Party Transactions	31
Note 12. Stock-based Compensation	32
Note 13. Subsequent Events	33

1. Basis of Presentation and Summary of Significant Accounting Policies

Amyris, Inc. and subsidiaries (collectively, Amyris or the Company) is a biotechnology company delivering sustainable science-based solutions for people and the planet. The Company creates, manufactures and commercializes consumer products and ingredients. Currently, the largest driver of the Company's revenue is derived from marketing and selling Clean Beauty, Personal Care and Health & Wellness consumer products through direct-to-consumer ecommerce platforms and a growing network of retail partners. The Company also sells sustainable ingredients to sector leaders that serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The Company's ingredients and consumer products are powered by the Company's fermentation-based Lab-to-MarketTM technology platform, which leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the Company to rapidly bring new innovation to market.

The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the 2021 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2021 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Our cash and cash equivalents of $99.8 million as of June 30, 2022 in and of itself will not be sufficient to fund expected cash flow requirements from operations, investments and financing obligations for the next 12 months. We are actively working on securing additional funding from debt and from a strategic transaction to meet our spending obligations within 12 months after issuing our financial statements for the second quarter of 2022. Management currently expects that the current cash position, the cash generated from operations, the expected F&F and Reb M-related earnout payments along with planned price increases, operating expense reduction actions and the aforementioned additional funding from debt and a strategic transaction, to not raise substantial doubt about the Company's ability to continue as a going concern for the next 12 months.

Significant Accounting Policies

Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2021 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the six months ended June 30, 2022.

11

Use of Estimates and Judgements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.

Accounting Update Recently Adopted

In the six months ended June 30, 2022, the Company adopted this accounting standard update:

Convertible Debt, and Derivatives and Hedging. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 became effective for the Company in the first quarter of 2022. Adoption of this standard on January 1, 2022 in connection with the 2026 Convertible Senior Notes (see Note 4, "Debt"), decreased additional paid-in capital by $368.0 million, increased debt by the same amount and decreased accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption.

Accounting Standards or Updates Not Yet Adopted

Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. Because the Company met the SEC definition of a smaller reporting company when ASU 2016-13 was issued, this new accounting standard will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This standard will be effective for the Company in the first quarter of 2023 and will be applied prospectively to business combinations occurring on or after the effective date of the standard. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the guidance and the impact on its consolidated financial statements and related disclosures.

12

2. Balance Sheet Details

Allowance for Doubtful Accounts

(In thousands)	Balance at Beginning of Period		Provisions		Write-offs, Net		Balance at End of Period
Six months ended June 30, 2022	$	945	$	392	$	—	$	1,337
Six months ended June 30, 2021	$	137	$	806	$	—	$	943

Inventories

(In thousands)	June 30, 2022		December 31, 2021
Raw materials	$	35,403	$	25,733
Work-in-process	8,783		6,941
Finished goods	55,009		42,396
Inventories	$	99,195	$	75,070

Prepaid Expenses and Other Current Assets

(In thousands)	June 30, 2022		December 31, 2021
Prepayments, advances and deposits	$	34,229	$	25,140
Non-inventory production supplies	4,462		3,956
Recoverable taxes from Brazilian government entities	1,658		1,188
Other	4,318		3,229
Total prepaid expenses and other current assets	$	44,667	$	33,513

Property, Plant and Equipment, Net

(In thousands)	June 30, 2022		December 31, 2021
Manufacturing facilities and equipment	$	70,423	$	51,855
Leasehold improvements	49,097		45,780
Computers and software	11,430		9,174
Furniture and office equipment, vehicles and land	3,737		3,688
Construction in progress	112,869		48,032
	247,556		158,529
Less: accumulated depreciation and amortization	(96,419)		(85,694)
Property, plant and equipment, net	$	151,137	$	72,835

During the three and six months ended June 30, 2022 and 2021, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Depreciation and amortization expense	$	2,586	$	2,186	$	4,986	$	4,300

Goodwill

The changes in the carrying amount of goodwill were as follows:

(In thousands)	June 30, 2022
Balance at beginning of year	$	131,259
Acquisitions	13,437
Effect of currency translation adjustment	(10,532)
Ending balance	$	134,164

13

Additions to goodwill during the six months ended June 30, 2022 related to acquisitions completed during the period. See Note 7, "Acquisitions".

Intangible Assets, Net

During the six months ended June 30, 2022, the Company recorded $22.9 million of intangible assets which related to customer relationships, trademarks and trade names, branded products, and software as a result of acquisitions completed during the period. See Note 7, "Acquisitions".

The following table summarizes the components of intangible assets (in thousands, except estimated useful life):

		June 30, 2022						December 31, 2021
Amounts in thousands	Estimated Useful Life (in Years)	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Trademarks and trade names, and branded products	10	$	29,758	$	(1,573)	$	28,185	$	11,484	$	(496)	$	10,988
Customer relationships	5 - 16	8,703		(667)		8,036		8,197		(267)		7,930
Developed technology and software applications	5 - 12	21,545		(689)		20,856		19,962		(200)		19,762
Patents	17	600		(32)		568		600		(15)		585
Total intangible assets		$	60,606	$	(2,961)	$	57,645	$	40,243	$	(978)	$	39,265

Amortization expense for intangible assets was $1.2 million and $2.1 million for the three and six months ended June 30, 2022 and is included in general and administrative expenses.

Total future amortization of intangible assets as of June 30, 2022 is as follows (in thousands):

Amounts in thousands
2022 (remainder)	$	2,311
2023	6,177
2024	7,254
2025	7,386
2026	7,140
Thereafter	27,377
Total future amortization	$	57,645

Leases

Operating Leases

The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 18 years, and often include one or more options to renew. These renewal terms can extend the lease term for an additional 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $90.1 million and $32.4 million of operating lease right-of-use assets as of June 30, 2022 and December 31, 2021, respectively. Operating lease liabilities were $76.9 million and $27.5 million as of June 30, 2022 and December 31, 2021, respectively. During the three months ended June 30, 2022 and 2021, respectively, the Company recorded $4.1 million and $1.7 million of operating lease amortization that was charged to expense, of which $0.3 million and $0.2 million was recorded to cost of products sold. During the six months ended June 30, 2022 and 2021, respectively, the Company recorded $7.8 million and $3.5 million of operating lease amortization that was charged to expense, of which $0.6 million and $0.4 million was recorded to cost of products sold.

14

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component.

Information related to the Company's right-of-use assets and related lease liabilities were as follows:

	Six Months Ended June 30,
	2022	2021
Cash paid for operating lease liabilities, in thousands	$6,092	$2,369
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands	$51,789	$1,110
Weighted-average remaining lease term	11.6	2.6
Weighted-average discount rate	19.5%	17.0%

Financing Leases

The Company has financing leases primarily for laboratory equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $1.4 million and $6.8 million as of June 30, 2022 and December 31, 2021, respectively.

Maturities of Financing and Operating Leases

Maturities of lease liabilities as of June 30, 2022 were as follows:

Years ending December 31: (In thousands)	Financing Leases		Operating Leases		Total Leases
2022 (Remaining Six Months)	$	11	$	6,964	$	6,975
2023	21		12,962		12,983
2024	21		22,075		22,096
2025	21		22,374		22,395
2026	16		22,807		22,823
Thereafter	—		229,717		229,717
Total lease payments	90		316,899		316,989
Less: amount representing interest	(24)		(239,974)		(239,998)
Total lease liability	$	66	$	76,925	$	76,991
Current lease liability	$	12	$	1,640	$	1,652
Noncurrent lease liability	54		75,285		75,339
Total lease liability	$	66	$	76,925	$	76,991

Other Assets

(In thousands)	June 30, 2022		December 31, 2021
Investment in non-trade receivable(1)	$	10,251	$	—
Equity-method investments in affiliates	4,682		9,443
Deposits	517		129
Other	2,801		994
Total other assets	$	18,251	$	10,566

______________

(1) In March 2022, the Company loaned a privately held company $10 million in exchange for a senior secured convertible promissory note (the Note) which matures in March 2025, unless earlier redeemed or converted into equity of the privately held company. The Note bears interest at 8% per annum and is convertible, at the Company's option, into equity of the privately held company upon maturity of the Note or in the event of an initial public offering, equity

15

financing, or corporate transaction (such as a sale or merger), in each case, at a conversion price that is dependent on a variety of factors. In addition, the Note is redeemable prior to maturity, at the issuer's option, in the event of one or more equity or debt financings, one or more asset sales, or an initial public offering, in each case equal to or greater than $50 million in the aggregate. The Company concluded that the arrangement qualifies for accounting as a loan as required by ASC 310-10. The Company will periodically evaluate the collectability of the loan, and an allowance for credit losses will be recorded when the Company concludes that all or a portion of the loan balance is no longer collectible.

16

Accrued and Other Current Liabilities

(In thousands)	June 30, 2022		December 31, 2021
Business acquisitions contingent consideration payable(1)	$	32,411	$	30,000
Payroll and related expenses	15,160		9,151
Accrued interest	11,111		9,572
Liability in connection with acquisition of equity-method investment	9,921		8,735
Asset retirement obligation(2)	3,791		3,336
Professional services	2,295		2,447
Contract termination fees	1,368		1,345
Tax-related liabilities	1,057		988
License fee payable	1,050		1,050
Other	2,525		4,833
Total accrued and other current liabilities	$	80,689	$	71,457

______________

(1)    Business acquisitions contingent consideration payable is the current portion of total acquisition-related contingent consideration.

(2)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with the Company's 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.

17

3. Fair Value Measurement

Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:

(In thousands)	June 30, 2022								December 31, 2021
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Liabilities
Foris Convertible Note	$	—	$	—	$	51,516	$	51,516	$	—	$	—	$	107,427	$	107,427
Freestanding derivative instruments issued in connection with debt and equity instruments	—		—		1,649		1,649		—		—		7,062		7,062
Acquisition-related contingent consideration	—		—		40,275		40,275		—		—		64,762		64,762
Total liabilities measured and recorded at fair value	$	—	$	—	$	93,440	$	93,440	$	—	$	—	$	179,251	$	179,251

The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of June 30, 2022 or December 31, 2021. Also, there were no transfers between the levels during the six months ended June 30, 2022 or the year ended December 31, 2021.

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates.

Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments".

Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt".

Freestanding Derivative Instruments

The Company has a contingent obligation to issue warrants for 1.9 million shares of common stock at a $2.87 purchase price and a two-year term. The warrants did not meet the derivative scope exception or equity classification criteria and was accounted for as a derivative liability. At June 30, 2022, the fair value of the contingently issuable warrants derivative liability was $1.6 million. For the three and six months ended June 30, 2022, the Company recorded gains of $3.6 million and $5.4 million related to change in fair value of these warrants.

Fair Value of Debt — Foris Convertible Note

At June 30, 2022, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $51.5 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $1.85 stock price, (ii) 27% discount yield, (iii) 2.8% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. For the three and six months ended June 30, 2022, the Company recorded gains of $35.1 million and $55.9 million related to change in fair value of the Foris Convertible Note.

Binomial Lattice Model

A binomial lattice model was used to determine whether the Foris Convertible Note would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Foris Convertible Note using the "with-and-without method", where the fair value of the Foris Convertible Note including the embedded features is defined as the "with," and the

18

fair value of the Foris Convertible Note excluding the embedded features is defined as the "without." This method estimates the fair value of the Foris Convertible Note by considering the incremental value of the Foris Convertible Note with the embedded features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Foris Convertible Note and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period.

Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments

The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):

(In thousands)	Derivative Liability
Balance at December 31, 2021	$	7,062
Change in fair value of derivative instruments	(5,413)
Balance at June 30, 2022	$	1,649

Valuation Methodology and Approach to Measuring the Debt Instrument Derivative Liabilities

The Company's outstanding derivative liabilities at June 30, 2022 and December 31, 2021 represent the fair value of a freestanding equity instrument. See Note 6, "Stockholders' Deficit" for further information regarding the host instrument. There is no current observable market for this type of derivative and, as such, the Company determined the fair value of the freestanding instrument using the Black-Scholes-Merton option pricing model, which is discussed in more detail below.

The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants for the periods ended June 30, 2022 and December 31, 2021. Input assumptions for the freestanding instrument are as follows:

	Range for Period Ended
Input assumptions for liability classified warrants:	June 30, 2022		December 31, 2021
Fair value of common stock on valuation date	$1.85 - $4.36		$5.41 - $19.10
Exercise price of warrants	$2.87		$2.87
Expected volatility	106% - 110%		107% - 114%
Risk-free interest rate	2.28% - 2.92%		0.16% – 0.73%
Expected term in years	2		2
Dividend yield	0.0	%	0.0 %

Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields, term to maturity/conversion or stock price volatility increases the value of the derivative liability.

Acquisition related contingent consideration

The fair value of acquisition related contingent consideration (Earnout Payments) was determined using a Monte Carlo simulation to estimate the probability of the acquired business units achieving the relevant financial and operational milestones. The model results reflect the time value of money, non-performance risk within the required time frame and the risk due to uncertainty in the estimated cash flows. Key inputs to the Monte Carlo simulation for the MenoLabs acquisition were: Revenue Risk Adjustment of 6.2% and Annual Revenue Volatility of 35%. A significant decrease or increase in an acquired business unit’s financial performance and the timing of such changes could materially decrease or increase the fair value of contingent consideration period over period. Contingent consideration is recorded in other liabilities in the accompanying consolidated balance sheets.

The fair value of contingent consideration is classified as Level 3. Contingent consideration activity and balances are as follows:

19

(In thousands)	June 30, 2022
Beginning balance January 1, 2022	$	64,762
Issuance of contingent consideration in connection with acquisitions	440
Measurement period adjustment	(55)
Reclassification to short-term contingent liabilities	(24,872)
Ending balance June 30, 2022	$	40,275

Any change in the fair value of the contingent consideration liability is recognized in general and administrative expense and reflects the changes in the business unit’s expected performance over the remaining earnout period and the Company’s estimate of the likelihood of achieving the applicable operational milestones (see Note 7, “Acquisitions”).

Assets and Liabilities Recorded at Carrying Value

Financial Assets and Liabilities

The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at June 30, 2022 and at December 31, 2021, excluding the debt instruments recorded at fair value, was $673.9 million and $310.0 million, respectively. The fair value of such debt at June 30, 2022 and at December 31, 2021 was $202.1 million and $328.0 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments.

20

4. Debt

Net carrying amounts of debt are as follows:

	June 30, 2022								December 31, 2021
(In thousands)	Principal		Unaccreted Debt Discount		Change in Fair Value		Net		Principal		Unaccreted Debt Discount		Change in Fair Value		Net
Convertible notes
2026 convertible senior notes	$	690,000	$	(17,035)	$	—	$	672,965	$	690,000	$	(380,939)	$	—	$	309,061
Related party convertible notes
Foris convertible note	50,041		—		1,475		51,516		50,041		—		57,386		107,427
Loans payable and credit facilities
Other loans payable (revolving)	955		—		—		955		896		—		—		896
Total debt	$	740,996	$	(17,035)	$	1,475	725,436		$	740,937	$	(380,939)	$	57,386	417,384
Less: current portion							(955)								(108,323)
Long-term debt, net of current portion							$	724,481							$	309,061

Interest expense was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Contractual interest expense in connection with debt	$	3,441	$	2,322	$	6,831	$	5,850
Debt discount accretion	961		933		1,923		1,646
Interest expense in connection with debt	4,402		3,255		8,754		7,496
Discount accretion on liability in connection with acquisition of equity-method investment and with partnership liability, and other	902		1,468		1,813		3,040
Total interest expense	$	5,304	$	4,723	$	10,567	$	10,536

Adoption of ASU 2020-06

ASU 2020-06 became effective for the Company in the first quarter of 2022. The January 1, 2022 adoption of this standard, in connection with the 2026 Convertible Senior Notes, decreased additional paid-in capital by $368.0 million, increased debt by the same amount, and decreased the accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption.

Amendment to Foris Convertible Note

On June 30, 2022, the Company and Foris Ventures, LLC (Foris) entered into an agreement to extend the maturity of the Foris convertible note from July 1, 2022 to July 1, 2023. The Company determined that the amendment constituted a debt modification under U.S. GAAP, which resulted in no accounting consequences other than reclassification of the note from a current liability to noncurrent.

Future Minimum Payments

Future minimum payments under the Company's debt agreements as of June 30, 2022 are as follows:

21

(In thousands)	Convertible Notes		Related Party Convertible Notes		Loans Payable and Credit Facilities		Total
2022 (Remaining Six Months)	$	5,175	$	—	$	104	$	5,279
2023	10,350		62,622		1,010		73,982
2024	10,350		—		—		10,350
2025	10,350		—		—		10,350
2026	700,379		—		—		700,379
Thereafter	—		—		—		—
Total future minimum payments	736,604		62,622		1,114		800,340
Less: amount representing interest	(46,604)		(12,581)		(159)		(59,344)
Present value of minimum debt payments	690,000		50,041		955		740,996
Less: current portion of debt principal	—		—		(955)		(955)
Noncurrent portion of debt principal	$	690,000	$	50,041	$	—	$	740,041

5. Mezzanine Equity

Gates Foundation

Contingently redeemable common stock as of June 30, 2022 and December 31, 2021 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill & Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults on its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%. The Company concluded a redemption event was not probable to occur. As of June 30, 2022, the Company's remaining research and development obligation under this arrangement was $0.1 million.

Ingredion Contingently Redeemable Noncontrolling Interest in Subsidiary

On June 1, 2021, the Company entered into a Membership Interest Purchase Agreement (MIPA) with Ingredion Corporation (Ingredion) to purchase 31% of the member units in RealSweet LLC (RealSweet), a 100% owned Amyris, Inc. subsidiary. Total consideration was $28.5 million in the form of a $10 million cash payment, the exchange of a $4 million payable previously due to Ingredion and $14.5 million of manufacturing intellectual property rights. The terms of the MIPA provide both parties with put/call rights under certain circumstances, including the occurrence of either or both of the following: (i) a change in ownership of fifty percent (50%) or more of the voting shares of such Member; or (ii) a change in the right to appoint or remove a majority of the board of directors of such Member. The Company concluded this change in control provision was not solely within its control and Ingredion’s contingently redeemable noncontrolling interest should be reflected outside of permanent equity in accordance with SEC’s Accounting Series Release 268, Presentation in Financial Statements of Redeemable Preferred Stocks (ASR 268).

The redemption price of this common-share noncontrolling interest is considered to be at fair value on the redemption date. Ingredion’s noncontrolling interest is not currently redeemable and the Company concluded a contingent redemption event is not probable to occur. The primary redemption contingency relates to a decrease in Ingredion’s ownership percentage below 8.4%, which is not likely to occur given that capital transactions require the unanimous consent of each member. Consequently, the noncontrolling interest will not be subsequently remeasured to its redemption amount until such contingency event and the related redemption are probable to occur; however, the Company will continue to reflect the attribution of any losses and distribution of dividends to the noncontrolling interest each quarter in accordance with ASC 810-10. At the transaction date, the Company recorded the $28.5 million noncontrolling interest in RealSweet as Mezzanine equity - contingently redeemable noncontrolling interest, which represented the value of Ingredion’s 31% ownership interest in the net assets of the RealSweet subsidiary. Under the terms of the MIPA, Amyris, Inc. is funding the construction costs of the project, which are estimated to be approximately $130 million. As of June 30, 2022, the Company has funded approximately $100 million towards the project and has $22 million of contractual purchase commitments for construction related costs.

22

EcoFabulous Contingently Redeemable Noncontrolling Interest in Subsidiary

On January 26, 2022, the Company and certain of its subsidiaries entered into an Agreement and Plan of Merger for the acquisition of 70% of No Planet B LLC (d/b/a EcoFabulous), a privately held company. In connection with the merger, the name of No Planet B LLC has been changed to EcoFab, LLC (EcoFab). No Planet B Investments, LLC holds 30% of the outstanding units of membership interests in EcoFab as of the effective time of the merger (the Minority Member). See Note 7, "Acquisitions". Concurrently, the Company and No Planet B Investments, LLC entered into the EcoFab, LLC Agreement, the terms of which provide the Minority Member a right to require EcoFab to repurchase its 30% noncontrolling interest after (i) EcoFab achieving Net Revenues in excess of $100 million on an annualized basis or, if earlier, (ii) December 31, 2026. The Company concluded this provision was not solely within its control and EcoFab’s contingently redeemable noncontrolling interest should be reflected outside of permanent equity in accordance with SEC’s Accounting Series Release 268, Presentation in Financial Statements of Redeemable Preferred Stocks (ASR 268) and ASC 480-10-S99, “Distinguishing Liabilities from Equity” (ASC 480).

The redemption price of this noncontrolling interest is considered to be at fair value on the redemption date. EcoFab’s noncontrolling interest is not currently redeemable and the Company concluded a contingent redemption event is probable to occur as the redemption date is no later than December 31, 2026. As a result, the noncontrolling interest will be recorded at the higher of (1) the cumulative amount that would result from applying the measurement guidance in ASC 810-10 (i.e., initial carrying amount, increased or decreased for the noncontrolling interest’s share of net income or loss, OCI or other comprehensive loss, and dividends) or (2) the redemption price. When it is determined the redemption price exceeds the noncontrolling interest’s carrying amount, the Company will record an ASC 480 measurement adjustment. As of June 30, 2022, the Company recorded $2.5 million EcoFab noncontrolling interest as Mezzanine equity - contingently redeemable noncontrolling interest, which included $3.1 million of the initial value of the Minority Member’s 30% ownership interest in the net assets of EcoFab and $0.6 million of losses attributable to the Minority Member during the period.

6. Stockholders' (Deficit) Equity

Warrants and Rights Activity Summary

In connection with various debt and equity transactions (see Note 4, “Debt” above, and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2021 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at June 30, 2022:

Transaction	Year Issued	Expiration Date	Number Outstanding as of December 31, 2021	Exercises	Expired	Exercise Price per Share of Warrants Exercised		Number Outstanding as of June 30, 2022	Exercise Price per Share as of June 30, 2022
Blackwell / Silverback warrants	2020	July 10, 2022	1,000,000	—	—	$	—	1,000,000	$	3.25
January 2020 warrant exercise right shares	2020	January 31, 2022	431,378	(431,378)	—	$	2.87	—	$	—
May 2019 6.50% Note Exchange warrants	2019	January 31, 2022	960,225	(960,225)	—	$	2.87	—	$	—
May 2017 cash warrants	2017	July 10, 2022	1,492,652	(904,732)	—	$	2.87	587,920	$	2.87
May 2017 dilution warrants	2017	July 10, 2022	56,910	—	—	$	—	56,910	$	—
July 2015 related party debt exchange	2015	July 29, 2025	58,690	—	—	$	—	58,690	$	0.15
			3,999,855	(2,296,335)	—	$	2.87	1,703,520

Warrant Exercises

During the six months ended June 30, 2022, warrant-holders exercised warrants to purchase 2,296,335 shares of the Company’s common stock at a weighted-average exercise price of $2.87 per share, for proceeds to the Company of $6.6 million.

23

7. Acquisitions

The purchase accounting for the net assets acquired, including goodwill, and the fair value of the contingent consideration and noncontrolling interest for the following acquisitions is preliminarily recorded based on available information and incorporates management's best estimates. The purchase accounting for taxes remains preliminary pending receipt of certain information required to finalize the determination of fair value. The net assets acquired in the transaction are generally recorded at their estimated acquisition-date fair values, while transaction costs associated with the acquisition are expensed as incurred. These transactions were accounted for by the acquisition method, and accordingly, the results of operations were included in the Company’s consolidated financial statements from their respective acquisition dates. Pro forma financial information is not presented as amounts are not material to the Company’s consolidated financial statements.

EcoFab LLC.

On January 26, 2022, the Company and certain of its subsidiaries entered into an Agreement and Plan of Merger for the acquisition of 70% of No Planet B LLC (d/b/a EcoFabulous), a privately held company. EcoFabulous is focused on delivering high performance, makeup artist-quality clean beauty products in ecofriendly packaging, and priced for Gen Z consumers. In connection with the merger, the name of No Planet B LLC has been changed to EcoFab, LLC (EcoFab). No Planet B Investments, LLC holds 30% of the outstanding units of membership interests in EcoFab as of the effective time of the merger, which is accounted for as Mezzanine equity - contingently redeemable noncontrolling interest. See Note 5, "Mezzanine Equity".

The purchase consideration for the acquisition of EcoFab consisted of $1.7 million in cash and 1,292,776 shares of Amyris stock with a fair value of $5.5 million. The noncontrolling interest had a fair value of $3.1 million as of the acquisition date.

The following table summarizes the purchase price allocation:

(In thousands)
Trademarks, trade names and other intellectual property	$	8,705
Customer relationships	512
Goodwill	1,023
Less: noncontrolling interest	$	(3,072)
Total consideration	$	7,168

Goodwill associated with this acquisition is not deductible for tax purposes.

The Company has determined that (i) EcoFab is a variable-interest entity (VIE) due to insufficient equity at risk, (ii) the Company is the primary beneficiary of EcoFab due to its power to direct the activities that most significantly affect EcoFab’s economic performance, and (iii) the Company has the ability to exert significant influence over EcoFab through its 70% equity ownership. As a result, the Company accounts for its investment in EcoFab on a consolidation basis in accordance with ASC 810, Consolidation.

MenoLabs, LLC.

On March 9, 2022, Amyris and Amyris Clean Beauty, Inc., a wholly owned subsidiary of Amyris, entered into an Asset Purchase Agreement with MenoLabs, LLC, (MenoLabs), an Arizona limited liability company, to purchase substantially all of the assets and assume the liabilities of MenoLabs. The transaction closed on March 10, 2022 (the Closing Date). MenoLabs was founded to fundamentally change how menopause is addressed by offering research-backed all-natural treatments of menopause symptoms. Prior to the Closing Date, Amyris and MenoLabs entered into that certain Loan Agreement and Promissory Note in January 2022, pursuant to which Amyris loaned to MenoLabs the aggregate principal amount of $0.5 million. In connection with the acquisition of MenoLabs, Amyris has assumed the Bridge Loan. The acquisition of MenoLabs will serve as a catalyst to accelerate growth and establish a leadership position in the fast-growing menopause market.

MenoLabs was acquired for total purchase consideration of $16.2 million, consisting of $11.3 million in cash, the Bridge Loan of $0.5 million, 852,234 shares of Amyris stock with a fair value of $3.9 million, and contingent consideration with a fair value of $0.4 million. The contingent consideration consists of two potential payments of up to $10 million each during the twelve (12) month period beginning on the first day of the first calendar month commencing after the Closing Date and the fourth quarter of 2024 respectively if both MenoLabs’s product revenues and profit margin meet the targets set forth for such period in the Asset Purchase Agreement (the Earnout Payments). The Earnout Payments will be in the form of cash or in an aggregate number of shares of Amyris Stock equal to the earnout achieved divided by the stock price on achievement date, at Amyris’s sole discretion. The $0.4 million fair value of the Earnout Payments is recorded as other liabilities in the accompanying condensed consolidated balance sheets. Allocation of the contingent consideration payments between short-term

24

and long-term liabilities on the accompanying consolidated balance sheets is based on management’s best estimates of when the relevant milestone will be achieved.

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible assets	$	311
Branded products	5,600
Application (App)	3,600
Goodwill	6,642
Total consideration	$	16,153

Goodwill associated with this acquisition is expected to be deductible for tax purposes.

Onda Beauty Inc.

On April 11, 2022, Amyris and Amyris-O Merger Sub, Inc., a wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger and Reorganization with Onda Beauty Inc. (“Onda”) and the stockholders’ representative for the acquisition of the outstanding shares of Onda. Founded in 2014, Onda offers a curated matrix of brands as well as services, such as facials. Onda provides Amyris with a venue to test products, host events and produce content in a luxury retail setting.

Onda was acquired for total purchase consideration of $4.9 million, consisting of cash payment of $1.0 million at closing, Amyris stock valued at $3.5 million, estimated net working capital adjustment of $(0.1) million and holdback consideration of $0.5 million to be issued in the form of Amyris stock within 12 months after the closing date subject to the indemnification provision in accordance with the Agreement and Plan of Merger and Reorganization.

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible liabilities	$	(164)
Trademarks, trade names and other intellectual property	4,275
Customer relationships	251
Goodwill	553
Total consideration	$	4,915

Goodwill associated with this acquisition is not deductible for tax purposes.

Interfaces Indústria E Comércio De Cosméticos Ltda.

On April 29, 2022, Amyris and Amyris Biossance do Brasil Comércio de Cosméticos Ltda., a wholly owned subsidiary of the Company, entered into a Contract for the Purchase and Sale of Quotas and Other Covenants with Interfaces Indústria e Comércio de Cosméticos Ltda. (“Interfaces”) and its stockholders for the acquisition of the outstanding shares of Interfaces. The transaction closed on May 16, 2022. Interfaces was a limited liability company incorporated under the laws of Brazil, headquartered in the City of Vinhedo, State of São Paulo, specializing in producing cosmetics for skin care, hair care, and makeup. The acquisition of Interfaces is deemed critical to sustain the Company’s growth, add operational resilience to its supply chain, reduce its dependency on third-party manufacturing, and increase the ability to source strategic components.

Interfaces was acquired for total purchase consideration of $6.7 million, consisting of cash payment of $3.4 million at closing and cash payment of $3.3 million to be released to the sellers in 24 (twenty-four) monthly and successive installments.

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible assets	$	1,474
Goodwill	5,219
Total consideration	$	6,693

Goodwill associated with this acquisition is not deductible for tax purposes.

25

8. Net Loss per Share Attributable to Common Stockholders

The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses.

The following table presents the calculation of basic and diluted loss per share:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except shares and per share amounts)	2022		2021		2022		2021
Numerator:
Net (loss) income attributable to Amyris, Inc.	$	(110,013)	$	15,381	$	(217,318)	$	(275,870)
Less: loss (income) allocated to participating securities	—		(13)		—		1,086
Net (loss) income attributable to Amyris, Inc. common stockholders, basic	$	(110,013)	$	15,368	$	(217,318)	$	(274,784)
Adjustment to earnings allocated to participating securities	—		13		—		—
Interest on convertible debt	759		902		1,216		—
Gain from change in fair value of debt	(35,114)		(71,067)		(47,764)		—
Gain from change in fair value of derivative instruments	(3,598)		—		(5,413)		—
Net loss attributable to Amyris, Inc. common stockholders, diluted	$	(147,966)	$	(54,784)	$	(269,279)	$	(274,784)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic	319,916,244		320,088,143		316,425,739		279,819,520
Net loss per share, basic	$	(0.34)	$	0.05	$	(0.69)	$	(0.98)
Weighted-average shares of common stock outstanding	319,916,244		320,088,143		316,425,739		279,819,520
Weighted-average shares of preferred stock outstanding	—		277,666		—		—
Effect of dilutive convertible debt	16,680,334		18,442,040		18,532,262		—
Effect of dilutive common stock warrants	46,301		—		840,274		—
Weighted-average shares of common stock equivalents used in computing net loss per share of common stock, diluted	336,642,879		338,807,849		335,798,275		279,819,520
Net loss per share, diluted	$	(0.44)	$	(0.16)	$	(0.80)	$	(0.98)

For the three months ended June 30, 2022 and 2021 and for the six months ended June 30, 2022, basic income per share differed from diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was dilutive. For the six months ended June 30, 2021, basic loss per share equaled diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was antidilutive. The following table presents outstanding shares of potentially dilutive securities:

	Three Months Ended June 30,		Six Months Ended June 30,
	2022	2021	2022	2021
Period-end common stock warrants	1,587,920	10,034,295	1,587,920	10,034,295
Convertible promissory notes(1)	86,683,389	—	86,683,389	16,680,334
Period-end stock options to purchase common stock	4,718,507	6,357,163	4,718,507	6,357,163
Period-end restricted stock units	17,313,912	8,196,960	17,313,912	8,196,960
Contingently issuable common shares	3,593,193	—	3,593,193	—
Total potentially dilutive securities excluded from computation of diluted loss per share	113,896,921	24,588,418	113,896,921	41,268,752

______________

(1)    The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

26

9. Commitments and Contingencies

Guarantor Arrangements

The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of June 30, 2022 and December 31, 2021.

The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM, the Company's international subsidiaries and the Company’s ownership interests in joint ventures. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note.

In October 2021, the Company entered into a 10-year manufacturing partnership agreement with Renfield Manufacturing, LLC (Renfield) to provide manufacturing services and third-party logistics processes, including inventory management, warehousing, and fulfillment for certain of the Company’s consumer product lines. The Company also provided a $0.5 million letter of credit and guarantee to the lessor of the Renfield manufacturing facility, which extends through August 2032. If Renfield fails to perform under the facility lease, the Company can terminate the manufacturing agreement. The Company expects that its potential future performance under the guarantee is not probable of occurrence. Accordingly, the Company had no liabilities recorded for the guarantee as of June 30, 2022 and December 31, 2021.

Other Matters

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. In early 2021, the parties attended court-ordered mediation, but as the case did not settle, the parties commenced discovery. On July 30, 2021, plaintiffs filed a motion seeking class certification and the Company filed its opposition on September 24, 2021; after briefing and argument, it was granted in part on December 8, 2021. On December 22, 2021, the Company filed a petition seeking interlocutory review of that order in the U.S. Court of Appeals for the Ninth Circuit, which was fully briefed on January 14, 2022. On February 4, 2022, the parties reached a tentative settlement of the securities class action, which requires the court’s review and approval. On March 24, 2022, the parties submitted the proposed settlement agreement to the Court. A slightly revised proposed settlement agreement and supporting documents were filed on July 21, 2022. On July 22, 2022, the Court preliminarily approved the settlement agreement and set the hearing date for final approval on November 8, 2022. If the settlement is approved by the Court, the settlement amount will be covered by the Company’s directors and officers insurance policy.

27

Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021, and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021, and re-filed in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. The Company's motion to dismiss was granted without prejudice on June 30, 2021. After obtaining an extension, Bonner amended its complaint on February 22, 2022. On March 24, 2022, the Company filed a motion seeking full dismissal with prejudice of claims alleged in Bonner’s amended complaint. On June 20, 2022, the Court granted the Company's motion to dismiss Bonner's amended complaint without prejudice. On July 14, 2022, Bonner informed the Court that it does not intend to file a second amended complaint.

On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended. The Company filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The Court denied the Company's motions on July 26, 2021, and the Company appealed the Court's ruling regarding its motion to compel arbitration on July 27, 2021, filing its appeal to the U.S. Court of Appeals for the Second Circuit on November 4, 2021. The appellate briefing process was completed on January 19, 2022. The Court scheduled oral argument for September 9, 2022. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom.

The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s expectations, the Company’s condensed consolidated financial statements for the relevant reporting period could be materially adversely affected.

10. Revenue Recognition, and Contract Assets and Liabilities

Disaggregation of Revenue

The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:

28

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
North America	$	39,963	$	—	$	1,244	$	41,207	$	30,123	$	11,000	$	—	$	41,123
Europe	6,338		6,454		2,927		15,719		2,500		—		2,903		5,403
Asia	5,171		—		192		5,363		3,929		—		1,241		5,170
South America	2,094		—		—		2,094		332		—		—		332
Other	824		—		—		824		288		—		—		288
	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
North America	$	72,919	$	433	$	2,720	$	76,072	$	50,175	$	11,000	$	250	$	61,425
Europe	13,627		15,334		6,190		35,151		5,472		143,800		5,250		154,522
Asia	6,659		—		384		7,043		8,334		—		3,524		11,858
South America	3,113		—		—		3,113		789		—		—		789
Other	1,537		—		—		1,537		581		—		—		581
	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

The following table presents revenue by major product and service, as well as by management classification:

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total		Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total
Consumer	$	42,219	$	5	$	749	$	42,973	$	20,695	$	—	$	—	$	20,695
Technology access	12,171		6,449		3,614		22,234		16,477		11,000		4,144		31,621
	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total		Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total
Consumer	$	74,861	$	438	$	2,225	$	77,524	$	36,347	$	—	$	—	$	36,347
Technology access	22,994		15,329		7,069		45,392		29,004		154,800		9,024		192,828
	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

Significant Revenue Agreements and Customers

In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2021 Form 10-K), the Company recognized the following revenue:

29

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
Sephora	$	10,092	$	—	$	—	$	10,092	$	8,078	$	—	$	—	$	8,078
DSM - related party	2,965		6,454		2,000		11,419		4,620		—		2,000		6,620
Ingredion / PureCircle	1,197		—		—		1,197		2,253		10,000		—		12,253
Subtotal revenue from significant revenue agreements	14,254		6,454		2,000		22,708		14,951		10,000		2,000		26,951
Revenue from all other customers	40,136		—		2,363		42,499		22,221		1,000		2,144		25,365
Total revenue from all customers	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
Sephora	$	17,725	$	—	$	—	$	17,725	$	12,519	$	—	$	—	$	12,519
DSM - related party	7,377		15,270		4,000		26,647		6,281		143,612		4,000		153,893
Ingredion / PureCircle	2,748		—		—		2,748		2,253		10,000		—		12,253
Subtotal revenue from significant revenue agreements	27,850		15,270		4,000		47,120		21,053		153,612		4,000		178,665
Revenue from all other customers	70,005		497		5,294		75,796		44,298		1,188		5,024		50,510
Total revenue from all customers	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

DSM Ingredients Collaboration

Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with $2.0 million quarterly from January 1, 2022 to June 30, 2022 for services focused on achieving certain fermentation yield and cost targets related to certain molecules. During the three and six months ended June 30, 2022, the Company recognized $2.0 million and $4.0 million of collaboration revenue in connection with the agreement.

DSM License Agreement and Contract Assignment

In March 2021 the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property of the Company and assigned the Company’s rights and obligations under certain F&F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain commercial milestones are achieved in each of the calendar years 2022 through 2024. The Company determined the licenses to be functional intellectual property and allocated $143.6 million of the transaction price to the licenses and recorded $143.6 million of licenses and royalties revenues in the three-months ended March 31, 2021. The Company also concluded the additional contingent consideration represents variable consideration that is subject to a sales/usage-based threshold and is dependent up on the IP License. The Company is required to apply the royalty recognition constrain guidance in ASC 606-10-55-65 and will recognize revenue at the later of (1) when the underlying sales or usage has occurred and (2) the related performance obligation has been satisfied (or partially satisfied). During the three and six months ended June 30, 2022, the Company recorded $6.5 million and $15.3 million, respectively, of license and royalties revenue and a corresponding contract asset under the contingent consideration provisions of the agreements.

Contract Assets and Liabilities

When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional.

30

Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer.

Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company.

Contract Balances

The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:

(In thousands)	June 30, 2022		December 31, 2021
Accounts receivable, net	$	41,125	$	37,074
Accounts receivable - related party, net	$	5,001	$	5,667
Contract assets	$	3,946	$	4,227
Contract assets - related party	$	15,265	$	—
Contract liabilities	$	816	$	2,530
Contract liabilities, noncurrent(1)	$	—	$	111

(1)As of June 30, 2022 and December 31, 2021, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.

Remaining Performance Obligations

The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of June 30, 2022.

(In thousands)	As of June 30, 2022
Remaining 2022	$	526
2023	143
2024	143
2025	143
2026 and thereafter	143
Total from all customers	$	1,098

In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual property.

11. Related Party Transactions

Related Party Debt

Related party debt was as follows:

	June 30, 2022								December 31, 2021
In thousands	Principal		Unaccreted Debt Discount		Change in Fair Value		Net		Principal		Unaccreted Debt Discount		Change in Fair Value		Net
Foris convertible note	$	50,041	$	—	$	1,475	$	51,516	$	50,041	$	—	$	57,386	$	107,427

31

Related Party Equity

There we no related party equity transactions during the three or six months ended June 30, 2022.

Related Party Revenue

See Note 10, "Revenue Recognition, and Contract Assets and Liabilities", for information about related party revenue transactions with DSM.

Related Party Accounts Receivable, Contract Assets and Accounts Payable

Related party accounts receivable, contract assets and accounts payable were as follows:

(In thousands)	June 30, 2022		December 31, 2021
Accounts receivable - related party	$	5,001	$	5,667
Contract assets - related party	$	15,265	$	—
Accounts payable - related party	$	4,241	$	5,011

12. Stock-based Compensation

The Company’s stock option activity and related information for the six months ended June 30, 2022 was as follows:

	Quantity of Stock Options	Weighted- average Exercise Price		Weighted-average Remaining Contractual Life, in Years	Aggregate Intrinsic Value, in Thousands
Outstanding - December 31, 2021	3,087,225	$	9.91	7.1	$	2,580
Granted	1,916,237	$	3.03
Exercised	(36,021)	$	2.84
Forfeited or expired	(248,934)	$	11.55
Outstanding - June 30, 2022	4,718,507	$	7.09	8.0	$	1
Vested or expected to vest after June 30, 2022	4,451,407	$	7.24	7.9	$	1
Exercisable at June 30, 2022	1,785,373	$	10.66	5.8	$	—

Activity related to the Company’s restricted stock units (RSUs) (including performance-based restricted stock units (PSUs)) for the six months ended June 30, 2022 was as follows:

	Quantity of Restricted Stock Units	Weighted-average Grant-date Fair Value		Weighted-average Remaining Contractual Life, in Years
Outstanding - December 31, 2021	13,731,320	$	9.99	2.8
Awarded	5,965,118	$	3.60
Released	(1,726,412)	$	7.26
Forfeited	(656,114)	$	6.28
Outstanding - June 30, 2022	17,313,912	$	8.20	2.4
Vested or expected to vest after June 30, 2022	15,155,053	$	8.06	2.3

Stock-based compensation expense during the three and six months ended June 30, 2022 and 2021 is reflected in the condensed consolidated statements of operations as follows:

32

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2021		2020
Cost of products sold	$	81	$	73	$	159	$	137
Research and development	1,784		1,318		3,401		2,380
Sales, general and administrative	10,782		7,355		20,675		10,511
Total stock-based compensation expense	$	12,647	$	8,746	$	24,235	$	13,028

As of June 30, 2022, $122.0 million of unrecognized compensation expense related to stock options and RSUs is expected to be recognized over a weighted-average period of 3.2 years.

13. Subsequent Events

None.

33

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q. These discussions contain forward-looking statements reflecting our current expectations that involve risks and uncertainties which are subject to safe harbors under the Securities Act of 1933, as amended (the Securities Act), and the Securities Exchange Act of 1934 (the Exchange Act). These forward-looking statements include, but are not limited to, statements concerning our strategy of achieving a significant reduction in net cash outflows during the remainder of 2022 and 2023, aspects of our future operations, our future financial position, expectations for our future revenues, margins and projected costs, expectations regarding demand and acceptance for our technologies and products, introductions of new products, growth opportunities and trends in the market in which we operate, prospects, plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q, in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the 2021 Form 10-K), and as applicable, in our other filings with the Securities and Exchange Commission. We do not assume any obligation to update any forward-looking statements.

Overview

We are a biotechnology company at the forefront of delivering sustainable science-based solutions that are better for people and the planet. To accelerate the world’s transition to sustainable consumption, we create, manufacture and commercialize consumer products and ingredients that reach more than 300 million consumers. Currently, the largest source of revenue is the marketing and selling of Clean Beauty, Personal Care and Health & Wellness consumer products through our direct-to-consumer ecommerce platforms and a growing network of retail partners. We also sell sustainable ingredients to sector leaders that serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets.

We began 2021 with three consumer brands, Biossance® clean beauty skincare, Pipette® clean baby skincare, and PurecaneTM zero-calorie sweetener. During the second half of 2021, we launched five additional consumer brands in the Clean Beauty & Personal Care end market, including Terasana® clean skincare, Costa Brazil® luxury skincare, OLIKATM clean wellness, Rose Inc.TM clean color cosmetics, and JVNTM clean haircare. During the first half of 2022, we added MenoLabsTM, a brand focused on healthy living (including menopause).

Our ingredients and consumer products are powered by our Lab-to-MarketTM technology platform. This technology platform enables the portfolio connection between our proprietary science and formulation expertise, manufacturing capability at industrial scale, and expertise in commercializing high performance, sustainable products that make a difference in people’s lives. We believe that our technology platform offers advantages to traditional methods of sourcing similar ingredients (such as petrochemistry and extraction from organisms). Our technology platform allows for renewable and ethical sourcing of raw materials, less resource-intensive production, minimal impact on sensitive ecosystems, enhanced purity and safety profiles, less vulnerability to climate disruption, and improved supply chain resilience. We combine molecular biology and genetic engineering to generate more sustainable materials that are otherwise derived from scarce or endangered resources in nature. We leverage state-of-the-art machine learning, robotics and artificial intelligence to rapidly bring new innovation to market.

The time taken from lab to market for the commercialization of molecules has decreased from three to four years to less than a year for our most recent molecule, primarily due to improved proprietary strain construction, screening and analytics tools, advanced lab automation, and data integration. Our state-of-the-art infrastructure includes industry-leading strain engineering and lab automation located in Emeryville, California, pilot-scale production facilities in Emeryville and Campinas, Brazil, a demonstration-scale facility in Campinas and a commercial scale production facility in Leland, North Carolina (which is part of our Aprinnova joint venture). A wide variety of feedstocks for precision fermentation exists but we source Brazilian sugarcane for our large-scale production because of its supply resilience, renewability, low cost, and relative price stability. At the mid-year point, we commissioned the first line of a new purpose-built, large-scale precision fermentation facility in Brazil, which we anticipate will accommodate the production of up to five products concurrently. The other lines are expected to be

34

commissioned during the second half of 2022. Pending full commissioning of the new facility, we continue to manufacture our products at manufacturing sites in Brazil, the United States and Europe.

Sales and Revenue

We recognize revenue from consumer and ingredient product sales, license fees and royalties, and collaborations and grants.

Consumer products are being sold in-store and online through retail partners such as, but not limited to, Sephora, Target and Walmart. We also sell to consumers via our direct-to-consumer ecommerce platforms. Our ingredients are sold business-to-business directly to customers such as DSM, Ingredion and other flavor, fragrance, and cosmetic companies or through our distribution partners.

We have research and development collaboration arrangements for which we receive payments from our collaboration partners, which include Koninklijke DSM N.V. (DSM), Givaudan, Firmenich SA (Firmenich), Yifan Pharmaceutical Co. Ltd. (Yifan) and others. Some of our collaboration arrangements provide for advance payments to us in consideration for grants of exclusivity or research efforts that we will perform. Our collaboration agreements, which may require us to achieve milestones prior to receiving payments, are expected to contribute revenues from product sales and royalties if and when they are commercialized. See Note 10, “Revenue Recognition” in Part II, Item 8 of our 2021 Form 10-K for additional information.

We have several other collaboration molecules in our development pipeline with partners including DSM, Givaudan, Firmenich and Yifan that we expect will contribute revenues from product sales and royalties if and when they are commercialized.

COVID-19 Business Update

We closely monitor the impact of the global COVID-19 pandemic on all aspects of our business, including how it has and will impact our employees, partners, supply chain, and distribution network. Since the start of the pandemic in early 2020, we developed a comprehensive response strategy including establishing a cross-functional COVID-19 task force and implementing business continuity plans to manage the impact of the COVID-19 pandemic on our employees and our business. We have applied recommended public health strategies designed to prevent the spread of COVID-19 and have been focused on the health and welfare of our employees. We have successfully managed to sustain ongoing critical production campaigns and infrastructure while staying in compliance with applicable state and county public health orders.

Accordingly, since the end of the first quarter of 2020, we have initiated several precautions in accordance with local regulations and guidelines to mitigate the spread of COVID-19 infection across our businesses, which has impacted the way we carry out our business, including additional sanitation and cleaning procedures in our laboratories and other facilities, on-site COVID-19 testing, temperature and symptom confirmations and instituting remote working when possible. The operation of our sites, including a broader return to work in our offices, laboratories and production facilities, will continue to follow local public health plans and guidelines. As the effects of the COVID-19 pandemic and the availability of vaccines continue to evolve, even if our employees more broadly return to work in our offices, laboratories and production facilities, we have the flexibility to resume more restrictive on-site and remote work models, if needed, as a result of spikes or surges in COVID-19 infection, hospitalization rates or otherwise. See “Risk Factors – Business and Operational Risks – Our business is currently adversely affected and could be materially adversely affected in the future by the evolving effects of the COVID-19 pandemic and related global economic slowdown as a result of the recent and potential future impacts on our supply chain, manufacturing and commercialization activities and other business operations” in Part I, Item 1A of our 2021 Form 10-K.

The global business challenges associated with the COVID-19 pandemic have been recently compounded by the ongoing conflict in Ukraine, which has caused significant instability and disruptions in the capital and credit markets, as well as inflation and increasing interest rates. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our products and in our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our collaboration partners and our suppliers, possibly resulting in development or supply disruption. We cannot anticipate all the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business. See “Risk Factors – Business and Operational Risks” in Part I, Item 1A of our 2021 Form 10-K.

Critical Accounting Policies and Estimates

Management's discussion and analysis of results of operations and financial condition are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S.

35

GAAP). We believe that the critical accounting policies described in this section are those that significantly impact our financial condition and results of operations and require the most difficult, subjective or complex judgements, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. Because of this uncertainty, actual results may vary from these estimates.

Our most critical accounting estimates include:

•Recognition of revenue including arrangements with multiple performance obligations;

•Valuation and allocation of fair value to various elements of complex related party transactions;

•The valuation of freestanding and embedded derivatives, which impacts gains or losses on such derivatives, the carrying value of debt, interest expense and deemed dividends;

•The valuation of debt for which we have elected fair value accounting; and

•The valuation of goodwill, intangible assets and contingent consideration payables, which are generated through business acquisitions.

For a more detailed discussion of our critical accounting estimates and policies, see Note 1, "Basis of Presentation and Summary of Significant Accounting Policies" in Part II, Item 8 of our 2021 Form 10-K and Note 1, "Basis of Presentation and Summary of Significant Accounting Policies" in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Recently Issued Accounting Pronouncements

Refer to Note 1, "Basis of Presentation and Summary of Significant Accounting Policies" in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Accounting Pronouncements Issued but Not Yet Adopted

Refer to Note 1, "Basis of Presentation and Summary of Significant Accounting Policies" in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Results of Operations

Revenue

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Revenue
Renewable products	$	54,390	$	37,172	$	97,855	$	65,351
Licenses and royalties	6,454		11,000		15,767		154,800
Collaborations, grants and other	4,363		4,144		9,294		9,024
Total revenue	$	65,207	$	52,316	$	122,916	$	229,175

Three Months Ended June 30, 2022

Total revenue increased by 25% to $65.2 million for the three months ended June 30, 2022 compared to the same period in 2021. Excluding the $10.0 million of one-off license revenue from the strategic Reb M transaction with Ingredion in the three months ended June 30, 2021, total revenue for the three months ended June 30, 2022 increased by 54% or $22.9 million.

Renewable products revenue increased by 46% to $54.4 million for the three months ended June 30, 2022 compared to the same period in 2021. This increase was driven by a $22.3 million or 108% increase in consumer products revenue, partially offset by a $4.3 million decrease in ingredients product revenue. Consumer revenue growth was primarily driven by continued growth in our Biossance consumer product line and new revenue from consumer brands that were launched or acquired during the past 12 months, such as JVN, Rose Inc. and MenoLabs. Ingredients product revenue in the prior year quarter included $4.3 million for Patchouli which, due to timing and the campaign nature of our production process, was not repeated during this year’s quarter.

Licenses and royalties revenue decreased by $4.5 million for the three months ended June 30, 2022 compared to the same period in 2021, primarily due to the 2021 $10.0 million Reb M license to Ingredion, partly offset by the $6.4 million F&F earnout for the three months ended June 30, 2022.

36

Six Months Ended June 30, 2022

Total revenue decreased by 46% to $122.9 million for the six months ended June 30, 2022 compared to the same period in 2021. Excluding the 2021 sale of a $143.6 million flavors and fragrances intellectual property license to DSM and the 2021 sale of a $10.0 million RebM intellectual property license to Ingredion, total revenue for the six months ended June 30, 2022 increased by 63% or $47.4 million.

Renewable products revenue increased by 50% to $97.9 million for the six months ended June 30, 2022 compared to the same period in 2021. This increase was driven by a $41.2 million or 113% increase in consumer products revenue, partially offset by a $6.0 million decrease in ingredients product revenue. Consumer revenue growth was primarily driven by continued growth in our Biossance consumer product line and new revenue from consumer brands that were launched or acquired during the past 12 months, such as JVN, Rose Inc. and MenoLabs. Ingredients product revenue in the current year has been unfavorably impacted by lower squalane and hemisqualane revenue due to constrained third party manufacturing of intermediate products.

Licenses and royalties revenue decreased by $139.0 million for the six months ended June 30, 2022 compared to the same period in 2021, primarily due to the 2021 sale of a $143.6 million flavors and fragrances intellectual property license to DSM and the 2021 sale of a $10.0 million RebM intellectual property license to Ingredion, partly offset by the $15.3 million F&F earnout for the six months ended June 30, 2022.

Costs and Operating Expenses

Costs and operating expenses were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Cost of products sold	$	55,930	$	30,421	$	104,925	$	53,080
Research and development	26,111		22,424		52,469		45,756
Sales, general and administrative	126,587		54,340		233,503		92,262
Total cost and operating expenses	$	208,628	$	107,185	$	390,897	$	191,098

Included in costs and operating expenses were the following amounts of non-cash stock-based compensation expense:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Cost of products sold	$	81	$	73	$	159	$	137
Research and development	1,784		1,318		$	3,401	$	2,380
Sales, general and administrative	10,782		7,355		20,675		10,511
Total stock-based compensation expense	$	12,647	$	8,746	$	24,235	$	13,028

Cost of Products Sold

Cost of products sold represents the direct cost to produce our products and includes the costs of raw materials and related transportation costs, labor and overhead, amounts paid to contract manufacturers, inventory write-downs resulting from applying lower of cost or net realizable value inventory adjustments, and costs related to production scale-up. Due to our product mix of higher-margin, higher-volume consumer products and lower-margin, large-batch fermentation ingredients products, our cost of products sold may not change proportionately with changes in renewable product revenue in any given period.

Cost of products sold increased by 84% to $55.9 million for the three months ended June 30, 2022 and by 98% to $104.9 million for the six months ended June 30, 2022, compared to the same periods in 2021, primarily driven by significant increases in sales volume of our consumer products. Our cost of products sold was also directly impacted by a significant increase in raw material costs, transportation costs, with air freight as a principal driver, and other supply chain logistics costs. We expect that the insourcing of ingredients manufacturing following the full commissioning of the Barra Bonita facility, as well as the consolidation of the consumer production footprint, will mitigate unfavorable supply chain economics in future quarters.

Research and Development Expenses

37

Research and development expenses increased by 16% to $26.1 million for the three months ended June 30, 2022 and by 15% to $52.5 million for the six months ended June 30, 2022, compared to the same periods in 2021, primarily due to increased headcount and related employee compensation and benefit costs.

Sales, General and Administrative Expenses

Sales, general and administrative expenses increased by 133% to $126.6 million for the three months ended June 30, 2022 and by 153% to $233.5 million for the six months ended June 30, 2022, compared to the same periods in 2021. The increases were principally seen in Selling expense and primarily driven by a combination of increased headcount (both organic and from acquisitions), significant investments in both existing and developing brands for paid media and advertising, expanded retail and ecommerce sales in the U.S. and internationally, growth-driven consumer order fulfillment and shipping expense and comparatively low prior year travel expense due to COVID-19.

Other Income (Expense), Net

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Interest expense	$	(5,304)	$	(4,723)	$	(10,567)	$	(10,536)
Gain (loss) from change in fair value of derivative instruments	3,598		5,141		5,413		(17,604)
Gain (loss) from change in fair value of debt	35,114		70,132		55,910		(256,653)
Gain (loss) upon extinguishment of debt	—		935		—		(26,378)
Other income (expense), net	780		28		(2,272)		(650)
Total other income (expense), net	$	34,188	$	71,513	$	48,484	$	(311,821)

Three Months Ended June 30, 2022

Total other income, net was $34.2 million for the three months ended June 30, 2022, compared to total other income, net of $71.5 million for the same period in 2021. The $37.3 million decrease was primarily comprised of a $35.0 million decrease in gain from change in fair value of debt, no loss upon extinguishment of debt in 2022 as compared to a $0.9 million loss in 2021, and a $1.5 million change from a loss to a gain in the change in fair value of derivative instruments. The fluctuations to changes in fair value of debt and derivatives were driven by a decrease in our stock price during the three months ended June 30, 2022, resulting in lower fair value of the underlying debt and equity instruments. See Note 3, "Fair Value Measurement" in Part I, Item 1 of this Quarterly Report on Form 10-Q for details regarding our outstanding derivative instruments.

Six Months Ended June 30, 2022

Total other income, net was $48.5 million for the six months ended June 30, 2022, compared to total other expense, net of $311.8 million for the same period in 2021. The $360.3 million change was primarily comprised of a $312.6 million change from loss to gain from change in fair value of debt, no loss upon extinguishment of debt in 2022 as compared to a $26.4 million loss in 2021, and a $23.0 million change from a loss to a gain in the change in fair value of derivative instruments. The fluctuations to changes in fair value of debt and derivatives were driven by a decrease in our stock price during the six months ended June 30, 2022, resulting in lower fair value of the underlying debt and equity instruments.

Provision for Income Taxes

For the three and six months ended June 30, 2022, we recorded a tax benefit of $0.7 million and $1.5 million, respectively, related to a tax benefit in the United Kingdom. For the three and six months ended June 30, 2021, we recorded a tax provision of $0.1 million and $0.1 million, respectively, related to accrued interest on uncertain tax positions.

38

Liquidity and Capital Resources

(In thousands)	June 30, 2022		December 31, 2021
Working capital	$	123,035	$	369,407
Cash and cash equivalents	$	99,820	$	483,462
Debt principal and lease obligations	$	817,987	$	768,656
Accumulated deficit	$	(2,568,986)	$	(2,357,661)

	Six Months Ended June 30,
(In thousands)	2022		2021
Net cash provided by (used in):
Operating activities	$	(299,483)	$	30,205
Investing activities	$	(89,222)	$	(5,670)
Financing activities	$	7,220	$	159,238

Liquidity

We have made substantial investments in marketing, headcount and working capital investments as we have expanded our consumer portfolio. Additionally, we increased our capital expenditures for the construction of our precision fermentation facility in Barra Bonita, Brazil. These strategic investments support growth of our consumer portfolio, enhance consumer brand equity, and allow the insourcing of fermentation production to improve the unit cost profile of our ingredients portfolio.

In June 2022, we and Foris Ventures, LLC (Foris) executed an amendment to extend the maturity of the Foris $50.0 million convertible note from July 1, 2022 to July 1, 2023. See Note 4, "Debt" in the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. As such, there is no near-term demand on cash to pay down this note. As of June 30, 2022, the principal amounts due under our debt instruments (including related party debt) totaled $741.1 million, of which none is classified as current.

We anticipate receiving certain milestone payments (earnouts) under the March 2021 DSM transaction (F&F) and the June 2021 Ingredion transaction (Reb M) (see Note 10 "Revenue Recognition" and Note 5, "Mezzanine Equity," in the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information), which are subject to the successful commissioning of the Barra Bonita facility, producing ingredients and achieving certain unit cost metrics.

Our cash and cash equivalents of $99.8 million as of June 30, 2022 in and of itself will not be sufficient to fund expected cash flow requirements from operations, investments and financing obligations for the next 12 months. We are actively working on securing additional funding from debt and from a strategic transaction to meet our spending obligations within 12 months after issuing our financial statements for the second quarter of 2022. Management currently expects that the current cash position, the cash generated from operations, the expected F&F and Reb M-related earnout payments along with planned price increases, operating expense reduction actions and the aforementioned additional funding from debt and a strategic transaction, to not raise substantial doubt about the Company's ability to continue as a going concern for the next 12 months.

For details of our debt and equity, see the following Notes in Part I, Item 1 of this Quarterly Report on Form 10-Q:

•Note 4, "Debt"

•Note 5, "Mezzanine Equity"

•Note 6, "Stockholders' Deficit"

Cash Flows during the Six Months Ended June 30, 2022 and 2021

Cash Flows from Operating Activities

Our primary uses of cash from operating activities are costs related to the production and sale of our products and personnel-related expenditures, offset by cash received from renewable product sales, licenses and royalties, and collaborations.

For the six months ended June 30, 2022, net cash used in operating activities was $299.5 million, consisting primarily of a $223.8 million net loss, $21.0 million of unfavorable non-cash adjustments that were primarily comprised of a $55.9 million

39

gain from change in fair value of debt, partially offset by $24.2 million of stock-based compensation expense. Additionally, there was a $54.7 million decrease in working capital.

For the six months ended June 30, 2021, net cash provided by operating activities was $30.2 million, consisting primarily of a $274.6 million net loss, partially offset by $384.7 million of favorable non-cash adjustments that were primarily comprised of a $256.7 million loss from change in fair value of debt, a $26.4 million loss upon extinguishment of debt, and a $17.6 million loss from change in fair value of derivative instruments. Additionally, there was a $14.0 million decrease in working capital.

Cash Flows from Investing Activities

For the six months ended June 30, 2022, net cash used in investing activities was $89.2 million, comprised of $71.5 million of property, plant and equipment purchases, principally related to our new Barra Bonita facility, and $17.8 million of cash paid in business combinations.

For the six months ended June 30, 2021, net cash used in investing activities was $5.7 million, comprised of property, plant and equipment purchases.

Cash Flows from Financing Activities

For the six months ended June 30, 2022, net cash provided by financing activities was $7.2 million, primarily comprised of $6.6 million of proceeds from the exercise of warrants.

For the six months ended June 30, 2021, net cash provided by financing activities was $159.2 million, primarily comprised of $130.8 million from the April 2021 equity raise, $38.8 million of proceeds from the exercise of warrants and $2.8 million of proceeds from stock option exercises, partly offset by $23.4 million of debt principal payments, $2.5 million of issuance costs in connection with a debt modification, and $1.9 million of principal payments on financing leases.

Contractual Obligations

The following is a summary of our contractual obligations as of June 30, 2022:

Payable by year ending December 31, (In thousands)	Total		2022		2023		2024		2025		2026		Thereafter
Principal payments on debt	$	740,996	$	—	$	50,996	$	—	$	—	$	690,000	$	—
Interest payments on debt	59,344		5,279		22,986		10,350		10,350		10,379		—
Construction costs in connection with new production facility	22,000		22,000		—		—		—		—		—
Contract termination fees	1,000		1,000		—		—		—		—		—
Financing leases	90		11		21		21		21		16		—
Operating leases	316,899		6,964		12,962		22,075		22,374		22,807		229,717
Total	$	1,140,329	$	35,254	$	86,965	$	32,446	$	32,745	$	723,202	$	229,717

40

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The market risk inherent in our market risk sensitive instruments and positions is the potential loss arising from adverse changes in the price of our common stock, foreign currency exchange rates, interest rates and commodity prices.

Amyris Common Stock Price Risk

We are exposed to potential losses related to the price of our common stock. At each balance sheet date, the fair value of our derivative liabilities and certain of our outstanding debt instruments for which we have elected fair value accounting, is remeasured using current fair value inputs, one of which is the price of our common stock.

During any particular period, if the price of our common stock increases, there will likely be increases in the fair value of our derivative liabilities and our debt instruments for which we have elected fair value accounting. Such increases in fair value will result in losses in our condensed consolidated statements of operations from change in fair value of derivative instruments and from change in fair value of debt. Conversely, a decrease in the price of our stock during any particular period will likely result in gains in relation to these derivative and debt instruments. Given the current and historical volatility of our common stock price, any changes period-over-period have and could in the future result in a significant change in the fair value of our derivative liabilities and convertible debt instruments and significantly impact our net income during the period of change.

Foreign Currency Exchange Risk

Most of our sales contracts are denominated in U.S. dollars, and therefore our revenues are not currently subject to significant foreign currency risk.

The functional currency of our consolidated Brazilian subsidiary is the local currency (Brazilian Real), in which recurring business transactions occur. We do not use currency exchange contracts as hedges against our investment in that subsidiary.

Our permanent investment in Brazil was $190.2 million as of June 30, 2022 and $133.9 million as of December 31, 2021, using the exchange rate at each date. A hypothetical 10% adverse change in Brazilian Real exchange rates would have had an adverse impact to Other Comprehensive Loss of $19.0 million as of June 30, 2022 and $13.4 million as of December 31, 2021.

We have also evaluated foreign currency exposure in relation to our other non-U.S. Dollar denominated assets and liabilities and determined that there would be an immaterial effect on our results of operations from 10% exchange rate fluctuations between those currencies and the U.S. Dollar.

Interest Rate Risk

Our exposure to market risk for changes in interest rates relates primarily to our outstanding debt obligations, including embedded derivatives therein. We generally invest our cash in investments with short maturities or with frequent interest reset terms. Accordingly, our interest income fluctuates with short-term market conditions. As of June 30, 2022, our investment portfolio consisted of money market funds and certificates of deposit, both of which are highly liquid. Due to the short-term nature of our investment portfolio, we do not believe that an immediate 10% increase in interest rates would have a material effect on the fair value of our portfolio. Since we believe we have the ability to liquidate our investment portfolio, we expect that our operating results or cash flows would not be materially affected by a sudden change in market interest rates on the portfolio.

In addition, while not likely in the current and significantly extended low interest rate environment, changes in interest rates could significantly change the fair value of our embedded derivative liabilities.

As of June 30, 2022, all of our outstanding debt was in fixed rate instruments. As a result, changes in interest rates would not affect interest expense and payments in relation to our debt.

Commodity Price Risk

Our primary exposure to market risk for changes in commodity prices relates to our procurement of products from contract manufacturers, freight, packaging materials and other suppliers whose prices are affected by the price of sugar feedstocks and energy. The latter exposure is primarily managed through the use of feedstock pricing agreements.

41

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer (CEO) and chief financial officer (CFO), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of June 30, 2022, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control

There were no changes in our internal control over financial reporting identified in management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

42

PART II

ITEM 1. LEGAL PROCEEDINGS

For a description of our significant pending legal proceedings, please see Note 9, "Commitments and Contingencies" in the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

43

ITEM 1A. RISK FACTORS

The risks described in Part I, Item 1A, "Risk Factors" in our 2021 Form 10-K could materially and adversely affect our business, financial condition and results of operations, and the trading price of our common stock could decline. These risk factors do not identify all risks that we face; our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. The “Risk Factors” section of the 2021 Form 10-K remains current in all material respects.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In April 2022, we issued 907,946 shares to acquire 100% of the outstanding ownership interest of Onda Beauty Inc. (“Onda”) from Onda’s stockholders. The share issuance was exempt from registration. For more information, see Note 7, “Acquisitions” in Part I, Item I of this Quarterly Report on Form 10-Q.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

44

ITEM 6. EXHIBITS

Exhibit No.	Description	Incorporation by Reference
		Form	File No.	Exhibit	Filing Date	Filed Herewith
3.01	Certificate of Amendment of the Restated Certificate of Incorporation dated June 10, 2022					x
10.01	Seventh Amendment, dated June 27, 2022, to Lease, dated August 22, 2007, between registrant and ES East, LLC					x
10.02	Fourth Amendment, dated June 27, 2022, to Lease, dated April 25, 2008, between registrant and EmeryStation Triangle, LLC					x
10.03	Amendment to Amended and Restated Loan and Security Agreement, dated June 30, 2022, between registrant and Foris Ventures, LLC					x
31.01	Certification of Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(c) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					x
31.02	Certification of Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(c) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					x
32.01b	Certification of Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					x
32.02b	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					x
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

b This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

45

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

	AMYRIS, INC.
By:	/s/ John G. Melo
	John G. Melo
	President and Chief Executive Officer (Principal Executive Officer)
	August 9, 2022
By:	/s/ Han Kieftenbeld
	Han Kieftenbeld
	Chief Financial Officer (Principal Financial Officer)
	August 9, 2022

46

EX-3.01

CERTIFICATE OF AMENDMENT

OF THE

RESTATED CERTIFICATE OF INCORPORATION

OF

AMYRIS, INC.

Amyris, Inc., a corporation organized and existing under and by virtue of the General Corporation

Law of the State of Delaware (the “Corporation”),

DOES HEREBY CERTIFY THE FOLLOWING:

FIRST:    That the name of the Corporation is Amyris, Inc.

SECOND:     That the date on which the Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of Delaware is April 15, 2010 under the name Amyris Biotechnologies, Inc.

THIRD:     That, at a meeting of the Board of Directors of the Corporation (the “Board”), the Board duly adopted resolutions setting forth the following proposed amendment of the Restated Certificate of Incorporation of the Corporation, as amended, declaring said amendment to be advisable and directing the Corporation to submit said amendment to the next annual meeting of the stockholders of said Corporation for consideration thereof, and that, thereafter, pursuant to such resolutions, the Corporation submitted the amendment to the stockholders of the Corporation at such annual meeting of the stockholders of the Corporation duly called and held upon notice in accordance with Section 222 of the Delaware General Corporation Law at which meeting the necessary number of shares as required by statute were voted in favor of said amendment:

Section 1 of Article IV of the Corporation’s Restated Certificate of Incorporation is hereby amended to read in its entirety as follows:

“1. Total Authorized. The total number of shares of all classes of stock that the corporation has authority to issue is Five Hundred Fifty-Five Million (555,000,000) shares, consisting of two classes: Five Hundred Fifty Million (550,000,000) shares of Common Stock, $0.0001 par value per share, and Five Million (5,000,000) shares of Preferred Stock, $0.0001 par value per share.”

FOURTH:     That said amendment was duly adopted in accordance with the provisions of

Section 242 of the Delaware General Corporation Law.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment of the

Restated Certificate of Incorporation to be signed by its General Counsel and Secretary this 10th day of June, 2022 and the foregoing facts stated herein are true and correct.

AMYRIS, INC.

By: /s/ Nicole Kelsey

Name: Nicole Kelsey

Title: Chief Legal Officer and Secretary

EX-10.01

SEVENTH AMENDMENT TO LEASE
(5885 Hollis Street, Emeryville, California)

This Seventh Amendment To Lease (this “Amendment”), dated as of June 27, 2022, is entered into by and between ES EAST, LLC, a California limited liability company (“Landlord”), and AMYRIS, INC., a Delaware corporation (“Tenant”).

Recitals

A.Landlord (as successor-in-interest to ES East Associates, LLC) and Tenant (as successor-in-interest to Amyris Biotechnologies, Inc., a California corporation) are parties to that certain Lease dated as of August 22, 2007 (the “Original Lease”), as amended by that certain First Amendment to Lease dated as of March 10, 2008 (the “First Amendment”), that certain Second Amendment to Lease dated as of April 25, 2008 (the “Second Amendment”), that certain Third Amendment to Lease dated as of July 31, 2008 (the “Third Amendment”), that certain Commencement Date Agreement dated October 14, 2008 (the “Commencement Date Agreement”), that certain Fourth Amendment to Lease dated as of November 14, 2009 (the “Fourth Amendment”), that certain Fifth Amendment to Lease dated as of October 15, 2010 (“Fifth Amendment”), and that certain Sixth Amendment to Lease dated as of April 13, 2013 (“Sixth Amendment” and, collectively with the other amendments listed above, the “Amendments”) (the Original Lease, as amended by the First Amendment, the Second Amendment, the Third Amendment, the Commencement Date Agreement, the Fourth Amendment, the Fifth Amendment and the Sixth Amendment, is referred to herein as the “Lease”), whereby Tenant leases certain space known as Suites 100, 150 and 200, consisting of the entirety of the first and second floors of the Building (as defined below), including the four (4) private usable outdoor terraces located on such floors, and which space is deemed to contain approximately 114,591 square feet of Rentable Area (the “Premises”) within the building located at 5885 Hollis Street, Emeryville, California (the “Building”).

B.In addition, Landlord and Tenant’s predecessors in interest entered into that certain Storage Space Rental Agreement dated as of June 1, 2008 (the “Storage Agreement”), which Storage Agreement relates to Sections 1.1(14) and 6.8 of the Original Lease and under which Tenant leases storage space commonly referred to as P2043 and located within the P2 parking level (the “P2 Level”) of the Building (the “Storage Space”). Tenant also leases additional space on the PI Level of the Building and has improved that area to serve as a chemical waste storage area (the “Waste Space”). The Storage Space and the Waste Space are as shown on Exhibit A hereto, and are collectively known as the “Garage Spaces”.

C.The current Term of the Lease expires as of May 31, 2023 (the “Prior Expiration Date”), and the parties now desire to extend the Term of the Lease, on the following terms and conditions.

NOW THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the parties agree as follows:

Agreement

1.Definitions; Recitals. Unless otherwise specified herein, all capitalized terms used in this Amendment are used as defined in the Lease. The parties acknowledge the truthfulness of the foregoing Recitals, which are hereby incorporated into this

1

Amendment.

2.Inconsistencies. To the extent that there are any inconsistencies between the terms of the Lease and this Amendment, the terms of this Amendment shall control.

3.Extension. The Term of the Lease is hereby extended for a period of 180 months and shall expire on May 31, 2038 (the “Extended Expiration Date”), unless sooner terminated in accordance with the terms of the Lease. That portion of the Term commencing the day immediately following the Prior Expiration Date (the “Extension Date”) and ending on the Extended Termination Date shall be referred to herein as the “Extended Term”.

4.Monthly Base Rent. As of the Extension Date, the schedule of Monthly Base Rent due for the Premises (but not the Garage Spaces) shall be as follows:

Period	Monthly Base Rent*	Monthly Base Rent Rate (Approx.)
06/01/23 – 05/31/24	$744,841.50	$6.50
06/01/24 – 05/31/25	$770,910.95	$6.73
06/01/25 – 05/31/26	$797,892.83	$6.96
06/01/26 – 05/31/27	$825,819.08	$7.21
06/01/27 – 05/31/28	$854,722.75	$7.46
06/01/28 – 05/31/29	$884,638.05	$7.72
06/01/29 – 05/31/30	$915,600.38	$7.99
06/01/30 – 05/31/31	$947,646.39	$8.27
06/01/31 – 05/31/32	$980,814.01	$8.56
06/01/32 – 05/31/33	$1,015,142.50	$8.86
06/01/33 – 05/31/34	$1,050,672.49	$9.17
06/01/34 – 05/31/35	$1,087,446.03	$9.49
06/01/35 – 05/31/36	$1,120,069.41	$9.77
06/01/36 – 05/31/37	$1,159,271.84	$10.12
06/01/37 – 05/31/38	$1,199,846.35	$10.47

All such Monthly Base Rent shall be payable by Tenant in accordance with the terms of the Lease.

*Monthly Base Rent, but not Operating Expenses, shall be abated for the months of June 2023, June 2025, June 2028 and June 2031 (collectively, the “Abated Base Rent”)..

5.Garages Spaces Rent.

(a)Storage Space Rent. Section 10(b) of the Sixth Amendment is hereby deleted and replaced with the following:

    (b)    The Garage Storage Fee (as defined in the Original Lease) for the Storage Space is presently $603.57 per month. Such

2

Garage Storage Fee shall increase three and one-half percent (3½%) on June 1, 2023 and three and one-half percent (3½%) on every subsequent June 1st for the balance of the Term.

(b)Waste Space Rent. Section 11(b) of the Sixth Amendment is hereby deleted and replaced with the following:

    (b)    The Garage Storage for the Waste Space is presently $498.59 per month. Such Garage Storage Fee shall increase three and one-half percent (3½%) on June 1, 2023 and three and one-half percent (3½%) on every subsequent June 1st for the balance of the Term.

6.Rent Adjustments (Operating Expenses and Taxes). Tenant shall continue to pay Rent Adjustments, representing Tenant’s Share of Operating Expenses and Taxes, in accordance with the terms of the Lease.

7.Improvements to Premises.

(a)Condition of Premises. Tenant is in possession of the Premises and accepts the same “as is” without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment.

(b)Responsibility for Improvements to Premises. Landlord shall perform improvements to the Premises in accordance with the Work Agreement attached hereto as Exhibit B (the “Work Agreement”) and Tenant shall be entitled to an improvement allowance in connection with such work as more fully described in the Work Agreement.

(c)Surrender Obligations. Section 12.1 of the Original Lease (as amended by the First Amendment) is hereby further amended to add that, upon the expiration or earlier termination of the Lease (as amended hereby), Tenant shall have no obligation to remove the Tenant Work (as defined in Work Agreement) or any portion thereof nor any of the existing improvements or the Required Removables, provided that the Tenant Work is constructed in substantial conformance with the Space Plan (as defined in the Work Agreement).

8.Parking. As of the date of this Amendment, Landlord and Tenant acknowledge and agree that, in light of the area occupied by the Garage Spaces on the P1 Level, Tenant currently is entitled to use no more than 218 unreserved parking spaces and 10 reserved parking spaces, upon all the terms and conditions of Section 2.6 of the Original Lease.

9.Right of First Offer. All rights of first offer, rights of first refusal and expansion options in the Lease are hereby deleted, and the following is hereby substituted therefor:

(a)Tenant shall have an on-going right of first offer (the “Right of First Offer”) with respect to any space that becomes available in the Building, other than ground floor retail spaces, following the date of full execution of this Amendment (individually and collectively, an “Offering Space” and the “Offering Spaces”).

3

(b)Landlord and Tenant acknowledge that the Offering Spaces are currently

leased to existing tenants. Prior to the date Landlord offers an Offering Space for lease to a potential third-party tenant or other potential occupant (other than to Bayer Healthcare LLC, a Delaware limited liability company; “Bayer”), who has a superior right of first offer on spaces on the 3rd floor of the Building, as to any such Offering Space on the 3rd floor), Landlord shall advise Tenant (the “Advice”) of the terms under which Landlord is prepared to lease such Offering Space to Tenant, which terms shall reflect Landlord’s determination of Fair Market Rent (as specified in Section 9(d) below). Tenant may lease such Offering Space in its entirety only, under such terms, by delivering written notice of exercise to Landlord (the “Notice of Exercise”) within 15 days after the date of the Advice, except that Tenant shall have no such Right of First Offer, and Tenant may not exercise its right under this Section 9, if: (i) at the time that Landlord would otherwise deliver the Advice, a Default on the part of Tenant exists under the Lease; (ii) more than twenty percent (20%) of the Premises is sublet at the time Landlord would otherwise deliver the Advice; (iii) Tenant is not occupying the entire Premises (other than the up to 20% sublet referenced in subsection (ii) above) at the time Landlord would otherwise deliver the Advice; (iv) the Offering Space is not intended for the exclusive use of Tenant; or (v) Tenant cannot demonstrate to Landlord’s reasonable satisfaction that Tenant’s creditworthiness is sufficient in light of the increased Rent obligations associated with the Offering Space. Tenant shall deliver evidence of Tenant’s creditworthiness concurrently with delivery of the Notice of Exercise.

(c)The term with respect to the Offering Space (the “Offering Space Term”) shall be as stated in the Advice and upon commencement of the Offering Space Term, the Offering Space shall be considered a part of the Premises, provided that all of the terms stated in the Advice shall govern Tenant’s leasing of the Offering Space and only to the extent that they do not conflict with the Advice, the terms and conditions of this Lease shall apply to the Offering Space. The foregoing notwithstanding, if Landlord is unable to deliver possession of the Offering Space to Tenant on the commencement of the Offering Space Term as stated in the Advice, Landlord shall not be liable for any claims, damages or liabilities by reason thereof, but the Offering Space Term shall commence upon the date possession of the Offering Space is delivered by Landlord to Tenant. The Offering Space shall be accepted by Tenant in “AS IS” condition (unless otherwise stated in the Advice), and Landlord’s only obligation with respect to the condition of the Offering Space as of the commencement of the Offering Space Term shall be to deliver such Offering Space in such condition.

(d)Tenant shall pay Monthly Base Rent for the Offering Space at the rate or rates set forth in the Advice, which rate or rates shall reflect the Fair Market Rent for the Offering Space as determined by Landlord in Landlord’s reasonable judgment. For purposes of this Right of First Offer provision, “Fair Market Rent” shall mean the net effective annual rental rate per square foot for space comparable to the Offering Space in the Building and office buildings comparable to the Building in Emeryville, California under leases and renewal and expansion amendments being entered into at or about the time that the Fair Market Rent is being determined, giving appropriate consideration to tenant credit capability, tenant concessions, brokerage commissions, tenant improvement

4

allowances, and the method of allocating operating expenses and taxes when the net effective rate is being calculated. Notwithstanding the foregoing, space leased under any of the following circumstances shall not be considered to be comparable for purposes hereof: (i) the lease term is for materially less than the lease term of the Offering Space, (ii) the space is encumbered by the option rights of another tenant, or (iii) the space has a lack of windows and/or an awkward or unusual shape or configuration. The foregoing is not intended to be an exclusive list of space that will not be considered to be comparable. The determination of Fair Market Rent shall also take into consideration any reasonably anticipated changes in the Fair Market Rent from the time such Fair Market Rent is being determined and the time such Fair Market Rent will become effective under the Lease as well as other factors typically considered in Fair Market Rent determinations, including but not limited to delivery date and rent commencement date.

(e)The Right of First Offer shall terminate on the earliest to occur of: (i) Tenant’s failure to exercise its Right of First Offer within the 15-day period provided in Section 9(b) above as to the Offering (subject to the provisions of Section 9(f) below and unless and until such Offering Space again becomes vacant and available for lease); (ii) the date Landlord would have provided Tenant with an Advice if Tenant had not been in violation of one or more of the conditions set forth in Section 9(b), unless and until such Offering Space again becomes vacant and available for lease; (iii) the date Tenant has leased (or failed to deliver Notices of Exercise for) at least 30,000 square feet of Rentable Area of Offering Space(s) pursuant to this Section 9; or (iv) the expiration of the Extended Term.

(f)If Tenant does not deliver a Notice of Exercise for an Offering Space within the 15-day period specified in Section 9(b) above, then Landlord shall be free to lease the Offering Space to anyone to whom Landlord desires on substantially the same terms as stated in the Advice for such Offering Space for the nine (9)-month period following the expiration of such 15-day period (the “Offering Space Marketing Period”). If during the Offering Space Marketing Period, Landlord receives a bona fide offer to lease the Offering Space on terms that result in a net effective rent that is 93% or less than the terms stated in the Advice for such Offering Space, and Landlord desires to accept such bona fide offer to lease, then Landlord shall deliver a new Advice to Tenant that reflects such bona fide offer. Tenant may lease the Offering Space in its entirety only, under such revised terms, by delivering the Notice of Exercise within 15 days after the date of the new Advice. Landlord and Tenant acknowledge and agree that either Landlord’s leasing of the Offering Space to a third party pursuant to the terms set forth in the Advice, or the re-offering of the Offering Space to Tenant, in each case pursuant to this Section 9(f), shall be deemed an accurate determination of Fair Market Rent for the Offering Space.

(g)If Tenant exercises its Right of First Offer as to any of the Offering Spaces, Landlord shall prepare an amendment (the “Offering Amendment”) adding the subject Offering Space to the Premises on the terms set forth in the Advice and reflecting the changes in the Monthly Base Rent, Rentable Area of the Premises and other appropriate terms. A copy of the Offering Amendment shall be sent to Tenant within a reasonable time after Landlord’s receipt of the Notice of Exercise executed by Tenant, and Tenant shall execute and return the Offering Amendment to Landlord within 15 days thereafter, but an otherwise valid exercise of the Right of First Offer shall be fully effective whether or not the Offering Amendment is prepared and/or executed.

(h)Notwithstanding anything to the contrary contained herein, Tenant’s Right of First Offer is subject and subordinate to the expansion rights (whether such rights

5

are designated as a right of first offer, right of first refusal, expansion option or otherwise) of Bayer existing as of the date of this Amendment.

(i)Notwithstanding anything to the contrary contained herein, Tenant’s rights under this Section 9 are personal to the original Tenant executing this Amendment or a Permitted Transferee (“Named Tenant”) and shall not be assigned or assignable, in whole or in part, to any third-party. Any assignment or other transfer of such rights by Named Tenant shall be void and of no force or effect. Without limiting the generality of the foregoing, no sublessee of the Premises shall be permitted to exercise the rights granted to Tenant under this Section 9.

10.Renewal Option.

(a)Tenant shall have the option to renew the Term for one (1) additional term of ten (10) years (the “Renewal Option”), commencing upon expiration of the Extended Term (the “Renewal Term”). The Renewal Option must be exercised, if at all, by written notice given by Tenant to Landlord not earlier than fifteen (15) months nor later than twelve (12) months prior to expiration of the Extended Term, and must be exercised as to the entire Premises (as the same exists as of the date of exercise). If Tenant properly exercises the Renewal Option, references in the Lease to the Term shall be deemed to mean the Renewal Term, unless the context clearly provides otherwise. The Renewal Option shall be null and void and Tenant shall have no right to renew this Lease if on the date Tenant exercises the Renewal Option or on the date immediately preceding the commencement date of the Renewal Term a Default beyond the applicable cure period shall have occurred and be continuing hereunder.

(b)If Tenant properly exercises the Renewal Option, then during the Renewal Term, all of the terms and conditions set forth in the Lease as applicable to the Premises during the Extended Term shall apply during the Renewal Term, including without limitation the obligation to pay Operating Expenses and Taxes, except that (i) Tenant shall take the Premises in their then “as-is” state and condition and Landlord shall have no obligation to make or pay for any improvements to the Premises, and (ii) during the Renewal Term the Monthly Base Rent payable by Tenant shall be 100% of the monthly Fair Market Rent during the Renewal Term as hereinafter set forth.

(a)For purposes of this Section, the term “Fair Market Rent” shall mean the triple netrental rate periodic rental rate adjustment and other charges and increases, if any, for space comparable in size, location and quality of the Premises under primary lease (and not sublease) to new or renewing tenants, for a comparable term with a tenant improvement allowance and other concessions (including rent concessions), if applicable and taking into consideration such amenities as existing improvements, view, floor on which the Premises are situated and the like, situated in comparable buildings in Emeryville or Berkeley. The Fair Market Rent shall not take into account any Tenant Alterations paid for by Tenant.

(b)If Tenant properly exercises the Renewal Option to extend the term of the Lease, Landlord, by notice to Tenant not more than thirty (30) days after Tenant’s exercise of the Renewal Option, shall indicate Landlord’s determination of 100% of the Fair Market Rent. Tenant, within thirty (30) days after date on which Landlord provides such notice of 100% of the Fair Market Rent shall either (i) give Landlord final binding written notice (“Binding Notice”) of Tenant’s acceptance of Landlord’s determination of 100% of the Fair Market Rent, or (ii) if Tenant disagrees with Landlord’s determination, provide

6

Landlord with written notice of Tenant’s election to submit the Fair Market Rent to binding arbitration (the “Arbitration Notice”) . If Tenant fails to provide Landlord with either a Binding Notice or Arbitration Notice within such thirty (30) day period, Tenant shall have been deemed to have given the Binding Notice. If Tenant provides Landlord with a Binding Notice, Landlord and Tenant shall enter into the Renewal Amendment (as defined below) upon the terms and conditions set forth herein.

(c)If the parties are unable to agree upon the Fair Market Rent for the Premises within ten (10) days after Landlord’s receipt of the Arbitration Notice, Fair Market Rent as of commencement of the Renewal Term shall be determined as follows:

(i)Within twenty (20) days after receipt of Landlord’s notice specifying Fair Market Rent, Tenant, at its sole expense, shall obtain and deliver in writing to Landlord a determination of the Fair Market Rent for the Premises for a term equal to the Renewal Term from a broker or appraiser (“Tenant’s broker”) licensed in the State of California and engaged in the office and lab markets in Emeryville and Berkeley, California, for at least the immediately preceding five (5) years. If Landlord accepts such determination, Landlord shall provide written notice thereof within ten (10) days after Landlord’s receipt of such determination and the Base Rent for the Renewal Term shall be adjusted to an amount equal to 100% of the Fair Market Rent determined by Tenant’s broker. Landlord shall be deemed to have rejected Tenant’s determination if Landlord fails to respond within the ten (10) day period.

(ii)If Landlord provides notice that it does not accept such determination within twenty (20) days after receipt of the determination of Tenant’s broker, or is deemed to have rejected such determination, Landlord shall designate a broker or appraiser (“Landlord’s broker”) licensed in the State of California and possessing the qualifications set forth in (i) above. Landlord’s broker and Tenant’s broker shall name a third broker, similarly qualified and who is not then or has not previously acted for either party, within five (5) days after the appointment of Landlord’s broker (the “Neutral Broker”).

(iii)The Neutral Broker shall determine the Fair Market Rent for the Premises as of the commencement of the Renewal Term within fifteen (15) days after the appointment of the Neutral Broker by choosing the determination of the Landlord’s broker or the Tenant’s broker which is closer to its own determination of Fair Market Rent. The decision of the Neutral Broker shall be binding on Landlord and Tenant.

Landlord shall pay the costs and fees of Landlord’s broker in connection with any determination hereunder, and Tenant shall pay the costs and fees of Tenant’s broker in connection with such determination. The costs and fees of the Neutral Broker shall be paid one-half by Landlord and one-half by Tenant.

(d)If the amount of the Fair Market Rent has not been determined pursuant to this Section 10 as of the commencement of the Renewal Term, then Tenant shall continue to pay the Base Rent in effect at the expiration of the Extended Term until the amount of the Fair Market Rent is determined. When such determination is made, Tenant shall pay any deficiency to Landlord upon demand or Landlord shall credit any overage to Tenant.

11.Other Lease Revisions.

7

(a)Definition of Operating Expenses. Subpart (xiii), regarding costs associated with Hazardous Materials, is hereby deleted from the definition of exclusions from Operating Expenses in Section 1.3 of the Lease.

(b)Definition of Operating Expenses. The following is hereby added to the end of the definition of Taxes in Section 1.3 of the Lease:

Tenant and Landlord acknowledge that Proposition 13 was adopted by the voters of the State of California in the June 1978 election and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such purposes as fire protection, street, sidewalk, road, utility construction and maintenance, refuse removal and for other governmental services which may formerly have been provided without charge to property owners or occupants. It is the intention of the parties that all new and increased assessments, taxes, fees, levies and charges due to any cause whatsoever are to be included within the definition of Taxes for purposes of this Lease.

(c)Rent Adjustments – Estimated Statement of Operating Expenses. The following new paragraph is hereby added to the end of Section 4.1 of the Lease:

On or before the beginning of each calendar year or with Landlord’s Statement (as defined in Section 4.2 below), Landlord may estimate and notify Tenant in writing of its estimate of the amount of Operating Expenses and Taxes payable by Tenant for such calendar year. Prior to the first determination by Landlord of the amount of Operating Expenses and Taxes for the first calendar year, Landlord may estimate such amounts in the foregoing calculation. Landlord shall have the right from time to time during any calendar year to provide a new or revised estimate of Operating Expenses and/or Taxes and to notify Tenant in writing thereof, of corresponding adjustments in Tenant’s Rent Adjustment Deposit payable over the remainder of such year, and of the amount or revised amount due allocable to months preceding such change. The last estimate by Landlord shall remain in effect as the applicable Rent Adjustment Deposit unless and until Landlord notifies Tenant in writing of a change, which notice may be given by Landlord from time to time during any calendar year throughout the Term.

(d)Delays in Furnishing Services. The following sentence is hereby added to the end of Section 6.5 of the Lease: “Tenant hereby waives any benefits of any applicable existing or future Law, including the provisions of California Civil Code section 1932(1), permitting the termination of this Lease due to such interruption, failure or inability.”

(e)Intentionally Omitted

(f)ENERGY STAR Program. The following new Section 7.1(f) is hereby added to the end of Section 7.1:

(f)    Tenant agrees to use reasonable efforts to cooperate with Landlord and to comply with any and all guidelines or controls

8

concerning energy management and usage disclosure imposed upon Landlord by federal or state governmental organizations which is applicable to the Building, including, without limitation, the requirements of California’s Nonresidential Building Energy Use Disclosure Program, as more particularly specified in California Public Resources Code Sections 25402.10 et seq. and regulations adopted pursuant thereto, so long as such requirements do not limit Tenant’s ability to use the Premises for its intended purpose or materially increase the cost of occupancy. Further, Tenant hereby authorizes (and agrees that Landlord shall have the authority to authorize) any electric or gas utility company providing service to the Building to disclose from time to time so much of the data collected and maintained by it regarding Tenant’s energy consumption data as may be necessary to cause the Building to participate in the ENERGY STAR® Portfolio Manager system and similar programs; and Tenant further authorizes Landlord to disclose information concerning energy use by Tenant, either individually or in combination with the energy use of other tenants, as applicable as Landlord determines to be necessary to comply with applicable Laws pertaining to the Building or Landlord’s ownership thereof.

(g)Sudden Water Intrusion. The following new Section 8.3 is hereby added to the end of Article 8:

8.3    SUDDEN WATER INTRUSION.

    Notwithstanding anything in this Lease to the contrary, in the event of sudden water intrusion into the Premises, due to a leaking or bursting pipe or other water source, Landlord will have the right, but not the obligation, to undertake immediate mitigation and repairs measures (the “Water Damage Work”) of such nature as would normally be Tenant’s responsibility under Section 8.2 above and to notify Tenant promptly after the repairs have been undertaken (including notice by telephone, to the extent reasonably practicable). Landlord shall determine, in its sole and absolute discretion, the contractors to be used for the Water Damage Work, and Tenant will reimburse Landlord for the reasonable cost of the Water Damage Work, as additional Rent under this Lease, within 30 days following Tenant’s receipt of written demand from Landlord therefor.

(h)“All Risks” Property Insurance. The following phrase is hereby added to the end of Section 16.1(c): “from water damage, earthquake sprinkler leakage, and such other risks as Landlord may designate from time to time”.

(i)Exculpation. Section 25.8(ii)(a) of the Original Lease, as amended by the First Amendment, the Third Amendment and the Fifth Amendment, shall be further amended to mean and include the Tenant Improvement Allowance (as defined in the Work Agreement).

(j)Air Availability Fee. Section 7 of the Sixth Amendment is hereby amended to change “April 1, 2026” to “May 31, 2023”.

9

(k)Recapture. For avoidance of a doubt, Landlord’s Recapture Right relating to the Expansion Space as set forth in Section 2 of the Fourth Amendment has terminated and in no longer applicable to any portion of the Premises.

(l)Financial Statements: The following sentence is hereby added to the end of section 20.1(b): “Tenant need not provide the financial statements required under this Section 20.1(b) and shall be deemed to have satisfied the requirements of this Section 20.1(b), so long as such financial statements are publicly available free of charge.”

(m)Security System. Section 25.16 of the Lease is hereby deleted and replaced with the following:

    Landlord shall not be obligated to provide or maintain any security patrol or security system. Landlord shall not be liable in any manner to Tenant, or its agents, contractors, servants, employees, customers or invitees, for any acts (including criminal acts) of others, or for any direct, indirect, or consequential damages, or any injury or damage to, or interference with, Tenant’s business, including, but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, or other loss or damage, bodily injury or death, related to any malfunction, circumvention or other failure of any security program, or for the failure of any security program to prevent bodily injury, death, or property damage, or loss, or to apprehend any person suspected of causing such injury, death, damage or loss.

12.Inspection by a CASp in Accordance with Civil Code Section 1938. Pursuant to California Civil Code Section 1938, Landlord hereby notifies Tenant that as of the Effective Date, the Premises have not undergone inspection by a “Certified Access Specialist” (“CASp”) to determine whether the Premises meet all applicable construction-related accessibility standards under California Civil Code Section 55.53. Landlord hereby discloses pursuant to California Civil Code Section 1938 as follows: “A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.” Landlord and Tenant hereby acknowledge and agree that in the event that Tenant elects to perform a CASp inspection of the Premises hereunder (the “Inspection”), such Inspection shall be (a) performed at Tenant’s sole cost and expense, (b) limited to the Premises and (c) performed by a CASp who has been approved or designated by Landlord prior to the Inspection. Any Inspection must be performed in a manner which minimizes the disruption of business activities in the Building, and at a time reasonably approved by Landlord. Landlord reserves the right to be present during the Inspection. Tenant agrees to: (i) promptly provide to Landlord a copy of the report or certification prepared by the CASp inspector upon request (the “Report”), (ii) keep the information contained in the Report confidential, except to the extent required by Laws, or to the extent disclosure is needed in order to complete any necessary modifications or improvements required to comply with all

10

applicable accessibility standards under state or federal law, as well as any other repairs, upgrades, improvements, modifications or alterations required by the Report or that may be otherwise required to comply with applicable Regulations or accessibility requirements (the “Access Improvements”). Tenant shall be solely responsible for the cost of Access Improvements to the Premises or the Building necessary to correct any such violations of construction-related accessibility standards identified by such Inspection as required by Laws, which Access Improvements may, at Landlord’s option, be performed in whole or in part by Landlord at Tenant’s expense, payable as additional rent within ten (10) days following Landlord’s demand. The terms and conditions of this Section 12 shall apply only in the event Tenant conducts an Inspection; otherwise, the terms and conditions of the Lease, as amended, shall govern with respect to each of Landlord’s and Tenant’s liability for compliance with applicable Laws.

13.OFAC Representations. Tenant represents and warrants to Landlord that (a) each individual executing this Amendment on behalf of Tenant is authorized to do so on behalf of Tenant and that Tenant is not, and the entities or individuals constituting Tenant or which may own or control Tenant or which may be owned or controlled by Tenant are not, (i) in violation of any laws relating to terrorism or money laundering, or (ii) among the individuals or entities identified on any list compiled pursuant to Executive Order 13224 for the purpose of identifying suspected terrorists or on the most current list published by the U.S. Treasury Department Office of Foreign Assets Control at its official website, http://www.treas.gov/ofac/tllsdn.pdf or any replacement website or other replacement official publication of such list, and (b) Tenant shall not engage in any actions in violation of any such laws or associate with such individuals or entities during the Term of the Lease. Tenant hereby agrees to defend, indemnify and hold harmless Landlord from and against any and all claims, damages, losses, risks, liabilities and expenses (including attorney’s fees and costs) arising from or related to any breach of the foregoing representation and warranty.

14.Lease Status. As a material inducement to Landlord to enter into this Amendment, Tenant warrants, represents and certifies to Landlord that: (a) to the best of Tenant’s actual knowledge, Landlord is not in breach or default under the Lease, nor has any event occurred, which, with the passage of time or the giving of notice, or both, would constitute a breach of default by Landlord; (b) Landlord has fully performed all of Landlord’s construction obligations (if any) and paid any tenant improvement allowance (if any) owing to Tenant; (c) Tenant has accepted possession of the Premises; (d) Tenant does not have any defenses or offsets to payment of rent and performance of its obligations under the Lease as and when same becomes due; (e) no actions, whether voluntary of otherwise, are pending against Tenant under the bankruptcy laws of the United States or any state thereof; (f) Tenant has not assigned the Lease or subleased any portion of the Premises; and (g) the Lease, as amended by this Amendment, constitutes the complete agreement of Landlord and Tenant with respect to the Premises, and there are no other amendments, oral or written, to the Lease.

15.Confidentiality. Tenant agrees to keep the terms of the Lease and this Amendment confidential and shall not disclose same to any other person not a party hereto without the prior written consent of Landlord; however, Tenant may disclose the terms hereof to Tenant’s accountants, attorneys, managing employees, and others in privity with Tenant to the extent reasonably necessary for Tenant’s business purposes. The terms of this Lease may also be disclosed in response to a subpoena, court order or as otherwise required by law. Tenant agrees that a breach of this Section 15 will cause irreparable injury to Landlord and Landlord shall be entitled, together with all other remedies in law or equity

11

available to Landlord, to injunctive relief to restrain such breach.

16.Miscellaneous.

(a)This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements. Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless specifically set forth in this Amendment.

(b)Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.

(c)In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.

(d)Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant. Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant.

(e)The capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.

(f)Tenant hereby represents to Landlord that Tenant has dealt with no broker in connection with this Amendment other than Cushman & Wakefield (“Tenant’s Broker”). Landlord shall pay a fee to Tenant’s Broker (“Tenant’s Broker’s Commission”) pursuant to the terms of a separate agreement. Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents (collectively, the “Landlord Related Parties”) harmless from all claims of any brokers, including Tenant’s Broker (other than with regard to payment of Tenant’s Broker’s Commission), claiming to have represented Tenant in connection with this Amendment. Landlord hereby represents to Tenant that Landlord has dealt with no broker in connection with this Amendment. Landlord agrees to indemnify and hold Tenant, its members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such agents (collectively, the “Tenant Related Parties”) harmless from all claims of any brokers claiming to have represented Landlord in connection with this Amendment.

(g)This Amendment may be executed in counterparts each of which counterparts when taken together shall constitute one and the same agreement. Any facsimile, PDF or other electronic signature shall constitute a valid and binding method for executing this Amendment. Executed counterparts of this Amendment exchanged by facsimile transmission, PDF email, or other electronic means shall be fully enforceable.

12

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date set forth above.

LANDLORD:			TENANT:
ES EAST, LLC, a California limited liability company			AMYRIS, INC., a Delaware corporation By:     /s/ John Melo             Name:     John Melo             Its:     CEO
By:	ES East Associates, LLC, a California limited liability company, its Managing Member
	By:	Wareham-NZL, LLC, a California limited liability company, its Managing Member
	By:    /s/ Richard K. Robbins         Richard K. Robbins         its Manager

13

EX-10.02

FOURTH AMENDMENT
(5850 Hollis Street, Emeryville, California)

This Fourth Amendment (this “Amendment”), dated as of June 27, 2022, is entered into by and between EMERYSTATION TRIANGLE, LLC, a California limited liability company (“Landlord”), and AMYRIS, INC., a Delaware corporation (“Tenant”).

Recitals

A.Landlord and Tenant (as successor-in-interest to Amyris Biotechnologies, Inc., a California corporation) entered into that certain Lease dated April 25, 2008, as amended by that certain letter dated April 25, 2008, that certain Second Amendment to Lease dated February 5, 2010, and that certain Third Amendment to Lease dated May 1, 2013 (collectively, the “Lease”), whereby Tenant leases certain space agreed to contain 22,565 square feet of Rentable Area (the “Original Premises”) on the first floor of the building located at 5850 Hollis Street, Emeryville, California (the “Building”).

B.Tenant has requested that additional space agreed to contain 16,638 square feet of Rentable Area on the first floor of the Building shown on Exhibit A hereto (the “Expansion Space”) be added to the Premises and that the Lease be appropriately amended, and Landlord is willing to do the same on the following terms and conditions.

C.The current Term of the Lease expires as of April 30, 2023 (the “Prior Expiration Date”), and the parties now desire to extend the Term of the Lease, on the following terms and conditions.

NOW THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the parties agree as follows:

Agreement

1.Definitions; Recitals. Unless otherwise specified herein, all capitalized terms used in this Amendment are used as defined in the Lease. The parties acknowledge the truthfulness of the foregoing Recitals, which are hereby incorporated into this Amendment.

2.Inconsistencies. To the extent that there are any inconsistencies between the terms of the Lease and this Amendment, the terms of this Amendment shall control.

3.Expansion. Effective as of the Expansion Effective Date (defined below), the Premises, as defined in the Lease, is increased from 22,565 square feet of Rentable Area on the first floor to 39,203 square feet of Rentable Area on the first floor by the addition of the Expansion Space, and from and after the Expansion Effective Date, the Original Premises and the Expansion Space, collectively, shall be deemed the Premises, as defined in the Lease, and shall comprise the entirety of the Building. The Term for the Expansion Space shall commence on the Expansion Effective Date and end on the Extended Expiration Date (as hereinafter defined). The Expansion Space is subject to all the terms and conditions of the Lease except as expressly modified herein and except that Tenant shall not be entitled to receive any allowances, abatements or other financial concessions granted with respect to the Original Premises unless such concessions are expressly provided for herein with respect to the Expansion Space.

(a)The “Expansion Effective Date” shall be the earlier of (i) thirty (30) days after the date Landlord delivers the Expansion Space to Tenant, which date is projected to be between July 1, 2022 and October 31, 2022, as further described in Section 3(b) below (the “Target Expansion Delivery Date Window”); or (ii) the date Tenant commences business

1

operations (as opposed to commencing construction of the Tenant Work, as defined in the Work Agreement attached as Exhibit B hereto; the “Work Agreement”) in the Expansion Space.

(b)The Expansion Space currently is occupied by Zymergen Inc., a Delaware corporation (“Zymergen”), pursuant to the terms of the certain Lease dated March 20, 2017 (as amended, the “Zymergen Lease”), by and between Landlord, as landlord, and Zymergen, as tenant. Pursuant to the terms of the Zymergen Lease, Zymergen has agreed to surrender the Expansion Space to Landlord during the Target Expansion Delivery Date Window, with the exact date to be specified in a 30-day written notice from Zymergen to Landlord (the “Zymergen Termination Notice”). The Expansion Effective Date shall be delayed to the extent that Landlord fails to deliver possession of the Expansion Space for any reason, including but not limited to, Zymergen’s failure to deliver the Zymergen Termination Notice or holding over by Zymergen. Any such delay in the Expansion Effective Date shall not subject Landlord to any liability for any loss or damage resulting therefrom. Landlord shall use commercially reasonable efforts to evict Zymergen (pursuant to Landlord’s rights under the Zymergen Lease) if Zymergen (i) fails to timely delivery the Zymergen Termination Notice, or (ii) holds over in the Expansion Space beyond the date specified in the Zymergen Termination Notice. Landlord hereby agrees to not extend the term of the Zymergen Lease, and shall notify Zymergen of the existence of this Amendment after full execution hereof. If the Expansion Effective Date is delayed, the Extended Expiration Date shall not be similarly extended.

(c)Notwithstanding the provisions of Section 3(b) above to the contrary, if the Expansion Space is not delivered to Tenant by June 1, 2023 (the “Outside Expansion Space Delivery Date”), then Tenant may, at its option, by notice in writing (the “Expansion Space Termination Notice”) within thirty (30) days after the Outside Expansion Space Delivery Date terminate Tenant’s lease of the Expansion Space pursuant to this Amendment, in which event Landlord and Tenant shall be discharged from all obligations hereunder as to the Expansion Space only; Tenant’s obligations for the Original Premises for the Extended Term (as defined in Section 4 below) shall remain, and the Tenant Improvement Allowance (as defined in the Work Agreement) will be reduced to $575,593.71, the $424,406.29 reduction in the Tenant Improvement Allowance Landlord and Tenant acknowledge and agree was in consideration for Tenant leasing the Expansion Space. Notwithstanding the foregoing, Landlord may void the Expansion Space Termination Notice if Landlord actually delivers the Expansion Space to Tenant within thirty (30) days after Landlord’s receipt of the Expansion Space Termination Notice. If the Expansion Space Termination Notice is not received by Landlord within the thirty (30) day period specified above, Tenant’s right to cancel its lease of the Expansion Space as to such period shall terminate. The remedy set forth above shall be Tenant’s sole remedy in the event of a delay in delivering possession of the Expansion Space to Tenant. In no event shall Landlord be liable for special or consequential damages as a result of any such delay.

(d)At Landlord’s option, promptly after the determination of the Expansion Effective Date, Landlord and Tenant shall execute and deliver a commencement letter in the form attached hereto as Exhibit C (the “Expansion Effective Date Letter”). Tenant’s failure to execute and return the Expansion Effective Date Letter, or to provide written objection to the statements contained in the Expansion Effective Date Letter, within thirty (30) days after the date such Expansion Effective Date Letter is delivered to Tenant, if at all, shall be deemed an approval by Tenant of the statements contained therein.

4.Extension. The Term of the Lease is hereby extended for a period of 181 months and shall expire on May 31, 2038 (the “Extended Expiration Date”), unless sooner terminated in accordance with the terms of the Lease. That portion of the Term commencing the day immediately following the Prior Expiration Date (the “Extension Date”) and ending on the Extended Expiration Date shall be referred to herein as the “Extended Term”.

2

5.Monthly Base Rent.

(a)Original Premises Through Prior Termination Date. The Monthly Base Rent, additional Rent and all other charges under the Lease shall be payable as provided therein with respect to the Original Premises through and including the Prior Termination Date.

All such Monthly Base Rent shall be payable by Tenant in accordance with the terms of the Lease.

(b)Expansion Space From Expansion Effective Date Through Extended Expiration Date. As of the Expansion Effective Date, the schedule of Monthly Base Rent payable with respect to the Expansion Space for the balance of the original Term and the Extended Term is the following:

Months Following Expansion Effective Date	Monthly Base Rent	Monthly Base Rent Rate (approx.)
Months 01 – 12	$83,190.00*	$5.00
Months 13 – 24	$86,101.65	$5.18
Months 25 – 36	$89,115.21	$5.36
Months 37 – 48	$92,234.24	$5.54
Months 49 – 60	$95,462.44	$5.74
Months 61 – 72	$98,803.63	$5.94
Months 73 – 84	$102,261.76	$6.15
Months 85 – 96	$105,840.92	$6.36
Months 97 – 108	$109,545.35	$6.58
Months 109 – 120	$113,375.44	$6.81
Months 121 – 132	$117,343.58	$7.05
Months 133 – 144	$121,450.61	$7.30
Months 145 – 156	$125,701.38	$7.56
Months 157 – 168	$130,100.93	$7.82
Months 169 – 180	$134,654.46	$8.09
Months 181 – 05/31/38	$139,367.37	$8.38

*Monthly Base Rent, but not Operating Expenses or Taxes, shall be abated for the first three (3) months after the Expansion Effective Date (the “Abated Base Rent”). If the Expansion Effective Date is other than the first day of a month, Tenant shall pay the prorata amount of Monthly Base Rent due for the month containing the date which is three (3) months after the Expansion Effective Date in advance on the first date of such month, and full Monthly Base Rent starting the next month and continuing thereafter.

(c)Original Premises From Extension Date Through Extended Expiration Date. As of the Extension Date, the schedule of Monthly Base Rent payable with respect to the Original Premises during the Extended Term is the following: [Confirm rental rates]

3

Months Following Expansion Effective Date	Monthly Base Rent	Monthly Base Rent Rate (approx.)
Expansion Effective Date – 04/30/23	$45,806.95	$2.03
05/01/23 – Month 12	$112,825.00	$5.00
Months 13 – 24	$116,773.86	$5.18
Months 25 – 36	$120,860.97	$5.36
Months 37 – 48	$125,091.10	$5.54
Months 49 – 60	$129,469.29	$5.74
Months 61 – 72	$134,000.72	$5.94
Months 73 – 84	$138,690.75	$6.15
Months 85 – 96	$143,544.93	$6.36
Months 97 – 108	$148,569.00	$6.58
Months 109 – 120	$153,768.92	$6.81
Months 121 – 132	$159,150.83	$7.05
Months 133 – 144	$164,721.11	$7.30
Months 145 – 156	$170,486.35	$7.56
Months 157 – 168	$176,453.37	$7.82
Months 169 – 180	$182,629.24	$8.09
Months 181 – 05/31/38	$189,021.26	$8.38

All such Monthly Base Rent shall be payable by Tenant in accordance with the terms of the Lease.

Landlord and Tenant acknowledge that the foregoing schedules are based on the assumption that the Expansion Effective Date is September 1, 2022. If the Expansion Effective Date is other than September 1, 2022, the schedules set forth above with respect to the payment of any installment(s) of Monthly Base Rent for the Original Premises and the Expansion Space shall be appropriately adjusted on a per diem basis to reflect the actual Expansion Effective Date, and the actual Base Rent schedules shall be as set forth in the Expansion Effective Date Letter.

6.Tenant’s Share. For the period commencing with the Expansion Effective Date and ending on the Extended Expiration Date, Tenant’s Share for the Original Premises and the Expansion Space is 100%.

7.Operating Expenses and Taxes.

(a)Original Premises for the Extended Term. For the period commencing with the Extension Date and ending on the Extended Expiration Date, Tenant shall pay for Tenant’s Share of Operating Expenses and Taxes applicable to the Original Premises in accordance with the terms of the Lease.

(b)Expansion Space From Expansion Effective Date Through Extended Expiration Date. For the period commencing with the Expansion Effective Date and ending on the Extended Expiration Date, Tenant shall pay for Tenant’s Share of Operating Expenses and Taxes applicable to the Expansion Space in accordance with the terms of the Lease.

4

8.Letter of Credit. The definition of Letter of Credit in Section 1.3 of the Lease, as well as Sections 5(a) and 5(b) of the Lease, are hereby deleted and replaced with the following:

(a)Concurrently with its execution of this Amendment, Tenant shall deliver to Landlord, as protection for the full and faithful performance by Tenant of all of its obligations under the Lease and for all losses and damages Landlord may suffer (or that Landlord reasonably estimates it may suffer) as a result of any breach, default or failure to perform by Tenant under the Lease, an irrevocable and unconditional negotiable standby Letter of Credit (the “Letter of Credit”), in the form as is reasonably acceptable to Landlord, payable at an office in the San Francisco Bay Area, California, running in favor of Landlord and issued by a solvent, nationally recognized bank with a long term rating of BBB or higher, under the supervision of the Superintendent of Banks of the State of California, or a national banking association (an “Acceptable Issuing Bank”), in the amount of $392,030.00 (the “Letter of Credit Amount”). The Letter of Credit shall expire not later than sixty (60) days after the Extended Expiration Date. Tenant shall pay all expenses, points, or fees incurred by Tenant in obtaining the Letter of Credit and any replacement Letter of Credit. If an Acceptable Issuing Bank is declared insolvent or taken over by the Federal Deposit Insurance Corporation or any governmental agency for any reason or does not meet the standards to be approved an Acceptable Issuing Bank, Tenant shall deliver a replacement Letter of Credit from another Bank reasonably approved by Landlord that meets the standards for an Acceptable Issuing Bank within the earlier of (i) ninety (90) days after notice from Landlord that the Bank does not meet the standard for an Acceptable Issuing Bank, or (ii) the date the Bank is declared insolvent or taken over for any reason by the Federal Deposit Insurance Corporation or any other governmental agency. Landlord acknowledges and agrees that a letter of credit in the form attached as Exhibit E to this Amendment shall comply with the requirements of this Section 8. Within five (5) business days after receiving the Letter of Credit in the Letter of Credit amount from Tenant, Landlord shall relinquish to Tenant or Tenant’s issuing bank any existing letters of credit that it holds in connection with the Lease.

(b)The Letter of Credit shall also provide that Landlord, its successors, and assigns, may, at any time and without notice to Tenant and without first obtaining Tenant’s consent, transfer (one or more times) all of its interest in and to the Letter of Credit to another party, person, or entity, provided such transferee is the assignee of the Landlord’s rights and interests in and to the Lease and expressly assumes the same and Landlord’s obligations under the Lease, or to any lender providing financing to Landlord. In connection with any such transfer of the Letter of Credit by Landlord, Tenant shall execute and submit to the Bank such applications, documents, and instruments as may be necessary to effectuate such transfer, and Tenant shall be responsible for paying the Bank’s transfer and processing fees in connection with any such transfer.

(c)If, as a result of any drawing by Landlord on the Letter of Credit pursuant to the terms thereof, the amount of the Letter of Credit shall be less than the Letter of Credit Amount, Tenant shall, within ten (10) business days after the drawdown by Landlord and notice thereof to Tenant, take such actions as are required to restore the Letter of Credit Amount, which may include providing a replacement Letter of Credit for the full Letter of Credit Amount, provided such additional Letter(s) of Credit or replacement Letter of Credit comply with the applicable requirements of this Article 5 and all subsections thereof of the Lease.

(d)Tenant covenants and warrants that it will neither assign nor encumber the Letter of Credit or any part of it and that neither Landlord nor its successors or assigns will be bound by any such assignment, encumbrance, attempted assignment, or attempted encumbrance. Without limiting the generality of the foregoing, if the Letter of Credit expires earlier than the Expiration Date, Landlord will accept a renewal of the letter of credit (such renewal letter of credit to be in effect and delivered to Landlord, as applicable, not later than forty-five (45) days before the expiration of the Letter of Credit), which shall be irrevocable and automatically

5

renewable as required above through the Expiration Date on the same terms as the expiring Letter of Credit or such other terms as may be acceptable to Landlord in its sole discretion. However, if the Letter of Credit is not timely renewed, or if Tenant fails to maintain the Letter of Credit in the amount and in accordance with the terms set forth in this Article 5, Landlord shall have the right to present the Letter of Credit to the Bank to draw on the Letter of Credit, and the proceeds of the Letter of Credit may be applied by Landlord against any Rent payable by Tenant under the Lease that is not paid when due and to pay for all losses and damages that Landlord has suffered or that Landlord reasonably estimates that it will suffer as a result of any breach or default by Tenant under the Lease.

(e)Tenant acknowledges and agrees that Landlord is entering into the Lease in material reliance on the ability of Landlord to draw on the Letter of Credit on the occurrence of any breach, default or failure to perform on the part of Tenant under the Lease. If Tenant shall breach or fail to perform any provision of the Lease or otherwise be in default under the Lease, Landlord may, but without obligation to do so, and without notice to Tenant, draw on the Letter of Credit, in part or in whole, to cure any breach or default of Tenant and to compensate Landlord for any and all damages of any kind or nature sustained or which Landlord reasonably estimates that it will sustain resulting from Tenant’s breach or default and to which Landlord is entitled under the Lease, including any damages that accrue upon termination of the Lease under the Lease and/or Section 1951.2 of the California Civil Code or any similar provision.

9.Improvements to Expansion Space.

(a)Condition of Expansion Space. Tenant has inspected the Expansion Space and agrees to accept the same “as is” without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment. Notwithstanding the foregoing to the contrary, Landlord shall cause Zymergen to decommission and decontaminate the Expansion Space in accordance with the terms of the Zymergen Lease, and Landlord shall delivery a copy of such decommissioning and decontamination report to Tenant prior to the Expansion Effective Date.

(b)Responsibility for Improvements to Expansion Space. Tenant may perform improvements to the Expansion Space in accordance with the Work Agreement, and Tenant shall be entitled to an improvement allowance in connection with such work as more fully described in the Work Agreement.

10.Early Access to Expansion Space. [Intentionally omitted.]

11.Parking. Tenant previously had the right to lease up to 16 unreserved parking spaces in the EmeryStation East project (5885 Hollis) pursuant to Sections 1.1(12) and 2.7 of the Original Lease. As of the Expansion Effective Date, Tenant shall have the right to lease up to forty (40) total unreserved parking spaces within a parking garage(s) or lot(s) located on or in properties owned by Landlord or Landlord’s affiliates, at the then-current parking rates charged in such garage(s) or lot(s), pursuant to a commercially reasonable form of separate agreement or agreements executed by and between Tenant and Landlord or such Landlord’s affiliates within thirty (30) days of the date of full execution and delivery of this Amendment.

12.Furniture, Fixtures and Equipment. As of the Expansion Effective Date, and during the balance of the Term, at no charge to Tenant, Tenant shall be permitted to use the fixtures and equipment located in the Expansion Effective as of the Expansion Effective Date and described in more particular detail in Exhibit D attached hereto (the “FF&E”). Tenant shall accept the FF&E in its current “AS-IS” condition and “WITH ALL FAULTS”; Landlord specifically disclaims all express or implied warranties regarding the existence or condition of,

6

such FF&E, including without limitation the implied warranties of merchantability and suitability for a particular purpose. If the HVAC system serving the Expansion Space fails and cannot be repaired within the first ten (10) years after the Expansion Effective Date, Landlord shall replace such failed system at Landlord’s initial cost, with such cost to be amortized over the useful life of such replaced component and reimbursed 100% by Tenant through inclusion in Operating Expenses after such replacement occurs. Title to the FF&E shall pass to Tenant (without any warranty or representation whatsoever) as of the Expansion Effective Date, and upon the expiration or earlier termination of the Lease, Tenant shall remove the FF&E from the Expansion Space in accordance with Section 12.1 of the Lease.

13.Renewal Option.

(a)Tenant shall have the option to renew the Term for one (1) additional term of ten (10) years (the “Renewal Option”), commencing upon expiration of the Extended Term (the “Renewal Term”). The Renewal Option must be exercised, if at all, by written notice given by Tenant to Landlord not earlier than fifteen (15) months nor later than twelve (12) months prior to expiration of the Extended Term, and must be exercised as to the entire Premises (as the same exists as of the date of exercise). If Tenant properly exercises the Renewal Option, references in the Lease to the Term shall be deemed to mean the Renewal Term, unless the context clearly provides otherwise. The Renewal Option shall be null and void and Tenant shall have no right to renew the Lease if on the date Tenant exercises the Renewal Option or on the date immediately preceding the commencement date of the Renewal Term a Default beyond the applicable cure period shall have occurred and be continuing hereunder.

(b)If Tenant properly exercises the Renewal Option, then during the Renewal Term, all of the terms and conditions set forth in the Lease as applicable to the Premises during the Extended Term shall apply during the Renewal Term, including without limitation the obligation to pay Operating Expenses and Taxes, except that (i) Tenant shall take the Premises in their then “as-is” state and condition and Landlord shall have no obligation to make or pay for any improvements to the Premises, and (ii) during the Renewal Term the Monthly Base Rent payable by Tenant shall be 100% of the monthly Fair Market Rent during the Renewal Term as hereinafter set forth.

(c)For purposes of this Section, the term “Fair Market Rent” shall mean the triple net rental rate, periodic rental rate adjustment and other charges and increases, if any, for space comparable in size, location and quality of the Premises under primary lease (and not sublease) to new or renewing tenants, for a comparable term with a tenant improvement allowance and other concessions (including rent concessions), if applicable and taking into consideration such amenities as existing improvements, view, floor on which the Premises are situated and the like, situated in comparable buildings in Emeryville or Berkeley. The Fair Market Rent shall not take into account any Tenant Alterations paid for by Tenant.

(d)If Tenant properly exercises the Renewal Option to extend the term of the Lease, Landlord, by notice to Tenant not more than thirty (30) days after Tenant’s exercise of the Renewal Option, shall indicate Landlord’s determination of 100% of the Fair Market Rent. Tenant, within thirty (30) days after date on which Landlord provides such notice of 100% of the Fair Market Rent shall either (i) give Landlord final binding written notice (“Binding Notice”) of Tenant’s acceptance of Landlord’s determination of 100% of the Fair Market Rent, or (ii) if Tenant disagrees with Landlord’s determination, provide Landlord with written notice of Tenant’s election to submit the Fair Market Rent to binding arbitration (the “Arbitration Notice”) . If Tenant fails to provide Landlord with either a Binding Notice or Arbitration Notice within such thirty (30) day period, Tenant shall have been deemed to have given the Binding Notice. If Tenant provides Landlord with a Binding Notice, Landlord and Tenant shall enter into the Renewal Amendment (as defined below) upon the terms and conditions set forth herein.

7

(e)If the parties are unable to agree upon the Fair Market Rent for the Premises within ten (10) days after Landlord’s receipt of the Arbitration Notice, Fair Market Rent as of commencement of the Renewal Term shall be determined as follows:

(i)Within twenty (20) days after receipt of Landlord’s notice specifying Fair Market Rent, Tenant, at its sole expense, shall obtain and deliver in writing to Landlord a determination of the Fair Market Rent for the Premises for a term equal to the Renewal Term from a broker or appraiser (“Tenant’s broker”) licensed in the State of California and engaged in the office and lab markets in Emeryville and Berkeley, California, for at least the immediately preceding five (5) years. If Landlord accepts such determination, Landlord shall provide written notice thereof within ten (10) days after Landlord’s receipt of such determination and the Base Rent for the Renewal Term shall be adjusted to an amount equal to 100% of the Fair Market Rent determined by Tenant’s broker. Landlord shall be deemed to have rejected Tenant’s determination if Landlord fails to respond within the ten (10) day period.

(ii)If Landlord provides notice that it does not accept such determination within twenty (20) days after receipt of the determination of Tenant’s broker, broker, or is deemed to have rejected such determination, Landlord shall designate a broker or appraiser (“Landlord’s broker”) licensed in the State of California and possessing the qualifications set forth in (i) above. Landlord’s broker and Tenant’s broker shall name a third broker, similarly qualified and who is not then or has not previously acted for either party, within five (5) days after the appointment of Landlord’s broker (the “Neutral Broker”).

(iii)The Neutral Broker shall determine the Fair Market Rent for the Premises as of the commencement of the Renewal Term within fifteen (15) days after the appointment of the Neutral Broker by choosing the determination of the Landlord’s broker or the Tenant’s broker which is closer to its own determination of Fair Market Rent. The decision of the Neutral Broker shall be binding on Landlord and Tenant.

Landlord shall pay the costs and fees of Landlord’s broker in connection with any determination hereunder, and Tenant shall pay the costs and fees of Tenant’s broker in connection with such determination. The costs and fees of the Neutral Broker shall be paid one-half by Landlord and one-half by Tenant.

(f)    If the amount of the Fair Market Rent has not been determined pursuant to this Section 10 as of the commencement of the Renewal Term, then Tenant shall continue to pay the Base Rent in effect at the expiration of the Extended Term until the amount of the Fair Market Rent is determined. When such determination is made, Tenant shall pay any deficiency to Landlord upon demand or Landlord shall credit any overage to Tenant.

14.Premises “As-Is”. Tenant is in possession of the Original Premises and accepts the same “as is” without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment.

15.Other Lease Revisions.

(a)Definition of Operating Expenses. Subpart (xiii), regarding costs associated with Hazardous Materials, is hereby deleted from the definition of exclusions from Operating Expenses in Section 1.3 of the Lease.

(b)Definition of Operating Expenses. The following is hereby added to the end of the definition of Taxes in Section 1.3 of the Lease:

8

Tenant and Landlord acknowledge that Proposition 13 was adopted by the voters of the State of California in the June, 1978 election and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such purposes as fire protection, street, sidewalk, road, utility construction and maintenance, refuse removal and for other governmental services which may formerly have been provided without charge to property owners or occupants. It is the intention of the parties that all new and increased assessments, taxes, fees, levies and charges due to any cause whatsoever are to be included within the definition of Taxes for purposes of this Lease.

(c)Expansion Options. Sections 2.7 and 2.8 of the Lease are hereby terminated and of no further force or effect.

(d)Surrender Obligations. Section 12.1 of the Original Lease is hereby amended to add that, upon the expiration or earlier termination of the Lease (as amended hereby), Tenant shall have no obligation to remove the Tenant Work (as defined in Work Agreement) or any portion thereof nor any of the existing improvements or the Required Removables, provided that the Tenant Work is constructed in substantial conformance with the Construction Drawings (as defined in the Work Agreement).

(e)Rent Adjustments – Estimated Statement of Operating Expenses. The following new paragraph is hereby added to the end of Section 4.1 of the Lease:

    (5)    On or before the beginning of each calendar year or with Landlord’s Statement (as defined in Section 4.2 below), Landlord may estimate and notify Tenant in writing of its estimate of the amount of Operating Expenses and Taxes payable by Tenant for such calendar year. Prior to the first determination by Landlord of the amount of Operating Expenses and Taxes for the first calendar year, Landlord may estimate such amounts in the foregoing calculation. Landlord shall have the right from time to time during any calendar year to provide a new or revised estimate of Operating Expenses and/or Taxes and to notify Tenant in writing thereof, of corresponding adjustments in Tenant’s Rent Adjustment Deposit payable over the remainder of such year, and of the amount or revised amount due allocable to months preceding such change. The last estimate by Landlord shall remain in effect as the applicable Rent Adjustment Deposit unless and until Landlord notifies Tenant in writing of a change, which notice may be given by Landlord from time to time during any calendar year throughout the Term.

(f)Delays in Furnishing Services. The following sentence is hereby added to the end of Section 6.4 of the Lease: “Tenant hereby waives any benefits of any applicable existing or future Law, including the provisions of California Civil Code section 1932(1), permitting the termination of this Lease due to such interruption, failure or inability.” [Discuss with Cushman]

(g)Intentionally Omitted.

(h)ENERGY STAR Program. The following new Section 7.1(f) is hereby added to the end of Section 7.1:

(f)    Tenant agrees to use reasonable efforts to cooperate with Landlord and to comply with any and all guidelines or controls concerning energy

9

management and usage disclosure imposed upon Landlord by federal or state governmental organizations which is applicable to the Building, including, without limitation, the requirements of California’s Nonresidential Building Energy Use Disclosure Program, as more particularly specified in California Public Resources Code Sections 25402.10 et seq. and regulations adopted pursuant thereto, so long as such requirements do not limit Tenant’s ability to use the Premises for its intended purpose or materially increase the cost of occupancy. Further, Tenant hereby authorizes (and agrees that Landlord shall have the authority to authorize) any electric or gas utility company providing service to the Building to disclose from time to time so much of the data collected and maintained by it regarding Tenant’s energy consumption data as may be necessary to cause the Building to participate in the ENERGY STAR® Portfolio Manager system and similar programs; and Tenant further authorizes Landlord to disclose information concerning energy use by Tenant, either individually or in combination with the energy use of other tenants, as applicable as Landlord determines to be necessary to comply with applicable Laws pertaining to the Building or Landlord’s ownership thereof.

(i)Sudden Water Intrusion. The following new Section 8.3 is hereby added to the end of Article 8:

8.3    SUDDEN WATER INTRUSION.

    Notwithstanding anything in this Lease to the contrary, in the event of sudden water intrusion into the Premises, due to a leaking or bursting pipe or other water source, Landlord will have the right, but not the obligation, to undertake immediate mitigation and repairs measures (the “Water Damage Work”) of such nature as would normally be Tenant’s responsibility under Section 8.2 above and to notify Tenant promptly after the repairs have been undertaken (including notice by telephone, to the extent reasonably practicable). Landlord shall determine, in its sole and absolute discretion, the contractors to be used for the Water Damage Work, and Tenant will reimburse Landlord for the reasonable cost of the Water Damage Work, as additional Rent under this Lease, within 30 days following Tenant’s receipt of written demand from Landlord therefor.

(j)“All Risks” Property Insurance. The following phrase is hereby added to the end of Section 16.1(c): “from water damage, earthquake sprinkler leakage, and such other risks as Landlord may designate from time to time”.

(k)Financial Statements: The following sentence is hereby added to the end of section 20.1(b): “Tenant need not provide the financial statements required under this Section 20.1(b) and shall be deemed to have satisfied the requirements of this Section 20.1(b), so long as such financial statements are publicly available free of charge.”

(l)Relocation. Article 21 of the Lease is hereby deleted.

(m)Security System. Section 25.16 of the Lease is hereby deleted and replaced with the following:

    Landlord shall not be obligated to provide or maintain any security patrol or security system. Landlord shall not be liable in any manner to

10

Tenant, or its agents, contractors, servants, employees, customers or invitees, for any acts (including criminal acts) of others, or for any direct, indirect, or consequential damages, or any injury or damage to, or interference with, Tenant’s business, including, but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, or other loss or damage, bodily injury or death, related to any malfunction, circumvention or other failure of any security program, or for the failure of any security program to prevent bodily injury, death, or property damage, or loss, or to apprehend any person suspected of causing such injury, death, damage or loss.

(n)Exculpation. Section 25.8(ii)(a) of the Original Lease shall be amended to mean and include the Tenant Improvement Allowance (as defined in the Work Agreement).

16.Inspection by a CASp in Accordance with Civil Code Section 1938. Pursuant to California Civil Code Section 1938, Landlord hereby notifies Tenant that as of the Effective Date, the Premises have not undergone inspection by a “Certified Access Specialist” (“CASp”) to determine whether the Premises meet all applicable construction-related accessibility standards under California Civil Code Section 55.53. Landlord hereby discloses pursuant to California Civil Code Section 1938 as follows: “A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.” Landlord and Tenant hereby acknowledge and agree that in the event that Tenant elects to perform a CASp inspection of the Premises hereunder (the “Inspection”), such Inspection shall be (a) performed at Tenant’s sole cost and expense, (b) limited to the Premises and (c) performed by a CASp who has been approved or designated by Landlord prior to the Inspection. Any Inspection must be performed in a manner which minimizes the disruption of business activities in the Building, and at a time reasonably approved by Landlord. Landlord reserves the right to be present during the Inspection. Tenant agrees to: (i) promptly provide to Landlord a copy of the report or certification prepared by the CASp inspector upon request (the “Report”), (ii) keep the information contained in the Report confidential, except to the extent required by Laws, or to the extent disclosure is needed in order to complete any necessary modifications or improvements required to comply with all applicable accessibility standards under state or federal law, as well as any other repairs, upgrades, improvements, modifications or alterations required by the Report or that may be otherwise required to comply with applicable Regulations or accessibility requirements (the “Access Improvements”). Tenant shall be solely responsible for the cost of Access Improvements to the Premises or the Building necessary to correct any such violations of construction-related accessibility standards identified by such Inspection as required by Laws, which Access Improvements may, at Landlord’s option, be performed in whole or in part by Landlord at Tenant’s expense, payable as additional rent within ten (10) days following Landlord’s demand. The terms and conditions of this Section 16 shall apply only in the event Tenant conducts an Inspection; otherwise, the terms and conditions of the Lease, as amended, shall govern with respect to each of Landlord’s and Tenant’s liability for compliance with applicable Laws.

17.OFAC Representations. Tenant represents and warrants to Landlord that (a) each individual executing this Amendment on behalf of Tenant is authorized to do so on behalf of Tenant and that Tenant is not, and the entities or individuals constituting Tenant or which may

11

own or control Tenant or which may be owned or controlled by Tenant are not, (i) in violation of any laws relating to terrorism or money laundering, or (ii) among the individuals or entities identified on any list compiled pursuant to Executive Order 13224 for the purpose of identifying suspected terrorists or on the most current list published by the U.S. Treasury Department Office of Foreign Assets Control at its official website, http://www.treas.gov/ofac/tllsdn.pdf or any replacement website or other replacement official publication of such list, and (b) Tenant shall not engage in any actions in violation of any such laws or associate with such individuals or entities during the Term of the Lease. Tenant hereby agrees to defend, indemnify and hold harmless Landlord from and against any and all claims, damages, losses, risks, liabilities and expenses (including attorney’s fees and costs) arising from or related to any breach of the foregoing representation and warranty.

18.Lease Status. As a material inducement to Landlord to enter into this Amendment, Tenant warrants, represents and certifies to Landlord that: (a) to the best of Tenant’s actual knowledge, Landlord is not in breach or default under the Lease, nor has any event occurred, which, with the passage of time or the giving of notice, or both, would constitute a breach of default by Landlord; (b) Landlord has fully performed all of Landlord's construction obligations (if any) and paid any tenant improvement allowance (if any) owing to Tenant; (c) Tenant has accepted possession of the Original Premises; (d) Tenant does not have any defenses or offsets to payment of rent and performance of its obligations under the Lease as and when same becomes due; (e) no actions, whether voluntary of otherwise, are pending against Tenant under the bankruptcy laws of the United States or any state thereof; (f) Tenant has not assigned the Lease or subleased any portion of the Original Premises; and (g) the Lease, as amended by this Amendment, constitutes the complete agreement of Landlord and Tenant with respect to the Original Premises and the Expansion Space, and there are no other amendments, oral or written, to the Lease.

19.Confidentiality. Tenant agrees to keep the terms of the Lease and this Amendment confidential and shall not disclose same to any other person not a party hereto without the prior written consent of Landlord; however, Tenant may disclose the terms hereof to Tenant’s accountants, attorneys, managing employees, and others in privity with Tenant to the extent reasonably necessary for Tenant’s business purposes. The terms of this Lease may also be disclosed in response to a subpoena, court order or as otherwise required by law. Tenant agrees that a breach of this Section 15 will cause irreparable injury to Landlord and Landlord shall be entitled, together with all other remedies in law or equity available to Landlord, to injunctive relief to restrain such breach.

20.Miscellaneous.

(a)This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements. Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless specifically set forth in this Amendment.

(b)Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.

(c)In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.

12

(d)Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant. Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant.

(e)The capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.

(f)Tenant hereby represents to Landlord that Tenant has dealt with no broker in connection with this Amendment other than Cushman & Wakefield (“Tenant’s Broker”). Landlord shall pay a fee to Tenant’s Broker (“Tenant’s Broker’s Commission”) pursuant to the terms of a separate agreement. Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents (collectively, the “Landlord Related Parties”) harmless from all claims of any brokers, including Tenant’s Broker (other than with regard to payment of Tenant’s Broker’s Commission), claiming to have represented Tenant in connection with this Amendment. Landlord hereby represents to Tenant that Landlord has dealt with no broker in connection with this Amendment. Landlord agrees to indemnify and hold Tenant, its members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such agents (collectively, the “Tenant Related Parties”) harmless from all claims of any brokers claiming to have represented Landlord in connection with this Amendment.

(g)This Amendment may be executed in counterparts each of which counterparts when taken together shall constitute one and the same agreement. Any facsimile, PDF or other electronic signature shall constitute a valid and binding method for executing this Amendment. Executed counterparts of this Amendment exchanged by facsimile transmission, PDF email, or other electronic means shall be fully enforceable.

13

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date set forth above.

LANDLORD:			TENANT:
EMERYSTATION TRIANGLE, LLC, a California limited liability company			AMYRIS, INC., a Delaware corporation
By:	EmeryStation Triangle Associates, LLC, a California limited liability company, its Managing Member		By:     /s/ John Melo             Name:     John Melo             Its:     CEO
	By:	Wareham-NZL, LLC, a California limited liability company, its Managing Member
		By:    /s/ Richard K. Robbins     Richard K. Robbins     Manager

14

EX-10.03

AMENDMENT TO
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT

Dated as of June 30, 2022

PARTIES:        Borrowers:    Amyris, Inc., a Delaware corporation ("Parent"), Amyris Fuels, LLC, a Delaware limited liability company, Amyris Clean Beauty, Inc., a Delaware corporation, and AB Technologies LLC, a Delaware limited liability company

        Lender:    Foris Ventures, LLC ("Foris")

RECITALS

A.    Foris is the administrative agent and lender pursuant to that certain Amended and Restated Loan and Security Agreement, dated as of October 28, 2019(as such Amended and Restated Loan and Security Agreement may from time to time be amended, modified or supplemented in accordance with its terms, the "Loan Agreement").

B.    Parent has requested that Foris agree to modify certain terms of the Loan Agreement and to provide certain other accommodations to the Borrowers.

C.    Foris has agreed to modify the Loan Agreement on the terms set forth in this Amendment ("Amendment").

D.    Capitalized terms used but not defined herein have the meaning given to such terms in the Loan Agreement.

AGREEMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrowers and Foris agree as follows:

SECTION 1.Amendment to Loan Agreement. With effect from the Effective Date, the Loan Agreement is modified as follows:

    (a)    in Section 1.1, the definition of Term Loan Maturity Date is deleted and replaced with “July 1, 2023”; and

(b)    in Section 7.1, adding the following as new clause (j):

“commencing with the calendar month ending June 30, 2022, as soon as practicable (and in any event within 10 days) after the end of each calendar month an updated 26-week cash flow forecast”

SECTION 2.Acknowledgments.

2.1.Borrowers hereby acknowledge, confirm and agree that as of close of business on June 30, 2022, Borrowers are indebted to Foris in respect of the Loan in the principal amount of not less than $ 50,041,000.

2.2.In consideration of the Lender’s willingness to enter into this Agreement and (among other things) to provide the extension set out in this Agreement, the Borrowers hereby

acknowledge, confirm, and agree that all Secured Obligations, together with any interest accrued and accruing thereon, and all fees, costs, expenses, and other charges now or hereafter payable to Foris, in each case in accordance with the terms of the Loan Documents, are unconditionally owing by the Borrowers, without offset, defense, or counterclaim of any kind, nature, or description whatsoever.

2.3.Each Borrower does hereby reaffirm the Loan Agreement and other Loan Documents to which it is a party, and ratifies the Loan Agreement and such other Loan Documents to which it is a party, as amended, modified, and supplemented.Each Borrower does hereby ratify, affirm, reaffirm, acknowledge, confirm and agree that (a) the prior grant or grants of Liens and guarantees in favor of Agent for the benefit of Agent and Lender in its properties and assets, whether under the Loan Agreement or under any Loan Document to which each Borrower is a party, shall also be for the benefit of Foris and in respect of the Secured Obligations under the Loan Agreement and the other Loan Documents; (b) all of its obligations owing to Foris under the Loan Agreement and the other Loan Documents, and all prior grants of Liens and guarantees in favor of Agent for the benefit of Lender under the Loan Agreement and each other Loan Document are hereby reaffirmed; and (c) the Loan Agreement and other Loan Documents to which each Borrower is a party are the legal, valid and binding obligations of each Borrower and are enforceable against each Borrower in accordance with their respective terms, except as enforceability may be limited by applicable equitable principles or by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors' rights generally.

SECTION 3.Representations and Warranties. Each Borrower hereby represents, warrants and covenants that:

(a)the Loan Documents as modified herein and in any Loan Documents executed concurrently herewith are the legal, valid, and binding obligation of Borrower, enforceable against such Borrower in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium, reorganization, or similar laws or by equitable principals of general application;

(b)    the execution, delivery, and performance of this Amendment by such Borrower will not violate any requirement of law or contractual obligation of such Borrower where any such violation could individually or in the aggregate reasonably be expected to have a Material Adverse Effect and will not result in, or require, the creation or imposition of any Lien on any of their properties or revenues (other than a Lien of Foris or Permitted Liens);

(c)    it understands fully the terms of this Amendment and the consequences of the execution and delivery of this Amendment, it has been afforded an opportunity to discuss this Amendment with, and have this Amendment reviewed by, such attorneys and other persons as such Borrower may wish, and it has entered into this Amendment and executed and delivered all documents in connection herewith of its own free will and accord and without threat, duress, or other coercion of any kind by any Person; and

(d)    as of the date of this Agreement and on the Effective Date, no Event of Default has occurred and is continuing.

SECTION 4.Release.

4.1.    In consideration of the agreements of Foris set forth herein, each Borrower hereby releases, remises, acquits and forever discharges Foris and Foris' employees, agents, representatives, consultants, attorneys, fiduciaries, servants, officers, directors, partners, predecessors, successors and assigns, subsidiary corporations, parent corporation, and related corporate divisions (all of the foregoing hereinafter called the "Released Parties"), from any and all action and causes of action, judgments, executions, suits, debts, claims, demands, liabilities,

2

obligations, damages and expenses of any and every character, known or unknown, direct and/or indirect, at law or in equity, of whatsoever kind or nature, whether heretofore or hereafter arising, for or because of any matter or things done, omitted or suffered to be done by any of the Released Parties prior to and including the date of execution hereof, and in any way directly or indirectly arising out of or in any way connected to this Amendment, the Loan Agreement and the other Loan Documents (all of the foregoing hereinafter called the "Released Matters"). Each Borrower acknowledges that the agreements in this section are intended to be in full satisfaction of all or any alleged injuries or damages arising in connection with the Released Matters. Each Borrower represents and warrants to Foris that it has not purported to transfer, assign or otherwise convey any right, title or interest of such Borrower in any Released Matter to any other Person and that the foregoing constitutes a full and complete release of all Released Matters.

4.2.    Each Borrower understands, acknowledges, and agrees that the release set forth above may be pleaded as a full and complete defense to any Released Matter and may be used as a basis for an injunction against any action, suit, or other proceeding which may be instituted, prosecuted, or attempted in breach of the provisions of such release.

4.3.    Each Borrower agrees that no fact, event, circumstance, evidence, or transaction which could now be asserted or which may hereafter be discovered will affect in any manner the final, absolute, and unconditional nature of the release set forth above.

4.4.    In furtherance hereof, each Borrower expressly acknowledges and waives any and all rights under Section 1542 of the California Civil Code, which provides as follows:

"A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party."

By entering into this Amendment, each Borrower recognizes that no facts or representations are ever absolutely certain and it may hereafter discover facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of such Borrower hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown, suspected or unsuspected; accordingly, if such Borrower should subsequently discover that any fact that it relied upon in entering into this Amendment was untrue, or that any understanding of the facts was incorrect, such Borrower shall not be entitled to set aside this Amendment or any release contained herein by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever. Each Borrower acknowledges that it is not relying upon and has not relied upon any representation or statement made by Foris with respect to the facts underlying this Amendment or with regard to any of such party's rights or asserted rights.

The release set forth in this Amendment may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release. Each Borrower acknowledges that the release contained in this Amendment constitutes a material inducement to Foris to enter into this Amendment and that Foris would not have done so but for Foris' expectation that such release is valid and enforceable in all events.

4.5.    Each Borrower hereby absolutely, unconditionally and irrevocably covenants and agrees with and in favor of each Released Party that it will not sue (at law, in equity, in any regulatory proceeding, or otherwise) any Released Party on the basis of any Released Matter released, remised, and discharged by such Borrower pursuant to Section 4.1 hereof. If any Borrower violates the foregoing covenant, such Borrower, for itself and its successors and assigns, and its present and former members, managers, shareholders, affiliates, subsidiaries,

3

divisions, predecessors, directors, officers, attorneys, employees, agents, legal representatives, and other representatives, agrees to pay, in addition to such other damages as any Released Party may sustain as a result of such violation, all attorneys' fees and costs incurred by any Released Party as a result of such violation.

SECTION 5.    Miscellaneous.

5.1.    In this Agreement, “Effective Date” means the date on which Foris has received the following documents and other evidence, each in form and substance satisfactory to it:

(a)    copies of signed resolutions of the board of directors of each Borrower (other than the Parent) approving this Agreement and the transactions contemplated by this Agreement; and

(c)    this Agreement, signed by all parties to it.

5.2.    Within five Business Days of the date of the meeting of the board of directors of the Parent meet for the third fiscal quarter 2022, the Parent will provide Foris with a certified copy of resolutions of its board of directors, in form and substance satisfactory to Foris, approving this Agreement and the transactions contemplated by this Agreement. The parties agree that failure to comply with this Section 5.2 will be an immediate Event of Default under Section 9.2 of the Loan Agreement.

5.3.    The Loan Documents as modified herein and in each of the Loan Documents executed concurrently herewith contain the entire understanding and agreement of each Borrower and Foris in respect of the Loan and supersede all prior representations, warranties, agreements, arrangements, and understandings with respect thereto. No provision of the Loan Documents as modified herein and in each of the Loan Documents executed concurrently herewith may be changed, discharged, supplemented, terminated, or waived except in a writing signed by Foris and the Borrowers. The Borrowers and Foris agree that this Amendment is a Loan Document.

5.4.    Except as specifically provided in this Amendment, no implied consent involving any of the matters set forth in this Amendment or otherwise shall be inferred or implied by Foris’ execution of this Amendment or any other action of Foris or Lender. Foris' execution of this Amendment shall not constitute a waiver, either express or implied, of the requirement that any waiver with respect to or further modification of the Loan or of the Loan Documents shall require the express written approval of Foris, as further set forth in the Loan Documents. Foris' execution of this Amendment shall not constitute a waiver of any of the rights and remedies that Foris may have against Borrower, or of any of Foris' rights and remedies arising out of the Loan Documents as modified herein and such rights and remedies are hereby expressly reserved.

5.5.    This Amendment shall be governed by the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

5.6.    The Loan Documents as modified herein are binding upon, and inure to the benefit of, the Borrowers and Foris and their respective successors and assigns.

5.7.    This Amendment may be executed in one or more counterparts, each of which is deemed an original and all of which together constitute one and the same document. Signature pages may be detached from the counterparts and attached to a single copy of this Amendment to physically form one document.

5.8.    All reasonable and documented out-of-pocket expenses and costs of Foris

4

(including, without limitation, the reasonable and documented attorney fees of counsel for Foris and expenses of counsel for Foris) in connection with the preparation, negotiation, execution and approval of this Amendment and any and all other documents, instruments and things contemplated hereby, whether or not such transactions are consummated, together with all other reasonable and documented expenses and costs incurred by Foris are Secured Obligations chargeable to the Borrowers pursuant to the terms of the Loan Agreement.

5.9.    At Borrower's expense, the parties hereto will execute and deliver such additional documents and take such further action as may be necessary or reasonably requested by Foris to effectuate the provisions and purposes of this Amendment, including providing evidence of the discharge of Indebtedness and Liens in accordance with the terms of the Loan Agreement.

5.10.    This Amendment will be binding upon and inure to the benefit of each of the parties hereto and their respective successors and assigns. No Person other than the parties hereto, and in the case of Section 4 hereof, the Released Parties, shall have any rights hereunder or be entitled to rely on this Amendment and all third-party beneficiary rights (other than the rights of the Released Parties under Section 4 hereof) are hereby expressly disclaimed.

5.11.    Any provision of this Amendment held by a court of competent jurisdiction to be invalid or unenforceable will not impair or invalidate the remainder of this Amendment.

5.12.    The parties hereto acknowledge and agree that no inference in favor of, or against, any party will be drawn from the fact that such party has drafted any portion of this Amendment, the Loan Agreement, or any other Loan Document, as each may be amended.

5.13.    If Foris is, for any reason, compelled by a court or other tribunal of competent jurisdiction to surrender or disgorge any payment, interest, or other consideration described hereunder to any person because the same is determined to be void or voidable as a preference, fraudulent conveyance, impermissible set-off or for any other reason, such indebtedness or part thereof intended to be satisfied by virtue of such payment, interest, or other consideration will be revived and continue as if such payment, interest, or other consideration had not been received by Foris, and the Borrowers will be liable to, and will indemnify, defend, and hold Foris harmless for, the amount of such payment or interest surrendered or disgorged. The provisions of this section will survive repayment of the Secured Obligations or any termination of the Loan Agreement or any other Loan Document.

5.14.    The Borrowers agree that the relationship between each of them, on one hand, and Foris, on the other hand, under the Loan Documents is that of creditor and debtor and not that of partners or joint venturers. This Amendment does not constitute a partnership agreement or any other association among the parties. The Borrowers acknowledge that Foris has acted at all times in connection with the Loan Documents only as a creditor to it within the normal and usual scope of the activities normally undertaken by a creditor and in no event has Foris attempted to exercise any control over it or its business or affairs. The Borrowers further acknowledge that Foris has not taken or failed to take any action under or in connection with its respective rights under the Loan Agreement or any of the other Loan Documents that in any way, or to any extent, has interfered with or adversely affected its ownership of Collateral.

[Signature Page Follows]

5

IN WITNESS WHEREOF, this Amendment is executed and delivered as of the day and year first above written.

Borrowers:

AMYRIS, INC., a Delaware corporation

By: /s/ Han Kieftenbeld    

Name:Han Kieftenbeld    

Title: Chief Financial Officer    

AMYRIS FUELS, LLC, a Delaware limited liability company

By: /s/ Han Kieftenbeld    

Name:Han Kieftenbeld    

Title: Chief Financial Officer    

AMYRIS CLEAN BEAUTY, INC., a Delaware corporation

By: /s/ Han Kieftenbeld    

Name:Han Kieftenbeld    

Title: Chief Financial Officer    

AB TECHNOLOGIES LLC, a Delaware limited liability company

By: /s/ Han Kieftenbeld    

Name:Han Kieftenbeld    

Title: Chief Financial Officer    

FORIS:

FORIS VENTURES, LLC, a Delaware limited liability company

By: /s/ Barbara Hager    

Name: Barbara Hager    

Title: Manager    

[Signature Page to Amendment to Amended and Restated Loan and Security Agreement]

EX-31.01

Exhibit 31.01

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(c) and 15d-(14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, John G. Melo, certify that:

    1.    I have reviewed this Quarterly Report on Form 10-Q of Amyris, Inc.;

    2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

    5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2022	/s/ John G. Melo
	John G. Melo
	President and Chief Executive Officer

1

EX-31.02

Exhibit 31.02

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(c) and 15d-(14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Han Kieftenbeld, certify that:

    1.    I have reviewed this Quarterly Report on Form 10-Q of Amyris, Inc.;

    2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

    5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2022	/s/ Han Kieftenbeld
	Han Kieftenbeld
	Chief Financial Officer

1

EX-32.01

Exhibit 32.01

Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant To

Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Amyris, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof, I, John G. Melo, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

(i) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended June 30, 2022 (the “Report”), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2022	/s/ John G. Melo
	John G. Melo
	President and Chief Executive Officer
	(Principal Executive Officer)

1

EX-32.02

Exhibit 32.02

Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant To

Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Amyris, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof, I, Han Kieftenbeld, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

(i) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended June 30, 2022 (the “Report”), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2022	/s/ Han Kieftenbeld
	Han Kieftenbeld
	Chief Financial Officer
	(Principal Financial Officer)

1

XML

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 04, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-34885
Entity Registrant Name	AMYRIS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	55-0856151
Entity Address, Address Line One	5885 Hollis Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	450-0761
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	AMRS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		321,402,149
Entity Central Index Key	0001365916
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 99,820	$ 483,462
Restricted cash	1,090	199
Accounts receivable, net of allowance of $1,337 and $945, respectively	41,125	37,074
Accounts receivable - related party, net of allowance of $0 and $0, respectively	5,001	5,667
Contract assets	3,946	4,227
Contract assets - related party	15,265	0
Inventories	99,195	75,070
Prepaid expenses and other current assets	44,667	33,513
Total current assets	310,109	639,212
Property, plant and equipment, net	151,137	72,835
Restricted cash, noncurrent	5,633	4,651
Recoverable taxes from Brazilian government entities	22,038	16,740
Right-of-use assets under financing leases, net	393	7,342
Right-of-use assets under operating leases, net	90,070	32,428
Goodwill	134,164	131,259
Intangible assets, net	57,645	39,265
Other assets	18,251	10,566
Total assets	789,440	954,298
Current liabilities:
Accounts payable	102,962	79,666
Accrued and other current liabilities	80,689	71,457
Financing lease liabilities	12	140
Operating lease liabilities	1,640	7,689
Contract liabilities	816	2,530
Debt, current portion	955	896
Related party debt, current portion, measured at fair value	0	107,427
Total current liabilities	187,074	269,805
Long-term debt, net of current portion	672,965	309,061
Related party debt, net of current portion, measured at fair value	51,516	0
Financing lease liabilities, net of current portion	54	61
Operating lease liabilities, net of current portion	75,285	19,829
Derivative liabilities	1,649	7,062
Acquisition-related contingent consideration (Note 3 and Note 7)	40,275	64,762
Other noncurrent liabilities	4,210	4,510
Total liabilities	1,033,028	675,090
Commitments and contingencies
Mezzanine equity:
Contingently redeemable common stock	5,000	5,000
Contingently redeemable noncontrolling interest	31,004	28,520
Stockholders’ (deficit) equity:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of June 30, 2022 and December 31, 2021; zero shares issued and outstanding as of June 30, 2022 and December 31, 2021	0	0
Common stock - $0.0001 par value, 550,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 321,111,428 and 308,899,906 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	32	31
Additional paid-in capital	2,357,311	2,656,838
Accumulated other comprehensive loss	(61,351)	(52,769)
Accumulated deficit	(2,568,986)	(2,357,661)
Total Amyris, Inc. stockholders’ (deficit) equity	(272,994)	246,439
Noncontrolling interest	(6,598)	(751)
Total stockholders' (deficit) equity	(279,592)	245,688
Total liabilities, mezzanine equity and stockholders' (deficit) equity	$ 789,440	$ 954,298

XML

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 1,337	$ 945
Accounts receivable, allowance, related parties	$ 0	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	550,000,000	550,000,000
Common stock, shares issued (in shares)	321,111,428	308,899,906
Common stock, shares outstanding (in shares)	321,111,428	308,899,906

XML

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue	$ 65,207	$ 52,316	$ 122,916	$ 229,175
Cost and operating expenses:
Cost of products sold	55,930	30,421	104,925	53,080
Research and development	26,111	22,424	52,469	45,756
Sales, general and administrative	126,587	54,340	233,503	92,262
Total cost and operating expenses	208,628	107,185	390,897	191,098
(Loss) income from operations	(143,421)	(54,869)	(267,981)	38,077
Other income (expense):
Interest expense	(5,304)	(4,723)	(10,567)	(10,536)
Gain (loss) from change in fair value of derivative instruments	3,598	5,141	5,413	(17,604)
Gain (loss) from change in fair value of debt	35,114	70,132	55,910	(256,653)
Gain (loss) upon extinguishment of debt	0	935	0	(26,378)
Other income (expense), net	780	28	(2,272)	(650)
Total other income (expense), net	34,188	71,513	48,484	(311,821)
(Loss) income before income taxes and loss from investment in affiliate	(109,233)	16,644	(219,497)	(273,744)
Benefit from (provision for) income taxes	685	(57)	1,505	(112)
(Loss) income from investment in affiliate	(4,972)	(1,140)	(5,761)	(748)
Net (loss) income	(113,520)	15,447	(223,753)	(274,604)
Loss (income) attributable to noncontrolling interest	3,507	(66)	6,435	(1,266)
Net (loss) income attributable to Amyris, Inc.	(110,013)	15,381	(217,318)	(275,870)
Less: loss (income) allocated to participating securities	0	(13)	0	1,086
Net (loss) income attributable to Amyris, Inc. common stockholders, basic	$ (110,013)	$ 15,368	$ (217,318)	$ (274,784)
Earnings Per Share, Basic [Abstract]
Net (loss) income per share attributable to common stockholders, basic (in dollars per share)	$ (0.34)	$ 0.05	$ (0.69)	$ (0.98)
Weighted-average shares of common stock outstanding used in computing net (loss) income per share of common stock, basic (in shares)	319,916,244	320,088,143	316,425,739	279,819,520
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.44)	$ (0.16)	$ (0.80)	$ (0.98)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)	336,642,879	338,807,849	335,798,275	279,819,520
Renewable Products
Revenue:
Revenue	$ 54,390	$ 37,172	$ 97,855	$ 65,351
Licenses and Royalties
Revenue:
Revenue	6,454	11,000	15,767	154,800
Collaborations, Grants and Other
Revenue:
Revenue	$ 4,363	$ 4,144	$ 9,294	$ 9,024

XML

Condensed Consolidated Statements of Operations (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues, related party	$ 11,419	$ 6,620	$ 26,647	$ 153,894
Renewable Products
Revenues, related party	2,965	4,620	7,377	6,282
Licenses and Royalties
Revenues, related party	6,454	0	15,270	143,612
Collaborations, Grants and Other
Revenues, related party	$ 2,000	$ 2,000	$ 4,000	$ 4,000

XML

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Comprehensive income (loss):
Net income (loss)	$ (113,520)	$ 15,447	$ (223,753)	$ (274,604)
Foreign currency translation adjustment	(23,868)	4,773	(8,582)	2,735
Total comprehensive income (loss)	(137,388)	20,220	(232,335)	(271,869)
Loss (income) attributable to noncontrolling interest	3,507	(66)	6,435	(1,266)
Comprehensive income (loss) attributable to Amyris, Inc.	$ (133,881)	$ 20,154	$ (225,900)	$ (273,135)

XML

Condensed Consolidated Statements of Stockholders' Equity (Deficit) and Mezzanine Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Preferred Stock	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2020			8,280
Beginning balance at Dec. 31, 2020	$ (172,045)		$ 0	$ 24	$ 1,957,224		$ (47,375)	$ (2,086,692)		$ 4,774
Beginning balance (in shares) at Dec. 31, 2020				244,951,446
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)				496,341
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	(2)				(2)
Issuance of common stock and warrants upon conversion of debt principal (in shares)				5,827,164
Issuance of common stock and warrants upon conversion of debt principal	110,575			$ 1	110,574
Issuance of common stock upon exercise of stock options (in shares)				377,542
Issuance of common stock upon exercise of stock options	1,920				1,920
Issuance of common stock upon exercise of warrants (in shares)				15,557,480
Issuance of common stock upon exercise of warrants	32,219			$ 2	32,217
Issuance of common stock upon exercise of warrants - related party (in shares)				6,056,944
Stock-based compensation	4,281				4,281
Foreign currency translation adjustment	(2,038)						(2,038)
Net loss attributable to Amyris, Inc.	(290,051)							(291,251)		1,200
Ending balance (in shares) at Mar. 31, 2021			8,280
Ending balance at Mar. 31, 2021	(315,141)		$ 0	$ 27	2,106,214		(49,413)	(2,377,943)		5,974
Ending balance (in shares) at Mar. 31, 2021				273,266,917
Beginning balance, contingently redeemable common stock at Dec. 31, 2020	5,000
Ending balance, contingently redeemable common stock at Mar. 31, 2021	5,000
Beginning balance (in shares) at Dec. 31, 2020			8,280
Beginning balance at Dec. 31, 2020	$ (172,045)		$ 0	$ 24	1,957,224		(47,375)	(2,086,692)		4,774
Beginning balance (in shares) at Dec. 31, 2020				244,951,446
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting standards update [extensible enumeration]	Accounting Standards Update 2020-06 [Member]
Ending balance (in shares) at Dec. 31, 2021	0		0
Ending balance at Dec. 31, 2021	$ 245,688	$ (361,981)	$ 0	$ 31	2,656,838	$ (367,974)	(52,769)	(2,357,661)	$ 5,993	(751)
Ending balance (in shares) at Dec. 31, 2021	308,899,906			308,899,906
Beginning balance, contingently redeemable common stock at Dec. 31, 2020	$ 5,000
Ending balance, contingently redeemable common stock at Dec. 31, 2021	5,000
Ending balance, contingently redeemable noncontrolling interest at Dec. 31, 2021	28,520
Beginning balance (in shares) at Mar. 31, 2021			8,280
Beginning balance at Mar. 31, 2021	(315,141)		$ 0	$ 27	2,106,214		(49,413)	(2,377,943)		5,974
Beginning balance (in shares) at Mar. 31, 2021				273,266,917
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of contingently redeemable noncontrolling interest	(14,520)				(14,520)
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)				880,603
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	(1,479)				(1,479)
Issuance of common stock as purchase consideration in business combinations (in shares)				225,784
Issuance of common stock as purchase consideration in business combinations	3,167				3,167
Issuance of common stock in public offering (in shares)				8,805,345
Issuance of common stock in public offering	130,793			$ 1	130,792
Issuance of common stock upon conversion of debt principal (in shares)				2,862,772
Issuance of common stock upon conversion of debt principal	38,633			$ 1	38,632
Issuance of common stock upon conversion of preferred stock (in shares)			(8,280)	1,943,659
Issuance of common stock upon ESPP purchase (in shares)				145,112
Issuance of common stock upon ESPP purchase	321				321
Issuance of common stock upon exercise of stock options (in shares)				145,200
Issuance of common stock upon exercise of stock options	860				860
Issuance of common stock upon exercise of warrants (in shares)				1,381,940
Issuance of common stock upon exercise of warrants	6,622				6,622
Issuance of common stock upon exercise of warrants - related party (in shares)				8,057,966
Issuance of common stock upon exercise of warrants - related party	5,745			$ 1	5,744
Stock-based compensation	8,747				8,747
Foreign currency translation adjustment	4,773						4,773
Net loss attributable to Amyris, Inc.	15,447							15,381		66
Ending balance (in shares) at Jun. 30, 2021			0
Ending balance at Jun. 30, 2021	(116,032)		$ 0	$ 30	2,285,100		(44,640)	(2,362,562)		6,040
Ending balance (in shares) at Jun. 30, 2021				297,715,298
Beginning balance, contingently redeemable common stock at Mar. 31, 2021	5,000
Increase (Decrease) in Mezzanine Equity [Roll Forward]
Issuance of contingently redeemable noncontrolling interest	28,520
Ending balance, contingently redeemable common stock at Jun. 30, 2021	5,000
Ending balance, contingently redeemable noncontrolling interest at Jun. 30, 2021	$ 28,520
Beginning balance (in shares) at Dec. 31, 2021	0		0
Beginning balance at Dec. 31, 2021	$ 245,688	(361,981)	$ 0	$ 31	2,656,838	(367,974)	(52,769)	(2,357,661)	5,993	(751)
Beginning balance (in shares) at Dec. 31, 2021	308,899,906			308,899,906
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Acquisitions	$ 155									155
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)				528,704
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	(3)				(3)
Issuance of common stock as purchase consideration in business combinations (in shares)				7,121,806
Issuance of common stock as purchase consideration in business combinations	33,094			$ 1	33,093
Issuance of common stock upon exercise of stock options (in shares)				33,250
Issuance of common stock upon exercise of stock options	98				98
Issuance of common stock upon exercise of warrants (in shares)				1,391,603
Issuance of common stock upon exercise of warrants	3,994				3,994
Stock-based compensation	11,588				11,588
Foreign currency translation adjustment	15,286						15,286
Net loss attributable to Amyris, Inc.	(110,233)							(107,305)		(2,928)
Ending balance (in shares) at Mar. 31, 2022			0
Ending balance at Mar. 31, 2022	(162,314)		$ 0	$ 32	2,337,634		(37,483)	(2,458,973)		(3,524)
Ending balance (in shares) at Mar. 31, 2022				317,975,269
Beginning balance, contingently redeemable common stock at Dec. 31, 2021	5,000
Beginning balance, contingently redeemable noncontrolling interest at Dec. 31, 2021	28,520
Increase (Decrease) in Mezzanine Equity [Roll Forward]
Contingently redeemable noncontrolling interest, acquisitions	2,917
Ending balance, contingently redeemable common stock at Mar. 31, 2022	5,000
Ending balance, contingently redeemable noncontrolling interest at Mar. 31, 2022	$ 31,437
Beginning balance (in shares) at Dec. 31, 2021	0		0
Beginning balance at Dec. 31, 2021	$ 245,688	$ (361,981)	$ 0	$ 31	2,656,838	$ (367,974)	(52,769)	(2,357,661)	$ 5,993	(751)
Beginning balance (in shares) at Dec. 31, 2021	308,899,906			308,899,906
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	36,021
Ending balance (in shares) at Jun. 30, 2022	0		0
Ending balance at Jun. 30, 2022	$ (279,592)		$ 0	$ 32	2,357,311		(61,351)	(2,568,986)		(6,598)
Ending balance (in shares) at Jun. 30, 2022	321,111,428			321,111,428
Beginning balance, contingently redeemable common stock at Dec. 31, 2021	$ 5,000
Beginning balance, contingently redeemable noncontrolling interest at Dec. 31, 2021	28,520
Ending balance, contingently redeemable common stock at Jun. 30, 2022	5,000
Ending balance, contingently redeemable noncontrolling interest at Jun. 30, 2022	31,004
Beginning balance (in shares) at Mar. 31, 2022			0
Beginning balance at Mar. 31, 2022	(162,314)		$ 0	$ 32	2,337,634		(37,483)	(2,458,973)		(3,524)
Beginning balance (in shares) at Mar. 31, 2022				317,975,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)				1,087,200
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	(7)				(7)
Issuance of common stock as purchase consideration in business combinations (in shares)				806,757
Issuance of common stock as purchase consideration in business combinations	3,485				3,485
Issuance of common stock in lieu of cash compensation to non-employee directors	279				279
Issuance of common stock upon ESPP purchase (in shares)				334,699
Issuance of common stock upon ESPP purchase	671				671
Issuance of common stock upon exercise of stock options (in shares)				2,771
Issuance of common stock upon exercise of stock options	5				5
Issuance of common stock upon exercise of warrants (in shares)				904,732
Issuance of common stock upon exercise of warrants	2,597				2,597
Stock-based compensation	12,647				12,647
Foreign currency translation adjustment	(23,868)						(23,868)
Net loss attributable to Amyris, Inc.	$ (113,087)							(110,013)		(3,074)
Ending balance (in shares) at Jun. 30, 2022	0		0
Ending balance at Jun. 30, 2022	$ (279,592)		$ 0	$ 32	$ 2,357,311		$ (61,351)	$ (2,568,986)		$ (6,598)
Ending balance (in shares) at Jun. 30, 2022	321,111,428			321,111,428
Beginning balance, contingently redeemable common stock at Mar. 31, 2022	$ 5,000
Beginning balance, contingently redeemable noncontrolling interest at Mar. 31, 2022	31,437
Increase (Decrease) in Mezzanine Equity [Roll Forward]
Net income (loss) attributable to Amyris, Inc.	(433)
Ending balance, contingently redeemable common stock at Jun. 30, 2022	5,000
Ending balance, contingently redeemable noncontrolling interest at Jun. 30, 2022	$ 31,004

XML

Condensed Consolidated Statements of Stockholders' Equity (Deficit) and Mezzanine Equity (Parentheticals)	3 Months Ended
	Mar. 31, 2021 shares
2026 convertible senior notes | Convertible notes
Shares to be returned per agreement (in shares)	2,600,000

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (223,753)	$ (274,604)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of debt discount	1,923	1,646
Amortization of intangible assets	2,076	135
Amortization of right-of-use assets under operating leases	2,651	1,555
Depreciation and amortization	4,986	4,300
(Gain) loss from change in fair value of debt	(55,910)	256,653
(Gain) loss from change in fair value of derivative instruments	(5,413)	17,604
Loss from investment in affiliate	5,761	748
Gain on foreign currency exchange rates	(1,367)	(102)
Loss upon extinguishment of debt	0	26,378
Other	16	0
Stock-based compensation	24,235	13,028
Changes in assets and liabilities:
Accounts receivable	(3,876)	3,522
Contract assets	(14,984)	988
Inventories	(23,060)	(11,017)
Deferred cost of products sold - related party	0	6,678
Prepaid expenses and other assets	(28,388)	(18,969)
Accounts payable	25,418	6,855
Accrued and other liabilities	2,319	(478)
Lease liabilities	(10,415)	(2,440)
Contract liabilities	(1,702)	(2,275)
Net cash provided by (used in) operating activities	(299,483)	30,205
Investing activities
Purchases of property, plant and equipment	(71,462)	(5,382)
Acquisitions, net of cash acquired	(17,760)	(288)
Net cash used in investing activities	(89,222)	(5,670)
Financing activities
Issuance costs incurred in connection with debt modification	0	(2,500)
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units	(10)	(1,481)
Principal payments on debt	0	(23,396)
Principal payments on financing leases	(135)	(1,865)
Proceeds from exercises of common stock options	103	2,780
Proceeds from exercises of warrants	6,591	38,841
Proceeds from exercises of warrants - related party	0	5,745
Proceeds from issuance of common stock in public offering, net of issuance costs	0	130,793
Proceeds from issuance of common stock upon ESPP purchase	671	321
Proceeds from issuance of contingently redeemable noncontrolling interest in subsidiary	0	10,000
Net cash provided by financing activities	7,220	159,238
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(284)	440
Net increase in cash, cash equivalents and restricted cash	(381,769)	184,213
Cash, cash equivalents and restricted cash at beginning of period	488,312	31,422
Cash, cash equivalents and restricted cash at end of the period	106,543	215,635
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	99,820	214,424
Restricted cash, current	1,090	250
Restricted cash, noncurrent	5,633	961
Total cash, cash equivalents and restricted cash	106,543	215,635
Supplemental disclosures of cash flow information:
Cash paid for interest	5,307	4,444
Supplemental disclosures of non-cash investing and financing activities:
Acquisition of intangible assets in connection with business combinations	22,944	8,107
Acquisition of right-of-use assets under operating leases	60,195	1,108
Common stock and warrants issued in exchange for debt principal and accrued interest reduction	0	149,208
Common stock issued as purchase consideration in business combinations	36,579	3,167
Common stock issued in lieu of cash compensation to non-employee directors	279	0
Derecognition of derivative liabilities to equity upon extinguishment of debt	0	59
Goodwill recorded in connection with business combinations	13,437	4,013
Noncontrolling interest recorded in connection with business combinations	3,072	0
Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period	$ 5,729	$ 7,105

XML

Basis of Presentation and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Summary of Significant Accounting Policies

Amyris, Inc. and subsidiaries (collectively, Amyris or the Company) is a biotechnology company delivering sustainable science-based solutions for people and the planet. The Company creates, manufactures and commercializes consumer products and ingredients. Currently, the largest driver of the Company's revenue is derived from marketing and selling Clean Beauty, Personal Care and Health & Wellness consumer products through direct-to-consumer ecommerce platforms and a growing network of retail partners. The Company also sells sustainable ingredients to sector leaders that serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The Company's ingredients and consumer products are powered by the Company's fermentation-based Lab-to-MarketTM technology platform, which leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the Company to rapidly bring new innovation to market.

The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the 2021 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2021 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Our cash and cash equivalents of $99.8 million as of June 30, 2022 in and of itself will not be sufficient to fund expected cash flow requirements from operations, investments and financing obligations for the next 12 months. We are actively working on securing additional funding from debt and from a strategic transaction to meet our spending obligations within 12 months after issuing our financial statements for the second quarter of 2022. Management currently expects that the current cash position, the cash generated from operations, the expected F&F and Reb M-related earnout payments along with planned price increases, operating expense reduction actions and the aforementioned additional funding from debt and a strategic transaction, to not raise substantial doubt about the Company's ability to continue as a going concern for the next 12 months.

Significant Accounting Policies

Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2021 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the six months ended June 30, 2022.

Use of Estimates and Judgements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.

Accounting Update Recently Adopted

In the six months ended June 30, 2022, the Company adopted this accounting standard update:

Convertible Debt, and Derivatives and Hedging. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 became effective for the Company in the first quarter of 2022. Adoption of this standard on January 1, 2022 in connection with the 2026 Convertible Senior Notes (see Note 4, "Debt"), decreased additional paid-in capital by $368.0 million, increased debt by the same amount and decreased accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption.

Accounting Standards or Updates Not Yet Adopted

Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. Because the Company met the SEC definition of a smaller reporting company when ASU 2016-13 was issued, this new accounting standard will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This standard will be effective for the Company in the first quarter of 2023 and will be applied prospectively to business combinations occurring on or after the effective date of the standard. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the guidance and the impact on its consolidated financial statements and related disclosures.

XML

Balance Sheet Details

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Details

Balance Sheet Details

Allowance for Doubtful Accounts

(In thousands)	Balance at Beginning of Period		Provisions		Write-offs, Net		Balance at End of Period
Six months ended June 30, 2022	$	945	$	392	$	—	$	1,337
Six months ended June 30, 2021	$	137	$	806	$	—	$	943

Inventories

(In thousands)	June 30, 2022		December 31, 2021
Raw materials	$	35,403	$	25,733
Work-in-process	8,783		6,941
Finished goods	55,009		42,396
Inventories	$	99,195	$	75,070

Prepaid Expenses and Other Current Assets

(In thousands)	June 30, 2022		December 31, 2021
Prepayments, advances and deposits	$	34,229	$	25,140
Non-inventory production supplies	4,462		3,956
Recoverable taxes from Brazilian government entities	1,658		1,188
Other	4,318		3,229
Total prepaid expenses and other current assets	$	44,667	$	33,513

Property, Plant and Equipment, Net

(In thousands)	June 30, 2022		December 31, 2021
Manufacturing facilities and equipment	$	70,423	$	51,855
Leasehold improvements	49,097		45,780
Computers and software	11,430		9,174
Furniture and office equipment, vehicles and land	3,737		3,688
Construction in progress	112,869		48,032
	247,556		158,529
Less: accumulated depreciation and amortization	(96,419)		(85,694)
Property, plant and equipment, net	$	151,137	$	72,835

During the three and six months ended June 30, 2022 and 2021, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Depreciation and amortization expense	$	2,586	$	2,186	$	4,986	$	4,300

Goodwill

The changes in the carrying amount of goodwill were as follows:

(In thousands)	June 30, 2022
Balance at beginning of year	$	131,259
Acquisitions	13,437
Effect of currency translation adjustment	(10,532)
Ending balance	$	134,164

Additions to goodwill during the six months ended June 30, 2022 related to acquisitions completed during the period. See Note 7, "Acquisitions".

Intangible Assets, Net

During the six months ended June 30, 2022, the Company recorded $22.9 million of intangible assets which related to customer relationships, trademarks and trade names, branded products, and software as a result of acquisitions completed during the period. See Note 7, "Acquisitions".

The following table summarizes the components of intangible assets (in thousands, except estimated useful life):

		June 30, 2022						December 31, 2021
Amounts in thousands	Estimated Useful Life (in Years)	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Trademarks and trade names, and branded products	10	$	29,758	$	(1,573)	$	28,185	$	11,484	$	(496)	$	10,988
Customer relationships	5 - 16	8,703		(667)		8,036		8,197		(267)		7,930
Developed technology and software applications	5 - 12	21,545		(689)		20,856		19,962		(200)		19,762
Patents	17	600		(32)		568		600		(15)		585
Total intangible assets		$	60,606	$	(2,961)	$	57,645	$	40,243	$	(978)	$	39,265

Amortization expense for intangible assets was $1.2 million and $2.1 million for the three and six months ended June 30, 2022 and is included in general and administrative expenses.

Total future amortization of intangible assets as of June 30, 2022 is as follows (in thousands):

Amounts in thousands
2022 (remainder)	$	2,311
2023	6,177
2024	7,254
2025	7,386
2026	7,140
Thereafter	27,377
Total future amortization	$	57,645

Leases

Operating Leases

The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 18 years, and often include one or more options to renew. These renewal terms can extend the lease term for an additional 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $90.1 million and $32.4 million of operating lease right-of-use assets as of June 30, 2022 and December 31, 2021, respectively. Operating lease liabilities were $76.9 million and $27.5 million as of June 30, 2022 and December 31, 2021, respectively. During the three months ended June 30, 2022 and 2021, respectively, the Company recorded $4.1 million and $1.7 million of operating lease amortization that was charged to expense, of which $0.3 million and $0.2 million was recorded to cost of products sold. During the six months ended June 30, 2022 and 2021, respectively, the Company recorded $7.8 million and $3.5 million of operating lease amortization that was charged to expense, of which $0.6 million and $0.4 million was recorded to cost of products sold.

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component.

Information related to the Company's right-of-use assets and related lease liabilities were as follows:

	Six Months Ended June 30,
	2022	2021
Cash paid for operating lease liabilities, in thousands	$6,092	$2,369
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands	$51,789	$1,110
Weighted-average remaining lease term	11.6	2.6
Weighted-average discount rate	19.5%	17.0%

Financing Leases

The Company has financing leases primarily for laboratory equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $1.4 million and $6.8 million as of June 30, 2022 and December 31, 2021, respectively.

Maturities of Financing and Operating Leases

Maturities of lease liabilities as of June 30, 2022 were as follows:

Years ending December 31: (In thousands)	Financing Leases		Operating Leases		Total Leases
2022 (Remaining Six Months)	$	11	$	6,964	$	6,975
2023	21		12,962		12,983
2024	21		22,075		22,096
2025	21		22,374		22,395
2026	16		22,807		22,823
Thereafter	—		229,717		229,717
Total lease payments	90		316,899		316,989
Less: amount representing interest	(24)		(239,974)		(239,998)
Total lease liability	$	66	$	76,925	$	76,991
Current lease liability	$	12	$	1,640	$	1,652
Noncurrent lease liability	54		75,285		75,339
Total lease liability	$	66	$	76,925	$	76,991

Other Assets

(In thousands)	June 30, 2022		December 31, 2021
Investment in non-trade receivable(1)	$	10,251	$	—
Equity-method investments in affiliates	4,682		9,443
Deposits	517		129
Other	2,801		994
Total other assets	$	18,251	$	10,566

______________

(1) In March 2022, the Company loaned a privately held company $10 million in exchange for a senior secured convertible promissory note (the Note) which matures in March 2025, unless earlier redeemed or converted into equity of the privately held company. The Note bears interest at 8% per annum and is convertible, at the Company's option, into equity of the privately held company upon maturity of the Note or in the event of an initial public offering, equity

financing, or corporate transaction (such as a sale or merger), in each case, at a conversion price that is dependent on a variety of factors. In addition, the Note is redeemable prior to maturity, at the issuer's option, in the event of one or more equity or debt financings, one or more asset sales, or an initial public offering, in each case equal to or greater than $50 million in the aggregate. The Company concluded that the arrangement qualifies for accounting as a loan as required by ASC 310-10. The Company will periodically evaluate the collectability of the loan, and an allowance for credit losses will be recorded when the Company concludes that all or a portion of the loan balance is no longer collectible.

Accrued and Other Current Liabilities

(In thousands)	June 30, 2022		December 31, 2021
Business acquisitions contingent consideration payable(1)	$	32,411	$	30,000
Payroll and related expenses	15,160		9,151
Accrued interest	11,111		9,572
Liability in connection with acquisition of equity-method investment	9,921		8,735
Asset retirement obligation(2)	3,791		3,336
Professional services	2,295		2,447
Contract termination fees	1,368		1,345
Tax-related liabilities	1,057		988
License fee payable	1,050		1,050
Other	2,525		4,833
Total accrued and other current liabilities	$	80,689	$	71,457

______________

(1)    Business acquisitions contingent consideration payable is the current portion of total acquisition-related contingent consideration.

(2)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with the Company's 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.

XML

Fair Value Measurement

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurement

Fair Value Measurement

Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:

(In thousands)	June 30, 2022								December 31, 2021
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Liabilities
Foris Convertible Note	$	—	$	—	$	51,516	$	51,516	$	—	$	—	$	107,427	$	107,427
Freestanding derivative instruments issued in connection with debt and equity instruments	—		—		1,649		1,649		—		—		7,062		7,062
Acquisition-related contingent consideration	—		—		40,275		40,275		—		—		64,762		64,762
Total liabilities measured and recorded at fair value	$	—	$	—	$	93,440	$	93,440	$	—	$	—	$	179,251	$	179,251

The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of June 30, 2022 or December 31, 2021. Also, there were no transfers between the levels during the six months ended June 30, 2022 or the year ended December 31, 2021.

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates.

Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments".

Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt".

Freestanding Derivative Instruments

The Company has a contingent obligation to issue warrants for 1.9 million shares of common stock at a $2.87 purchase price and a two-year term. The warrants did not meet the derivative scope exception or equity classification criteria and was accounted for as a derivative liability. At June 30, 2022, the fair value of the contingently issuable warrants derivative liability was $1.6 million. For the three and six months ended June 30, 2022, the Company recorded gains of $3.6 million and $5.4 million related to change in fair value of these warrants.

Fair Value of Debt — Foris Convertible Note

At June 30, 2022, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $51.5 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $1.85 stock price, (ii) 27% discount yield, (iii) 2.8% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. For the three and six months ended June 30, 2022, the Company recorded gains of $35.1 million and $55.9 million related to change in fair value of the Foris Convertible Note.

Binomial Lattice Model

A binomial lattice model was used to determine whether the Foris Convertible Note would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Foris Convertible Note using the "with-and-without method", where the fair value of the Foris Convertible Note including the embedded features is defined as the "with," and the

fair value of the Foris Convertible Note excluding the embedded features is defined as the "without." This method estimates the fair value of the Foris Convertible Note by considering the incremental value of the Foris Convertible Note with the embedded features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Foris Convertible Note and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period.

Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments

The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):

(In thousands)	Derivative Liability
Balance at December 31, 2021	$	7,062
Change in fair value of derivative instruments	(5,413)
Balance at June 30, 2022	$	1,649

Valuation Methodology and Approach to Measuring the Debt Instrument Derivative Liabilities

The Company's outstanding derivative liabilities at June 30, 2022 and December 31, 2021 represent the fair value of a freestanding equity instrument. See Note 6, "Stockholders' Deficit" for further information regarding the host instrument. There is no current observable market for this type of derivative and, as such, the Company determined the fair value of the freestanding instrument using the Black-Scholes-Merton option pricing model, which is discussed in more detail below.

The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants for the periods ended June 30, 2022 and December 31, 2021. Input assumptions for the freestanding instrument are as follows:

	Range for Period Ended
Input assumptions for liability classified warrants:	June 30, 2022		December 31, 2021
Fair value of common stock on valuation date	$1.85 - $4.36		$5.41 - $19.10
Exercise price of warrants	$2.87		$2.87
Expected volatility	106% - 110%		107% - 114%
Risk-free interest rate	2.28% - 2.92%		0.16% – 0.73%
Expected term in years	2		2
Dividend yield	0.0	%	0.0 %

Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields, term to maturity/conversion or stock price volatility increases the value of the derivative liability.

Acquisition related contingent consideration

The fair value of acquisition related contingent consideration (Earnout Payments) was determined using a Monte Carlo simulation to estimate the probability of the acquired business units achieving the relevant financial and operational milestones. The model results reflect the time value of money, non-performance risk within the required time frame and the risk due to uncertainty in the estimated cash flows. Key inputs to the Monte Carlo simulation for the MenoLabs acquisition were: Revenue Risk Adjustment of 6.2% and Annual Revenue Volatility of 35%. A significant decrease or increase in an acquired business unit’s financial performance and the timing of such changes could materially decrease or increase the fair value of contingent consideration period over period. Contingent consideration is recorded in other liabilities in the accompanying consolidated balance sheets.

The fair value of contingent consideration is classified as Level 3. Contingent consideration activity and balances are as follows:

(In thousands)	June 30, 2022
Beginning balance January 1, 2022	$	64,762
Issuance of contingent consideration in connection with acquisitions	440
Measurement period adjustment	(55)
Reclassification to short-term contingent liabilities	(24,872)
Ending balance June 30, 2022	$	40,275

Any change in the fair value of the contingent consideration liability is recognized in general and administrative expense and reflects the changes in the business unit’s expected performance over the remaining earnout period and the Company’s estimate of the likelihood of achieving the applicable operational milestones (see Note 7, “Acquisitions”).

Assets and Liabilities Recorded at Carrying Value

Financial Assets and Liabilities

The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at June 30, 2022 and at December 31, 2021, excluding the debt instruments recorded at fair value, was $673.9 million and $310.0 million, respectively. The fair value of such debt at June 30, 2022 and at December 31, 2021 was $202.1 million and $328.0 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments.

XML

Debt

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

Debt

Debt

Net carrying amounts of debt are as follows:

	June 30, 2022								December 31, 2021
(In thousands)	Principal		Unaccreted Debt Discount		Change in Fair Value		Net		Principal		Unaccreted Debt Discount		Change in Fair Value		Net
Convertible notes
2026 convertible senior notes	$	690,000	$	(17,035)	$	—	$	672,965	$	690,000	$	(380,939)	$	—	$	309,061
Related party convertible notes
Foris convertible note	50,041		—		1,475		51,516		50,041		—		57,386		107,427
Loans payable and credit facilities
Other loans payable (revolving)	955		—		—		955		896		—		—		896
Total debt	$	740,996	$	(17,035)	$	1,475	725,436		$	740,937	$	(380,939)	$	57,386	417,384
Less: current portion							(955)								(108,323)
Long-term debt, net of current portion							$	724,481							$	309,061

Interest expense was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Contractual interest expense in connection with debt	$	3,441	$	2,322	$	6,831	$	5,850
Debt discount accretion	961		933		1,923		1,646
Interest expense in connection with debt	4,402		3,255		8,754		7,496
Discount accretion on liability in connection with acquisition of equity-method investment and with partnership liability, and other	902		1,468		1,813		3,040
Total interest expense	$	5,304	$	4,723	$	10,567	$	10,536

Adoption of ASU 2020-06

ASU 2020-06 became effective for the Company in the first quarter of 2022. The January 1, 2022 adoption of this standard, in connection with the 2026 Convertible Senior Notes, decreased additional paid-in capital by $368.0 million, increased debt by the same amount, and decreased the accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption.

Amendment to Foris Convertible Note

On June 30, 2022, the Company and Foris Ventures, LLC (Foris) entered into an agreement to extend the maturity of the Foris convertible note from July 1, 2022 to July 1, 2023. The Company determined that the amendment constituted a debt modification under U.S. GAAP, which resulted in no accounting consequences other than reclassification of the note from a current liability to noncurrent.

Future Minimum Payments

Future minimum payments under the Company's debt agreements as of June 30, 2022 are as follows:

(In thousands)	Convertible Notes		Related Party Convertible Notes		Loans Payable and Credit Facilities		Total
2022 (Remaining Six Months)	$	5,175	$	—	$	104	$	5,279
2023	10,350		62,622		1,010		73,982
2024	10,350		—		—		10,350
2025	10,350		—		—		10,350
2026	700,379		—		—		700,379
Thereafter	—		—		—		—
Total future minimum payments	736,604		62,622		1,114		800,340
Less: amount representing interest	(46,604)		(12,581)		(159)		(59,344)
Present value of minimum debt payments	690,000		50,041		955		740,996
Less: current portion of debt principal	—		—		(955)		(955)
Noncurrent portion of debt principal	$	690,000	$	50,041	$	—	$	740,041

XML

Mezzanine Equity

6 Months Ended

Jun. 30, 2022

Temporary Equity Disclosure [Abstract]

Mezzanine Equity

Mezzanine Equity

Gates Foundation

Contingently redeemable common stock as of June 30, 2022 and December 31, 2021 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill & Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults on its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%. The Company concluded a redemption event was not probable to occur. As of June 30, 2022, the Company's remaining research and development obligation under this arrangement was $0.1 million.

Ingredion Contingently Redeemable Noncontrolling Interest in Subsidiary

On June 1, 2021, the Company entered into a Membership Interest Purchase Agreement (MIPA) with Ingredion Corporation (Ingredion) to purchase 31% of the member units in RealSweet LLC (RealSweet), a 100% owned Amyris, Inc. subsidiary. Total consideration was $28.5 million in the form of a $10 million cash payment, the exchange of a $4 million payable previously due to Ingredion and $14.5 million of manufacturing intellectual property rights. The terms of the MIPA provide both parties with put/call rights under certain circumstances, including the occurrence of either or both of the following: (i) a change in ownership of fifty percent (50%) or more of the voting shares of such Member; or (ii) a change in the right to appoint or remove a majority of the board of directors of such Member. The Company concluded this change in control provision was not solely within its control and Ingredion’s contingently redeemable noncontrolling interest should be reflected outside of permanent equity in accordance with SEC’s Accounting Series Release 268, Presentation in Financial Statements of Redeemable Preferred Stocks (ASR 268).

The redemption price of this common-share noncontrolling interest is considered to be at fair value on the redemption date. Ingredion’s noncontrolling interest is not currently redeemable and the Company concluded a contingent redemption event is not probable to occur. The primary redemption contingency relates to a decrease in Ingredion’s ownership percentage below 8.4%, which is not likely to occur given that capital transactions require the unanimous consent of each member. Consequently, the noncontrolling interest will not be subsequently remeasured to its redemption amount until such contingency event and the related redemption are probable to occur; however, the Company will continue to reflect the attribution of any losses and distribution of dividends to the noncontrolling interest each quarter in accordance with ASC 810-10. At the transaction date, the Company recorded the $28.5 million noncontrolling interest in RealSweet as Mezzanine equity - contingently redeemable noncontrolling interest, which represented the value of Ingredion’s 31% ownership interest in the net assets of the RealSweet subsidiary. Under the terms of the MIPA, Amyris, Inc. is funding the construction costs of the project, which are estimated to be approximately $130 million. As of June 30, 2022, the Company has funded approximately $100 million towards the project and has $22 million of contractual purchase commitments for construction related costs.

EcoFabulous Contingently Redeemable Noncontrolling Interest in Subsidiary

On January 26, 2022, the Company and certain of its subsidiaries entered into an Agreement and Plan of Merger for the acquisition of 70% of No Planet B LLC (d/b/a EcoFabulous), a privately held company. In connection with the merger, the name of No Planet B LLC has been changed to EcoFab, LLC (EcoFab). No Planet B Investments, LLC holds 30% of the outstanding units of membership interests in EcoFab as of the effective time of the merger (the Minority Member). See Note 7, "Acquisitions". Concurrently, the Company and No Planet B Investments, LLC entered into the EcoFab, LLC Agreement, the terms of which provide the Minority Member a right to require EcoFab to repurchase its 30% noncontrolling interest after (i) EcoFab achieving Net Revenues in excess of $100 million on an annualized basis or, if earlier, (ii) December 31, 2026. The Company concluded this provision was not solely within its control and EcoFab’s contingently redeemable noncontrolling interest should be reflected outside of permanent equity in accordance with SEC’s Accounting Series Release 268, Presentation in Financial Statements of Redeemable Preferred Stocks (ASR 268) and ASC 480-10-S99, “Distinguishing Liabilities from Equity” (ASC 480).

The redemption price of this noncontrolling interest is considered to be at fair value on the redemption date. EcoFab’s noncontrolling interest is not currently redeemable and the Company concluded a contingent redemption event is probable to occur as the redemption date is no later than December 31, 2026. As a result, the noncontrolling interest will be recorded at the higher of (1) the cumulative amount that would result from applying the measurement guidance in ASC 810-10 (i.e., initial carrying amount, increased or decreased for the noncontrolling interest’s share of net income or loss, OCI or other comprehensive loss, and dividends) or (2) the redemption price. When it is determined the redemption price exceeds the noncontrolling interest’s carrying amount, the Company will record an ASC 480 measurement adjustment. As of June 30, 2022, the Company recorded $2.5 million EcoFab noncontrolling interest as Mezzanine equity - contingently redeemable noncontrolling interest, which included $3.1 million of the initial value of the Minority Member’s 30% ownership interest in the net assets of EcoFab and $0.6 million of losses attributable to the Minority Member during the period.

XML

Stockholders' (Deficit) Equity

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Stockholders' (Deficit) Equity

Stockholders' (Deficit) Equity

Warrants and Rights Activity Summary

In connection with various debt and equity transactions (see Note 4, “Debt” above, and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2021 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at June 30, 2022:

Transaction	Year Issued	Expiration Date	Number Outstanding as of December 31, 2021	Exercises	Expired	Exercise Price per Share of Warrants Exercised		Number Outstanding as of June 30, 2022	Exercise Price per Share as of June 30, 2022
Blackwell / Silverback warrants	2020	July 10, 2022	1,000,000	—	—	$	—	1,000,000	$	3.25
January 2020 warrant exercise right shares	2020	January 31, 2022	431,378	(431,378)	—	$	2.87	—	$	—
May 2019 6.50% Note Exchange warrants	2019	January 31, 2022	960,225	(960,225)	—	$	2.87	—	$	—
May 2017 cash warrants	2017	July 10, 2022	1,492,652	(904,732)	—	$	2.87	587,920	$	2.87
May 2017 dilution warrants	2017	July 10, 2022	56,910	—	—	$	—	56,910	$	—
July 2015 related party debt exchange	2015	July 29, 2025	58,690	—	—	$	—	58,690	$	0.15
			3,999,855	(2,296,335)	—	$	2.87	1,703,520

Warrant Exercises

During the six months ended June 30, 2022, warrant-holders exercised warrants to purchase 2,296,335 shares of the Company’s common stock at a weighted-average exercise price of $2.87 per share, for proceeds to the Company of $6.6 million.

XML

Acquisitions

6 Months Ended

Jun. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Acquisitions

Acquisitions

The purchase accounting for the net assets acquired, including goodwill, and the fair value of the contingent consideration and noncontrolling interest for the following acquisitions is preliminarily recorded based on available information and incorporates management's best estimates. The purchase accounting for taxes remains preliminary pending receipt of certain information required to finalize the determination of fair value. The net assets acquired in the transaction are generally recorded at their estimated acquisition-date fair values, while transaction costs associated with the acquisition are expensed as incurred. These transactions were accounted for by the acquisition method, and accordingly, the results of operations were included in the Company’s consolidated financial statements from their respective acquisition dates. Pro forma financial information is not presented as amounts are not material to the Company’s consolidated financial statements.

EcoFab LLC.

On January 26, 2022, the Company and certain of its subsidiaries entered into an Agreement and Plan of Merger for the acquisition of 70% of No Planet B LLC (d/b/a EcoFabulous), a privately held company. EcoFabulous is focused on delivering high performance, makeup artist-quality clean beauty products in ecofriendly packaging, and priced for Gen Z consumers. In connection with the merger, the name of No Planet B LLC has been changed to EcoFab, LLC (EcoFab). No Planet B Investments, LLC holds 30% of the outstanding units of membership interests in EcoFab as of the effective time of the merger, which is accounted for as Mezzanine equity - contingently redeemable noncontrolling interest. See Note 5, "Mezzanine Equity".

The purchase consideration for the acquisition of EcoFab consisted of $1.7 million in cash and 1,292,776 shares of Amyris stock with a fair value of $5.5 million. The noncontrolling interest had a fair value of $3.1 million as of the acquisition date.

The following table summarizes the purchase price allocation:

(In thousands)
Trademarks, trade names and other intellectual property	$	8,705
Customer relationships	512
Goodwill	1,023
Less: noncontrolling interest	$	(3,072)
Total consideration	$	7,168

Goodwill associated with this acquisition is not deductible for tax purposes.

The Company has determined that (i) EcoFab is a variable-interest entity (VIE) due to insufficient equity at risk, (ii) the Company is the primary beneficiary of EcoFab due to its power to direct the activities that most significantly affect EcoFab’s economic performance, and (iii) the Company has the ability to exert significant influence over EcoFab through its 70% equity ownership. As a result, the Company accounts for its investment in EcoFab on a consolidation basis in accordance with ASC 810, Consolidation.

MenoLabs, LLC.

On March 9, 2022, Amyris and Amyris Clean Beauty, Inc., a wholly owned subsidiary of Amyris, entered into an Asset Purchase Agreement with MenoLabs, LLC, (MenoLabs), an Arizona limited liability company, to purchase substantially all of the assets and assume the liabilities of MenoLabs. The transaction closed on March 10, 2022 (the Closing Date). MenoLabs was founded to fundamentally change how menopause is addressed by offering research-backed all-natural treatments of menopause symptoms. Prior to the Closing Date, Amyris and MenoLabs entered into that certain Loan Agreement and Promissory Note in January 2022, pursuant to which Amyris loaned to MenoLabs the aggregate principal amount of $0.5 million. In connection with the acquisition of MenoLabs, Amyris has assumed the Bridge Loan. The acquisition of MenoLabs will serve as a catalyst to accelerate growth and establish a leadership position in the fast-growing menopause market.

MenoLabs was acquired for total purchase consideration of $16.2 million, consisting of $11.3 million in cash, the Bridge Loan of $0.5 million, 852,234 shares of Amyris stock with a fair value of $3.9 million, and contingent consideration with a fair value of $0.4 million. The contingent consideration consists of two potential payments of up to $10 million each during the twelve (12) month period beginning on the first day of the first calendar month commencing after the Closing Date and the fourth quarter of 2024 respectively if both MenoLabs’s product revenues and profit margin meet the targets set forth for such period in the Asset Purchase Agreement (the Earnout Payments). The Earnout Payments will be in the form of cash or in an aggregate number of shares of Amyris Stock equal to the earnout achieved divided by the stock price on achievement date, at Amyris’s sole discretion. The $0.4 million fair value of the Earnout Payments is recorded as other liabilities in the accompanying condensed consolidated balance sheets. Allocation of the contingent consideration payments between short-term

and long-term liabilities on the accompanying consolidated balance sheets is based on management’s best estimates of when the relevant milestone will be achieved.

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible assets	$	311
Branded products	5,600
Application (App)	3,600
Goodwill	6,642
Total consideration	$	16,153

Goodwill associated with this acquisition is expected to be deductible for tax purposes.

Onda Beauty Inc.

On April 11, 2022, Amyris and Amyris-O Merger Sub, Inc., a wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger and Reorganization with Onda Beauty Inc. (“Onda”) and the stockholders’ representative for the acquisition of the outstanding shares of Onda. Founded in 2014, Onda offers a curated matrix of brands as well as services, such as facials. Onda provides Amyris with a venue to test products, host events and produce content in a luxury retail setting.

Onda was acquired for total purchase consideration of $4.9 million, consisting of cash payment of $1.0 million at closing, Amyris stock valued at $3.5 million, estimated net working capital adjustment of $(0.1) million and holdback consideration of $0.5 million to be issued in the form of Amyris stock within 12 months after the closing date subject to the indemnification provision in accordance with the Agreement and Plan of Merger and Reorganization.

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible liabilities	$	(164)
Trademarks, trade names and other intellectual property	4,275
Customer relationships	251
Goodwill	553
Total consideration	$	4,915

Goodwill associated with this acquisition is not deductible for tax purposes.

Interfaces Indústria E Comércio De Cosméticos Ltda.

On April 29, 2022, Amyris and Amyris Biossance do Brasil Comércio de Cosméticos Ltda., a wholly owned subsidiary of the Company, entered into a Contract for the Purchase and Sale of Quotas and Other Covenants with Interfaces Indústria e Comércio de Cosméticos Ltda. (“Interfaces”) and its stockholders for the acquisition of the outstanding shares of Interfaces. The transaction closed on May 16, 2022. Interfaces was a limited liability company incorporated under the laws of Brazil, headquartered in the City of Vinhedo, State of São Paulo, specializing in producing cosmetics for skin care, hair care, and makeup. The acquisition of Interfaces is deemed critical to sustain the Company’s growth, add operational resilience to its supply chain, reduce its dependency on third-party manufacturing, and increase the ability to source strategic components.

Interfaces was acquired for total purchase consideration of $6.7 million, consisting of cash payment of $3.4 million at closing and cash payment of $3.3 million to be released to the sellers in 24 (twenty-four) monthly and successive installments.

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible assets	$	1,474
Goodwill	5,219
Total consideration	$	6,693

Goodwill associated with this acquisition is not deductible for tax purposes.

XML

Net Loss per Share Attributable to Common Stockholders

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Net Loss per Share Attributable to Common Stockholders

Net Loss per Share Attributable to Common Stockholders

The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses.

The following table presents the calculation of basic and diluted loss per share:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except shares and per share amounts)	2022		2021		2022		2021
Numerator:
Net (loss) income attributable to Amyris, Inc.	$	(110,013)	$	15,381	$	(217,318)	$	(275,870)
Less: loss (income) allocated to participating securities	—		(13)		—		1,086
Net (loss) income attributable to Amyris, Inc. common stockholders, basic	$	(110,013)	$	15,368	$	(217,318)	$	(274,784)
Adjustment to earnings allocated to participating securities	—		13		—		—
Interest on convertible debt	759		902		1,216		—
Gain from change in fair value of debt	(35,114)		(71,067)		(47,764)		—
Gain from change in fair value of derivative instruments	(3,598)		—		(5,413)		—
Net loss attributable to Amyris, Inc. common stockholders, diluted	$	(147,966)	$	(54,784)	$	(269,279)	$	(274,784)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic	319,916,244		320,088,143		316,425,739		279,819,520
Net loss per share, basic	$	(0.34)	$	0.05	$	(0.69)	$	(0.98)
Weighted-average shares of common stock outstanding	319,916,244		320,088,143		316,425,739		279,819,520
Weighted-average shares of preferred stock outstanding	—		277,666		—		—
Effect of dilutive convertible debt	16,680,334		18,442,040		18,532,262		—
Effect of dilutive common stock warrants	46,301		—		840,274		—
Weighted-average shares of common stock equivalents used in computing net loss per share of common stock, diluted	336,642,879		338,807,849		335,798,275		279,819,520
Net loss per share, diluted	$	(0.44)	$	(0.16)	$	(0.80)	$	(0.98)

For the three months ended June 30, 2022 and 2021 and for the six months ended June 30, 2022, basic income per share differed from diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was dilutive. For the six months ended June 30, 2021, basic loss per share equaled diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was antidilutive. The following table presents outstanding shares of potentially dilutive securities:

	Three Months Ended June 30,		Six Months Ended June 30,
	2022	2021	2022	2021
Period-end common stock warrants	1,587,920	10,034,295	1,587,920	10,034,295
Convertible promissory notes(1)	86,683,389	—	86,683,389	16,680,334
Period-end stock options to purchase common stock	4,718,507	6,357,163	4,718,507	6,357,163
Period-end restricted stock units	17,313,912	8,196,960	17,313,912	8,196,960
Contingently issuable common shares	3,593,193	—	3,593,193	—
Total potentially dilutive securities excluded from computation of diluted loss per share	113,896,921	24,588,418	113,896,921	41,268,752

______________

(1)    The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Guarantor Arrangements

The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of June 30, 2022 and December 31, 2021.

The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM, the Company's international subsidiaries and the Company’s ownership interests in joint ventures. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note.

In October 2021, the Company entered into a 10-year manufacturing partnership agreement with Renfield Manufacturing, LLC (Renfield) to provide manufacturing services and third-party logistics processes, including inventory management, warehousing, and fulfillment for certain of the Company’s consumer product lines. The Company also provided a $0.5 million letter of credit and guarantee to the lessor of the Renfield manufacturing facility, which extends through August 2032. If Renfield fails to perform under the facility lease, the Company can terminate the manufacturing agreement. The Company expects that its potential future performance under the guarantee is not probable of occurrence. Accordingly, the Company had no liabilities recorded for the guarantee as of June 30, 2022 and December 31, 2021.

Other Matters

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. In early 2021, the parties attended court-ordered mediation, but as the case did not settle, the parties commenced discovery. On July 30, 2021, plaintiffs filed a motion seeking class certification and the Company filed its opposition on September 24, 2021; after briefing and argument, it was granted in part on December 8, 2021. On December 22, 2021, the Company filed a petition seeking interlocutory review of that order in the U.S. Court of Appeals for the Ninth Circuit, which was fully briefed on January 14, 2022. On February 4, 2022, the parties reached a tentative settlement of the securities class action, which requires the court’s review and approval. On March 24, 2022, the parties submitted the proposed settlement agreement to the Court. A slightly revised proposed settlement agreement and supporting documents were filed on July 21, 2022. On July 22, 2022, the Court preliminarily approved the settlement agreement and set the hearing date for final approval on November 8, 2022. If the settlement is approved by the Court, the settlement amount will be covered by the Company’s directors and officers insurance policy.

Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021, and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021, and re-filed in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. The Company's motion to dismiss was granted without prejudice on June 30, 2021. After obtaining an extension, Bonner amended its complaint on February 22, 2022. On March 24, 2022, the Company filed a motion seeking full dismissal with prejudice of claims alleged in Bonner’s amended complaint. On June 20, 2022, the Court granted the Company's motion to dismiss Bonner's amended complaint without prejudice. On July 14, 2022, Bonner informed the Court that it does not intend to file a second amended complaint.

On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended. The Company filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The Court denied the Company's motions on July 26, 2021, and the Company appealed the Court's ruling regarding its motion to compel arbitration on July 27, 2021, filing its appeal to the U.S. Court of Appeals for the Second Circuit on November 4, 2021. The appellate briefing process was completed on January 19, 2022. The Court scheduled oral argument for September 9, 2022. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom.

The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s expectations, the Company’s condensed consolidated financial statements for the relevant reporting period could be materially adversely affected.

XML

Revenue Recognition and Contract Assets and Liabilities

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenue Recognition and Contract Assets and Liabilities

Revenue Recognition, and Contract Assets and Liabilities

Disaggregation of Revenue

The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
North America	$	39,963	$	—	$	1,244	$	41,207	$	30,123	$	11,000	$	—	$	41,123
Europe	6,338		6,454		2,927		15,719		2,500		—		2,903		5,403
Asia	5,171		—		192		5,363		3,929		—		1,241		5,170
South America	2,094		—		—		2,094		332		—		—		332
Other	824		—		—		824		288		—		—		288
	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
North America	$	72,919	$	433	$	2,720	$	76,072	$	50,175	$	11,000	$	250	$	61,425
Europe	13,627		15,334		6,190		35,151		5,472		143,800		5,250		154,522
Asia	6,659		—		384		7,043		8,334		—		3,524		11,858
South America	3,113		—		—		3,113		789		—		—		789
Other	1,537		—		—		1,537		581		—		—		581
	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

The following table presents revenue by major product and service, as well as by management classification:

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total		Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total
Consumer	$	42,219	$	5	$	749	$	42,973	$	20,695	$	—	$	—	$	20,695
Technology access	12,171		6,449		3,614		22,234		16,477		11,000		4,144		31,621
	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total		Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total
Consumer	$	74,861	$	438	$	2,225	$	77,524	$	36,347	$	—	$	—	$	36,347
Technology access	22,994		15,329		7,069		45,392		29,004		154,800		9,024		192,828
	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

Significant Revenue Agreements and Customers

In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2021 Form 10-K), the Company recognized the following revenue:

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
Sephora	$	10,092	$	—	$	—	$	10,092	$	8,078	$	—	$	—	$	8,078
DSM - related party	2,965		6,454		2,000		11,419		4,620		—		2,000		6,620
Ingredion / PureCircle	1,197		—		—		1,197		2,253		10,000		—		12,253
Subtotal revenue from significant revenue agreements	14,254		6,454		2,000		22,708		14,951		10,000		2,000		26,951
Revenue from all other customers	40,136		—		2,363		42,499		22,221		1,000		2,144		25,365
Total revenue from all customers	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
Sephora	$	17,725	$	—	$	—	$	17,725	$	12,519	$	—	$	—	$	12,519
DSM - related party	7,377		15,270		4,000		26,647		6,281		143,612		4,000		153,893
Ingredion / PureCircle	2,748		—		—		2,748		2,253		10,000		—		12,253
Subtotal revenue from significant revenue agreements	27,850		15,270		4,000		47,120		21,053		153,612		4,000		178,665
Revenue from all other customers	70,005		497		5,294		75,796		44,298		1,188		5,024		50,510
Total revenue from all customers	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

DSM Ingredients Collaboration

Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with $2.0 million quarterly from January 1, 2022 to June 30, 2022 for services focused on achieving certain fermentation yield and cost targets related to certain molecules. During the three and six months ended June 30, 2022, the Company recognized $2.0 million and $4.0 million of collaboration revenue in connection with the agreement.

DSM License Agreement and Contract Assignment

In March 2021 the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property of the Company and assigned the Company’s rights and obligations under certain F&F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain commercial milestones are achieved in each of the calendar years 2022 through 2024. The Company determined the licenses to be functional intellectual property and allocated $143.6 million of the transaction price to the licenses and recorded $143.6 million of licenses and royalties revenues in the three-months ended March 31, 2021. The Company also concluded the additional contingent consideration represents variable consideration that is subject to a sales/usage-based threshold and is dependent up on the IP License. The Company is required to apply the royalty recognition constrain guidance in ASC 606-10-55-65 and will recognize revenue at the later of (1) when the underlying sales or usage has occurred and (2) the related performance obligation has been satisfied (or partially satisfied). During the three and six months ended June 30, 2022, the Company recorded $6.5 million and $15.3 million, respectively, of license and royalties revenue and a corresponding contract asset under the contingent consideration provisions of the agreements.

Contract Assets and Liabilities

When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional.

Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer.

Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company.

Contract Balances

The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:

(In thousands)	June 30, 2022		December 31, 2021
Accounts receivable, net	$	41,125	$	37,074
Accounts receivable - related party, net	$	5,001	$	5,667
Contract assets	$	3,946	$	4,227
Contract assets - related party	$	15,265	$	—
Contract liabilities	$	816	$	2,530
Contract liabilities, noncurrent(1)	$	—	$	111

(1)As of June 30, 2022 and December 31, 2021, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.

Remaining Performance Obligations

The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of June 30, 2022.

(In thousands)	As of June 30, 2022
Remaining 2022	$	526
2023	143
2024	143
2025	143
2026 and thereafter	143
Total from all customers	$	1,098

In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual property.

XML

Related Party Transactions

6 Months Ended

Jun. 30, 2022

Related Party Transactions [Abstract]

Related Party Transactions

Related Party Transactions

Related Party Debt

Related party debt was as follows:

	June 30, 2022								December 31, 2021
In thousands	Principal		Unaccreted Debt Discount		Change in Fair Value		Net		Principal		Unaccreted Debt Discount		Change in Fair Value		Net
Foris convertible note	$	50,041	$	—	$	1,475	$	51,516	$	50,041	$	—	$	57,386	$	107,427

Related Party Equity

There we no related party equity transactions during the three or six months ended June 30, 2022.

Related Party Revenue

See Note 10, "Revenue Recognition, and Contract Assets and Liabilities", for information about related party revenue transactions with DSM.

Related Party Accounts Receivable, Contract Assets and Accounts Payable

Related party accounts receivable, contract assets and accounts payable were as follows:

(In thousands)	June 30, 2022		December 31, 2021
Accounts receivable - related party	$	5,001	$	5,667
Contract assets - related party	$	15,265	$	—
Accounts payable - related party	$	4,241	$	5,011

XML

Stock-based Compensation

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation

Stock-based Compensation

The Company’s stock option activity and related information for the six months ended June 30, 2022 was as follows:

	Quantity of Stock Options	Weighted- average Exercise Price		Weighted-average Remaining Contractual Life, in Years	Aggregate Intrinsic Value, in Thousands
Outstanding - December 31, 2021	3,087,225	$	9.91	7.1	$	2,580
Granted	1,916,237	$	3.03
Exercised	(36,021)	$	2.84
Forfeited or expired	(248,934)	$	11.55
Outstanding - June 30, 2022	4,718,507	$	7.09	8.0	$	1
Vested or expected to vest after June 30, 2022	4,451,407	$	7.24	7.9	$	1
Exercisable at June 30, 2022	1,785,373	$	10.66	5.8	$	—

Activity related to the Company’s restricted stock units (RSUs) (including performance-based restricted stock units (PSUs)) for the six months ended June 30, 2022 was as follows:

	Quantity of Restricted Stock Units	Weighted-average Grant-date Fair Value		Weighted-average Remaining Contractual Life, in Years
Outstanding - December 31, 2021	13,731,320	$	9.99	2.8
Awarded	5,965,118	$	3.60
Released	(1,726,412)	$	7.26
Forfeited	(656,114)	$	6.28
Outstanding - June 30, 2022	17,313,912	$	8.20	2.4
Vested or expected to vest after June 30, 2022	15,155,053	$	8.06	2.3

Stock-based compensation expense during the three and six months ended June 30, 2022 and 2021 is reflected in the condensed consolidated statements of operations as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2021		2020
Cost of products sold	$	81	$	73	$	159	$	137
Research and development	1,784		1,318		3,401		2,380
Sales, general and administrative	10,782		7,355		20,675		10,511
Total stock-based compensation expense	$	12,647	$	8,746	$	24,235	$	13,028

As of June 30, 2022, $122.0 million of unrecognized compensation expense related to stock options and RSUs is expected to be recognized over a weighted-average period of 3.2 years.

XML

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsNone.

XML

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Use of Estimates and Judgements

Use of Estimates and Judgements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.

Accounting Update Recently Adopted and Accounting Standards or Updates Not Yet Adopted

Accounting Update Recently Adopted

In the six months ended June 30, 2022, the Company adopted this accounting standard update:

Convertible Debt, and Derivatives and Hedging. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 became effective for the Company in the first quarter of 2022. Adoption of this standard on January 1, 2022 in connection with the 2026 Convertible Senior Notes (see Note 4, "Debt"), decreased additional paid-in capital by $368.0 million, increased debt by the same amount and decreased accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption.

Accounting Standards or Updates Not Yet Adopted

Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. Because the Company met the SEC definition of a smaller reporting company when ASU 2016-13 was issued, this new accounting standard will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This standard will be effective for the Company in the first quarter of 2023 and will be applied prospectively to business combinations occurring on or after the effective date of the standard. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the guidance and the impact on its consolidated financial statements and related disclosures.

XML

Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

(In thousands)	Balance at Beginning of Period		Provisions		Write-offs, Net		Balance at End of Period
Six months ended June 30, 2022	$	945	$	392	$	—	$	1,337
Six months ended June 30, 2021	$	137	$	806	$	—	$	943

Schedule of Inventories

Inventories

(In thousands)	June 30, 2022		December 31, 2021
Raw materials	$	35,403	$	25,733
Work-in-process	8,783		6,941
Finished goods	55,009		42,396
Inventories	$	99,195	$	75,070

Schedule of Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

(In thousands)	June 30, 2022		December 31, 2021
Prepayments, advances and deposits	$	34,229	$	25,140
Non-inventory production supplies	4,462		3,956
Recoverable taxes from Brazilian government entities	1,658		1,188
Other	4,318		3,229
Total prepaid expenses and other current assets	$	44,667	$	33,513

Schedule of Property, Plant and Equipment, Net

Property, Plant and Equipment, Net

(In thousands)	June 30, 2022		December 31, 2021
Manufacturing facilities and equipment	$	70,423	$	51,855
Leasehold improvements	49,097		45,780
Computers and software	11,430		9,174
Furniture and office equipment, vehicles and land	3,737		3,688
Construction in progress	112,869		48,032
	247,556		158,529
Less: accumulated depreciation and amortization	(96,419)		(85,694)
Property, plant and equipment, net	$	151,137	$	72,835

Schedule of Depreciation and Amortization

During the three and six months ended June 30, 2022 and 2021, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Depreciation and amortization expense	$	2,586	$	2,186	$	4,986	$	4,300

Schedule of Goodwill

The changes in the carrying amount of goodwill were as follows:

(In thousands)	June 30, 2022
Balance at beginning of year	$	131,259
Acquisitions	13,437
Effect of currency translation adjustment	(10,532)
Ending balance	$	134,164

Schedule of Finite-Lived Intangible Assets

The following table summarizes the components of intangible assets (in thousands, except estimated useful life):

		June 30, 2022						December 31, 2021
Amounts in thousands	Estimated Useful Life (in Years)	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Trademarks and trade names, and branded products	10	$	29,758	$	(1,573)	$	28,185	$	11,484	$	(496)	$	10,988
Customer relationships	5 - 16	8,703		(667)		8,036		8,197		(267)		7,930
Developed technology and software applications	5 - 12	21,545		(689)		20,856		19,962		(200)		19,762
Patents	17	600		(32)		568		600		(15)		585
Total intangible assets		$	60,606	$	(2,961)	$	57,645	$	40,243	$	(978)	$	39,265

Schedule of Finite-lived Intangible Assets Amortization Expense

Total future amortization of intangible assets as of June 30, 2022 is as follows (in thousands):

Amounts in thousands
2022 (remainder)	$	2,311
2023	6,177
2024	7,254
2025	7,386
2026	7,140
Thereafter	27,377
Total future amortization	$	57,645

Schedule of Lease, Cost

Information related to the Company's right-of-use assets and related lease liabilities were as follows:

	Six Months Ended June 30,
	2022	2021
Cash paid for operating lease liabilities, in thousands	$6,092	$2,369
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands	$51,789	$1,110
Weighted-average remaining lease term	11.6	2.6
Weighted-average discount rate	19.5%	17.0%

Schedule of Lessee, Lease Liability, Maturity

Maturities of lease liabilities as of June 30, 2022 were as follows:

Years ending December 31: (In thousands)	Financing Leases		Operating Leases		Total Leases
2022 (Remaining Six Months)	$	11	$	6,964	$	6,975
2023	21		12,962		12,983
2024	21		22,075		22,096
2025	21		22,374		22,395
2026	16		22,807		22,823
Thereafter	—		229,717		229,717
Total lease payments	90		316,899		316,989
Less: amount representing interest	(24)		(239,974)		(239,998)
Total lease liability	$	66	$	76,925	$	76,991
Current lease liability	$	12	$	1,640	$	1,652
Noncurrent lease liability	54		75,285		75,339
Total lease liability	$	66	$	76,925	$	76,991

Schedule of Other Assets

Other Assets

(In thousands)	June 30, 2022		December 31, 2021
Investment in non-trade receivable(1)	$	10,251	$	—
Equity-method investments in affiliates	4,682		9,443
Deposits	517		129
Other	2,801		994
Total other assets	$	18,251	$	10,566

______________

(1) In March 2022, the Company loaned a privately held company $10 million in exchange for a senior secured convertible promissory note (the Note) which matures in March 2025, unless earlier redeemed or converted into equity of the privately held company. The Note bears interest at 8% per annum and is convertible, at the Company's option, into equity of the privately held company upon maturity of the Note or in the event of an initial public offering, equity

financing, or corporate transaction (such as a sale or merger), in each case, at a conversion price that is dependent on a variety of factors. In addition, the Note is redeemable prior to maturity, at the issuer's option, in the event of one or more equity or debt financings, one or more asset sales, or an initial public offering, in each case equal to or greater than $50 million in the aggregate. The Company concluded that the arrangement qualifies for accounting as a loan as required by ASC 310-10. The Company will periodically evaluate the collectability of the loan, and an allowance for credit losses will be recorded when the Company concludes that all or a portion of the loan balance is no longer collectible.

Schedule of Accrued and Other Current Liabilities

Accrued and Other Current Liabilities

(In thousands)	June 30, 2022		December 31, 2021
Business acquisitions contingent consideration payable(1)	$	32,411	$	30,000
Payroll and related expenses	15,160		9,151
Accrued interest	11,111		9,572
Liability in connection with acquisition of equity-method investment	9,921		8,735
Asset retirement obligation(2)	3,791		3,336
Professional services	2,295		2,447
Contract termination fees	1,368		1,345
Tax-related liabilities	1,057		988
License fee payable	1,050		1,050
Other	2,525		4,833
Total accrued and other current liabilities	$	80,689	$	71,457

______________

(1)    Business acquisitions contingent consideration payable is the current portion of total acquisition-related contingent consideration.

(2)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with the Company's 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.

XML

Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:

(In thousands)	June 30, 2022								December 31, 2021
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Liabilities
Foris Convertible Note	$	—	$	—	$	51,516	$	51,516	$	—	$	—	$	107,427	$	107,427
Freestanding derivative instruments issued in connection with debt and equity instruments	—		—		1,649		1,649		—		—		7,062		7,062
Acquisition-related contingent consideration	—		—		40,275		40,275		—		—		64,762		64,762
Total liabilities measured and recorded at fair value	$	—	$	—	$	93,440	$	93,440	$	—	$	—	$	179,251	$	179,251

Schedule of Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):

(In thousands)	Derivative Liability
Balance at December 31, 2021	$	7,062
Change in fair value of derivative instruments	(5,413)
Balance at June 30, 2022	$	1,649

Schedule of Fair Value Measurement Inputs and Valuation Techniques

Input assumptions for the freestanding instrument are as follows:

	Range for Period Ended
Input assumptions for liability classified warrants:	June 30, 2022		December 31, 2021
Fair value of common stock on valuation date	$1.85 - $4.36		$5.41 - $19.10
Exercise price of warrants	$2.87		$2.87
Expected volatility	106% - 110%		107% - 114%
Risk-free interest rate	2.28% - 2.92%		0.16% – 0.73%
Expected term in years	2		2
Dividend yield	0.0	%	0.0 %

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The fair value of contingent consideration is classified as Level 3. Contingent consideration activity and balances are as follows:

(In thousands)	June 30, 2022
Beginning balance January 1, 2022	$	64,762
Issuance of contingent consideration in connection with acquisitions	440
Measurement period adjustment	(55)
Reclassification to short-term contingent liabilities	(24,872)
Ending balance June 30, 2022	$	40,275

XML

Debt (Tables)

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

Schedule of Debt

Net carrying amounts of debt are as follows:

	June 30, 2022								December 31, 2021
(In thousands)	Principal		Unaccreted Debt Discount		Change in Fair Value		Net		Principal		Unaccreted Debt Discount		Change in Fair Value		Net
Convertible notes
2026 convertible senior notes	$	690,000	$	(17,035)	$	—	$	672,965	$	690,000	$	(380,939)	$	—	$	309,061
Related party convertible notes
Foris convertible note	50,041		—		1,475		51,516		50,041		—		57,386		107,427
Loans payable and credit facilities
Other loans payable (revolving)	955		—		—		955		896		—		—		896
Total debt	$	740,996	$	(17,035)	$	1,475	725,436		$	740,937	$	(380,939)	$	57,386	417,384
Less: current portion							(955)								(108,323)
Long-term debt, net of current portion							$	724,481							$	309,061

Interest Income and Interest Expense Disclosure

Interest expense was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Contractual interest expense in connection with debt	$	3,441	$	2,322	$	6,831	$	5,850
Debt discount accretion	961		933		1,923		1,646
Interest expense in connection with debt	4,402		3,255		8,754		7,496
Discount accretion on liability in connection with acquisition of equity-method investment and with partnership liability, and other	902		1,468		1,813		3,040
Total interest expense	$	5,304	$	4,723	$	10,567	$	10,536

Schedule of Long-term Debt Instruments

Future minimum payments under the Company's debt agreements as of June 30, 2022 are as follows:

(In thousands)	Convertible Notes		Related Party Convertible Notes		Loans Payable and Credit Facilities		Total
2022 (Remaining Six Months)	$	5,175	$	—	$	104	$	5,279
2023	10,350		62,622		1,010		73,982
2024	10,350		—		—		10,350
2025	10,350		—		—		10,350
2026	700,379		—		—		700,379
Thereafter	—		—		—		—
Total future minimum payments	736,604		62,622		1,114		800,340
Less: amount representing interest	(46,604)		(12,581)		(159)		(59,344)
Present value of minimum debt payments	690,000		50,041		955		740,996
Less: current portion of debt principal	—		—		(955)		(955)
Noncurrent portion of debt principal	$	690,000	$	50,041	$	—	$	740,041

XML

Stockholders' Deficit (Tables)

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Warrants and Rights Activity Summary

The following table summarizes warrants outstanding at June 30, 2022:

Transaction	Year Issued	Expiration Date	Number Outstanding as of December 31, 2021	Exercises	Expired	Exercise Price per Share of Warrants Exercised		Number Outstanding as of June 30, 2022	Exercise Price per Share as of June 30, 2022
Blackwell / Silverback warrants	2020	July 10, 2022	1,000,000	—	—	$	—	1,000,000	$	3.25
January 2020 warrant exercise right shares	2020	January 31, 2022	431,378	(431,378)	—	$	2.87	—	$	—
May 2019 6.50% Note Exchange warrants	2019	January 31, 2022	960,225	(960,225)	—	$	2.87	—	$	—
May 2017 cash warrants	2017	July 10, 2022	1,492,652	(904,732)	—	$	2.87	587,920	$	2.87
May 2017 dilution warrants	2017	July 10, 2022	56,910	—	—	$	—	56,910	$	—
July 2015 related party debt exchange	2015	July 29, 2025	58,690	—	—	$	—	58,690	$	0.15
			3,999,855	(2,296,335)	—	$	2.87	1,703,520

XML

Acquisitions (Tables)

6 Months Ended

Jun. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the purchase price allocation:

(In thousands)
Trademarks, trade names and other intellectual property	$	8,705
Customer relationships	512
Goodwill	1,023
Less: noncontrolling interest	$	(3,072)
Total consideration	$	7,168

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible assets	$	311
Branded products	5,600
Application (App)	3,600
Goodwill	6,642
Total consideration	$	16,153

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible liabilities	$	(164)
Trademarks, trade names and other intellectual property	4,275
Customer relationships	251
Goodwill	553
Total consideration	$	4,915

The following table summarizes the purchase price allocation:

(In thousands)
Net tangible assets	$	1,474
Goodwill	5,219
Total consideration	$	6,693

XML

Net Loss per Share Attributable to Common Stockholders (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table presents the calculation of basic and diluted loss per share:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except shares and per share amounts)	2022		2021		2022		2021
Numerator:
Net (loss) income attributable to Amyris, Inc.	$	(110,013)	$	15,381	$	(217,318)	$	(275,870)
Less: loss (income) allocated to participating securities	—		(13)		—		1,086
Net (loss) income attributable to Amyris, Inc. common stockholders, basic	$	(110,013)	$	15,368	$	(217,318)	$	(274,784)
Adjustment to earnings allocated to participating securities	—		13		—		—
Interest on convertible debt	759		902		1,216		—
Gain from change in fair value of debt	(35,114)		(71,067)		(47,764)		—
Gain from change in fair value of derivative instruments	(3,598)		—		(5,413)		—
Net loss attributable to Amyris, Inc. common stockholders, diluted	$	(147,966)	$	(54,784)	$	(269,279)	$	(274,784)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic	319,916,244		320,088,143		316,425,739		279,819,520
Net loss per share, basic	$	(0.34)	$	0.05	$	(0.69)	$	(0.98)
Weighted-average shares of common stock outstanding	319,916,244		320,088,143		316,425,739		279,819,520
Weighted-average shares of preferred stock outstanding	—		277,666		—		—
Effect of dilutive convertible debt	16,680,334		18,442,040		18,532,262		—
Effect of dilutive common stock warrants	46,301		—		840,274		—
Weighted-average shares of common stock equivalents used in computing net loss per share of common stock, diluted	336,642,879		338,807,849		335,798,275		279,819,520
Net loss per share, diluted	$	(0.44)	$	(0.16)	$	(0.80)	$	(0.98)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table presents outstanding shares of potentially dilutive securities:

	Three Months Ended June 30,		Six Months Ended June 30,
	2022	2021	2022	2021
Period-end common stock warrants	1,587,920	10,034,295	1,587,920	10,034,295
Convertible promissory notes(1)	86,683,389	—	86,683,389	16,680,334
Period-end stock options to purchase common stock	4,718,507	6,357,163	4,718,507	6,357,163
Period-end restricted stock units	17,313,912	8,196,960	17,313,912	8,196,960
Contingently issuable common shares	3,593,193	—	3,593,193	—
Total potentially dilutive securities excluded from computation of diluted loss per share	113,896,921	24,588,418	113,896,921	41,268,752

______________

(1)    The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

XML

Revenue Recognition and Contract Assets and Liabilities (Tables)

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
North America	$	39,963	$	—	$	1,244	$	41,207	$	30,123	$	11,000	$	—	$	41,123
Europe	6,338		6,454		2,927		15,719		2,500		—		2,903		5,403
Asia	5,171		—		192		5,363		3,929		—		1,241		5,170
South America	2,094		—		—		2,094		332		—		—		332
Other	824		—		—		824		288		—		—		288
	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
North America	$	72,919	$	433	$	2,720	$	76,072	$	50,175	$	11,000	$	250	$	61,425
Europe	13,627		15,334		6,190		35,151		5,472		143,800		5,250		154,522
Asia	6,659		—		384		7,043		8,334		—		3,524		11,858
South America	3,113		—		—		3,113		789		—		—		789
Other	1,537		—		—		1,537		581		—		—		581
	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

The following table presents revenue by major product and service, as well as by management classification:

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total		Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total
Consumer	$	42,219	$	5	$	749	$	42,973	$	20,695	$	—	$	—	$	20,695
Technology access	12,171		6,449		3,614		22,234		16,477		11,000		4,144		31,621
	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total		Renewable Products		Licenses and Royalties		Grants, Collaborations and Other		Total
Consumer	$	74,861	$	438	$	2,225	$	77,524	$	36,347	$	—	$	—	$	36,347
Technology access	22,994		15,329		7,069		45,392		29,004		154,800		9,024		192,828
	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

Revenue in Connection with Significant Revenue Agreement

In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2021 Form 10-K), the Company recognized the following revenue:

	Three Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
Sephora	$	10,092	$	—	$	—	$	10,092	$	8,078	$	—	$	—	$	8,078
DSM - related party	2,965		6,454		2,000		11,419		4,620		—		2,000		6,620
Ingredion / PureCircle	1,197		—		—		1,197		2,253		10,000		—		12,253
Subtotal revenue from significant revenue agreements	14,254		6,454		2,000		22,708		14,951		10,000		2,000		26,951
Revenue from all other customers	40,136		—		2,363		42,499		22,221		1,000		2,144		25,365
Total revenue from all customers	$	54,390	$	6,454	$	4,363	$	65,207	$	37,172	$	11,000	$	4,144	$	52,316
	Six Months Ended June 30,
(In thousands)	2022								2021
	Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total		Renewable Products		Licenses and Royalties		Collaborations, Grants and Other		Total
Sephora	$	17,725	$	—	$	—	$	17,725	$	12,519	$	—	$	—	$	12,519
DSM - related party	7,377		15,270		4,000		26,647		6,281		143,612		4,000		153,893
Ingredion / PureCircle	2,748		—		—		2,748		2,253		10,000		—		12,253
Subtotal revenue from significant revenue agreements	27,850		15,270		4,000		47,120		21,053		153,612		4,000		178,665
Revenue from all other customers	70,005		497		5,294		75,796		44,298		1,188		5,024		50,510
Total revenue from all customers	$	97,855	$	15,767	$	9,294	$	122,916	$	65,351	$	154,800	$	9,024	$	229,175

Contract with Customer, Asset and Liability

The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:

(In thousands)	June 30, 2022		December 31, 2021
Accounts receivable, net	$	41,125	$	37,074
Accounts receivable - related party, net	$	5,001	$	5,667
Contract assets	$	3,946	$	4,227
Contract assets - related party	$	15,265	$	—
Contract liabilities	$	816	$	2,530
Contract liabilities, noncurrent(1)	$	—	$	111

(1)As of June 30, 2022 and December 31, 2021, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction

The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of June 30, 2022.

(In thousands)	As of June 30, 2022
Remaining 2022	$	526
2023	143
2024	143
2025	143
2026 and thereafter	143
Total from all customers	$	1,098

XML

Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2022

Related Party Transactions [Abstract]

Schedule of Related Party Debt

Related party debt was as follows:

	June 30, 2022								December 31, 2021
In thousands	Principal		Unaccreted Debt Discount		Change in Fair Value		Net		Principal		Unaccreted Debt Discount		Change in Fair Value		Net
Foris convertible note	$	50,041	$	—	$	1,475	$	51,516	$	50,041	$	—	$	57,386	$	107,427

Schedule of Related Party Accounts Receivables

Related party accounts receivable, contract assets and accounts payable were as follows:

(In thousands)	June 30, 2022		December 31, 2021
Accounts receivable - related party	$	5,001	$	5,667
Contract assets - related party	$	15,265	$	—
Accounts payable - related party	$	4,241	$	5,011

XML

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity

The Company’s stock option activity and related information for the six months ended June 30, 2022 was as follows:

	Quantity of Stock Options	Weighted- average Exercise Price		Weighted-average Remaining Contractual Life, in Years	Aggregate Intrinsic Value, in Thousands
Outstanding - December 31, 2021	3,087,225	$	9.91	7.1	$	2,580
Granted	1,916,237	$	3.03
Exercised	(36,021)	$	2.84
Forfeited or expired	(248,934)	$	11.55
Outstanding - June 30, 2022	4,718,507	$	7.09	8.0	$	1
Vested or expected to vest after June 30, 2022	4,451,407	$	7.24	7.9	$	1
Exercisable at June 30, 2022	1,785,373	$	10.66	5.8	$	—

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

Activity related to the Company’s restricted stock units (RSUs) (including performance-based restricted stock units (PSUs)) for the six months ended June 30, 2022 was as follows:

	Quantity of Restricted Stock Units	Weighted-average Grant-date Fair Value		Weighted-average Remaining Contractual Life, in Years
Outstanding - December 31, 2021	13,731,320	$	9.99	2.8
Awarded	5,965,118	$	3.60
Released	(1,726,412)	$	7.26
Forfeited	(656,114)	$	6.28
Outstanding - June 30, 2022	17,313,912	$	8.20	2.4
Vested or expected to vest after June 30, 2022	15,155,053	$	8.06	2.3

Share-based Payment Arrangement, Expensed and Capitalized, Amount

Stock-based compensation expense during the three and six months ended June 30, 2022 and 2021 is reflected in the condensed consolidated statements of operations as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2021		2020
Cost of products sold	$	81	$	73	$	159	$	137
Research and development	1,784		1,318		3,401		2,380
Sales, general and administrative	10,782		7,355		20,675		10,511
Total stock-based compensation expense	$	12,647	$	8,746	$	24,235	$	13,028

XML

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 483,462	$ 99,820		$ 214,424
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	245,688	(279,592)	$ (162,314)	(116,032)	$ (315,141)	$ (172,045)
Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	2,656,838	2,357,311	2,337,634	2,285,100	2,106,214	1,957,224
Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	(2,357,661)	$ (2,568,986)	$ (2,458,973)	$ (2,362,562)	$ (2,377,943)	$ (2,086,692)
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	(361,981)
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	(367,974)
Debt increase (decrease)	368,000
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	$ 5,993

XML

Balance Sheet Details - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 945	$ 137
Provisions	392	806
Write-offs, Net	0	0
Balance at End of Period	$ 1,337	$ 943

XML

Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 35,403	$ 25,733
Work-in-process	8,783	6,941
Finished goods	55,009	42,396
Inventories	$ 99,195	$ 75,070

XML

Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepayments, advances and deposits	$ 34,229	$ 25,140
Non-inventory production supplies	4,462	3,956
Recoverable taxes from Brazilian government entities	1,658	1,188
Other	4,318	3,229
Total prepaid expenses and other current assets	$ 44,667	$ 33,513

XML

Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 247,556	$ 158,529
Less: accumulated depreciation and amortization	(96,419)	(85,694)
Property, plant and equipment, net	151,137	72,835
Manufacturing facilities and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	70,423	51,855
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	49,097	45,780
Computers and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	11,430	9,174
Furniture and office equipment, vehicles and land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,737	3,688
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 112,869	$ 48,032

XML

Balance Sheet Details - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation and amortization expense	$ 2,586	$ 2,186	$ 4,986	$ 4,300

XML

Balance Sheet Details - Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Goodwill [Roll Forward]
Balance at beginning of year	$ 131,259
Acquisitions	13,437	$ 4,013
Effect of currency translation adjustment	(10,532)
Ending balance	$ 134,164

XML

Balance Sheet Details - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Acquisition of intangible assets in connection with business combinations		$ 22,900
Gross	$ 60,606	60,606		$ 40,243
Accumulated Amortization	(2,961)	(2,961)		(978)
Net	57,645	57,645		39,265
Amortization of intangible assets	1,200	2,076	$ 135
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022 (remainder)	2,311	2,311
2023	6,177	6,177
2024	7,254	7,254
2025	7,386	7,386
2026	7,140	7,140
Thereafter	27,377	27,377
Net	57,645	$ 57,645		39,265
Trademarks and trade names, and branded products
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		10 years
Gross	29,758	$ 29,758		11,484
Accumulated Amortization	(1,573)	(1,573)		(496)
Net	28,185	28,185		10,988
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Net	28,185	28,185		10,988
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross	8,703	8,703		8,197
Accumulated Amortization	(667)	(667)		(267)
Net	8,036	8,036		7,930
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Net	8,036	$ 8,036		7,930
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		5 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		16 years
Developed technology and software applications
Finite-Lived Intangible Assets [Line Items]
Gross	21,545	$ 21,545		19,962
Accumulated Amortization	(689)	(689)		(200)
Net	20,856	20,856		19,762
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Net	20,856	$ 20,856		19,762
Developed technology and software applications | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		5 years
Developed technology and software applications | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		12 years
Patents
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		17 years
Gross	600	$ 600		600
Accumulated Amortization	(32)	(32)		(15)
Net	568	568		585
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Net	$ 568	$ 568		$ 585

XML

Balance Sheet Details - Leases (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) option	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) option	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Property, Plant and Equipment [Line Items]
Right-of-use assets under operating leases, net	$ 90,070		$ 90,070		$ 32,428
Operating lease liability	76,925		76,925		27,500
Operating lease expense	4,100	$ 1,700	7,800	$ 3,500
Lease, cost	300	$ 200	600	$ 400
Finance lease, right-of-use asset amortization	$ 1,400		$ 1,400		$ 6,800
Minimum
Property, Plant and Equipment [Line Items]
Operating lease remaining lease term (years)	1 year		1 year
Operating lease, option to renew | option	1		1
Operating lease renewal term (years)	1 year		1 year
Maximum
Property, Plant and Equipment [Line Items]
Operating lease remaining lease term (years)	18 years		18 years
Operating lease renewal term (years)	5 years		5 years

XML

Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash paid for operating lease liabilities, in thousands	$ 6,092	$ 2,369
Acquisition of right-of-use assets under operating leases	$ 51,789	$ 1,110
Weighted-average remaining lease term	11 years 7 months 6 days	2 years 7 months 6 days
Weighted-average discount rate	19.50%	17.00%

XML

Balance Sheet Details - Maturities of Financing and Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Financing Leases
2022 (Remaining Six Months)	$ 11
2023	21
2024	21
2025	21
2026	16
Thereafter	0
Total lease payments	90
Less: amount representing interest	(24)
Total lease liability	66
Current lease liability	12	$ 140
Noncurrent lease liability	54	61
Total lease liability	66
Operating Leases
2022 (Remaining Six Months)	6,964
2023	12,962
2024	22,075
2025	22,374
2026	22,807
Thereafter	229,717
Total lease payments	316,899
Less: amount representing interest	(239,974)
Total lease liability	76,925	27,500
Current lease liability	1,640	7,689
Noncurrent lease liability	75,285	19,829
Total lease liability	76,925	$ 27,500
2022 (Remaining Six Months)	6,975
2023	12,983
2024	22,096
2025	22,395
2026	22,823
Thereafter	229,717
Total lease payments	316,989
Less: amount representing interest	(239,998)
Total lease liability	76,991
Current lease liability	1,652
Noncurrent lease liability	$ 75,339

XML

Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Investment in non-trade receivable		$ 10,251	$ 0
Equity-method investments in affiliates		4,682	9,443
Deposits		517	129
Other		2,801	994
Total other assets		$ 18,251	$ 10,566
2025 Promissory Note | Convertible notes
Debt Instrument [Line Items]
Investment in non-trade receivable	$ 10,000
Debt instrument, interest rate, stated percentage	8.00%
Contingent redemption threshold	$ 50,000

XML

Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Payroll and related expenses	$ 15,160	$ 9,151
Accrued interest	11,111	9,572
Asset retirement obligation	3,791	3,336
Professional services	2,295	2,447
Contract termination fees	1,368	1,345
Tax-related liabilities	1,057	988
License fee payable	1,050	1,050
Other	2,525	4,833
Total accrued and other current liabilities	80,689	71,457
Total Acquisitions
Business Acquisition [Line Items]
Business acquisition, contingent consideration	32,411	30,000
Equity Method Investment Acquisitions
Business Acquisition [Line Items]
Business acquisition, contingent consideration	$ 9,921	$ 8,735

XML

Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	$ 1,649	$ 7,062
Acquisition-related contingent consideration	40,275	64,762
Total liabilities measured and recorded at fair value	93,440	179,251
Foris Convertible Note
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	51,516	107,427
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	0	0
Acquisition-related contingent consideration	0	0
Total liabilities measured and recorded at fair value	0	0
Level 1 | Foris Convertible Note
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	0	0
Acquisition-related contingent consideration	0	0
Total liabilities measured and recorded at fair value	0	0
Level 2 | Foris Convertible Note
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	1,649	7,062
Acquisition-related contingent consideration	40,275	64,762
Total liabilities measured and recorded at fair value	93,440	179,251
Level 3 | Foris Convertible Note
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	$ 51,516	$ 107,427

XML

Fair Value Measurement - Freestanding Derivative Instruments (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Gain (loss) from change in fair value of derivative instruments	$ 3,598	$ 5,141	$ 5,413	$ (17,604)
Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)	1.9		1.9
Exercise price per share (in dollars per share)	$ 2.87		$ 2.87
Class of warrant or right, term			2 years
Warrants and rights outstanding, derivative liability	$ 1,600		$ 1,600
Gain (loss) from change in fair value of derivative instruments	$ 3,600		$ 5,400

XML

Fair Value Measurement - Fair Value of Debt — Foris Convertible Note (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Principal	$ 740,996		$ 740,996		$ 740,937
Long term debt, fair value	725,436		725,436		417,384
Gain (loss) from change in fair value of debt	35,114	$ 70,132	55,910	$ (256,653)
Foris Convertible Note | Related party convertible notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Principal	50,041		50,041		50,041
Long term debt, fair value	$ 51,516		$ 51,516		$ 107,427
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares	$ 3.00		$ 3.00
Gain (loss) from change in fair value of debt	$ 35,100		$ 55,900
Foris Convertible Note | Related party convertible notes | Stock Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares	1.85		1.85
Foris Convertible Note | Related party convertible notes | Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.27		0.27
Foris Convertible Note | Related party convertible notes | Risk-free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.028		0.028
Foris Convertible Note | Related party convertible notes | Stock Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.45		0.45
Foris Convertible Note | Related party convertible notes | Probability of Change in Control
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.05		0.05

XML

Fair Value Measurement - Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	$ 64,762
Fair value, ending balance	40,275
Debt-related Derivative Liability | Level 3
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	7,062
Change in fair value of derivative instruments	(5,413)
Fair value, ending balance	$ 1,649

XML

Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)	Jun. 30, 2022 $ / shares year	Dec. 31, 2021 $ / shares year
Exercise price of warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	2.87	2.87
Expected term in years
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input | year	2	2
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.000	0.000
Minimum | Fair value of common stock on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	1.85	5.41
Minimum | Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	1.06	1.07
Minimum | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.0228	0.0016
Maximum | Fair value of common stock on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	4.36	19.10
Maximum | Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	1.10	1.14
Maximum | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.0292	0.0073

XML

Fair Value Measurement - Acquisition Related Contingent Consideration Narrative (Details) - MenoLabs LLC	Jun. 30, 2022 $ / shares
Revenue Risk Adjustment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent liability, measurement input	0.062
Annual Revenue Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent liability, measurement input	0.35

XML

Fair Value Measurement - Acquisition Related Contingent Consideration Roll forward (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	$ 64,762
Issuance of contingent consideration in connection with acquisitions	440
Measurement period adjustment	(55)
Reclassification to short-term contingent liabilities	(24,872)
Fair value, ending balance	$ 40,275

XML

Fair Value Measurement - Financial Assets and Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Combined debt amount	$ 673.9	$ 310.0
Debt instrument fair value disclosure	$ 202.1	$ 328.0

XML

Debt - Debt Components (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal	$ 740,996	$ 740,937
Unaccreted Debt Discount	(17,035)	(380,939)
Change in Fair Value	1,475	57,386
Net	725,436	417,384
Less: current portion	(955)	(108,323)
Long-term debt, net of current portion	724,481	309,061
Convertible notes | 2026 convertible senior notes
Debt Instrument [Line Items]
Principal	690,000	690,000
Unaccreted Debt Discount	(17,035)	(380,939)
Change in Fair Value	0	0
Net	672,965	309,061
Related party convertible notes | Foris convertible note
Debt Instrument [Line Items]
Principal	50,041	50,041
Unaccreted Debt Discount	0	0
Change in Fair Value	1,475	57,386
Net	51,516	107,427
Loans payable and credit facilities | Other loans payable (revolving)
Debt Instrument [Line Items]
Principal	955	896
Unaccreted Debt Discount	0	0
Change in Fair Value	0	0
Net	$ 955	$ 896

XML

Debt - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Disclosure [Abstract]
Contractual interest expense in connection with debt	$ 3,441	$ 2,322	$ 6,831	$ 5,850
Debt discount accretion	961	933	1,923	1,646
Interest expense in connection with debt	4,402	3,255	8,754	7,496
Discount accretion on liability in connection with acquisition of equity-method investment and with partnership liability, and other	902	1,468	1,813	3,040
Total interest expense	$ 5,304	$ 4,723	$ 10,567	$ 10,536

XML

Debt - Adoption of ASU (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	$ 245,688	$ (279,592)	$ (162,314)	$ (116,032)	$ (315,141)	$ (172,045)
Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	2,656,838	2,357,311	2,337,634	2,285,100	2,106,214	1,957,224
Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	(2,357,661)	$ (2,568,986)	$ (2,458,973)	$ (2,362,562)	$ (2,377,943)	$ (2,086,692)
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	(361,981)
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	(367,974)
Debt increase (decrease)	368,000
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity	$ 5,993

XML

Debt - Future Minimum Payments (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Instrument [Line Items]
2022 (Remaining Six Months)	$ 5,279
2023	73,982
2024	10,350
2025	10,350
2026	700,379
Thereafter	0
Total future minimum payments	800,340
Less: amount representing interest	(59,344)
Present value of minimum debt payments	740,996
Less: current portion of debt principal	(955)
Noncurrent portion of debt principal	740,041
Convertible notes
Debt Instrument [Line Items]
2022 (Remaining Six Months)	5,175
2023	10,350
2024	10,350
2025	10,350
2026	700,379
Thereafter	0
Total future minimum payments	736,604
Less: amount representing interest	(46,604)
Present value of minimum debt payments	690,000
Less: current portion of debt principal	0
Noncurrent portion of debt principal	690,000
Related Party Convertible Notes
Debt Instrument [Line Items]
2022 (Remaining Six Months)	0
2023	62,622
2024	0
2025	0
2026	0
Thereafter	0
Total future minimum payments	62,622
Less: amount representing interest	(12,581)
Present value of minimum debt payments	50,041
Less: current portion of debt principal	0
Noncurrent portion of debt principal	50,041
Loans payable and credit facilities
Debt Instrument [Line Items]
2022 (Remaining Six Months)	104
2023	1,010
2024	0
2025	0
2026	0
Thereafter	0
Total future minimum payments	1,114
Less: amount representing interest	(159)
Present value of minimum debt payments	955
Less: current portion of debt principal	(955)
Noncurrent portion of debt principal	$ 0

XML

Mezzanine Equity - Gates Foundation (Details) - Gates Foundation Purchase Agreement $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares
Subsidiary, Sale of Stock [Line Items]
Stock price (in dollars per share) | $ / shares	$ 17.10
Compound annual return (percentage)	10.00%
Research and development obligation, remaining amount | $	$ 0.1

XML

Mezzanine Equity - Ingredion Contingently Redeemable Noncontrolling Interest In Subsidiary (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Jun. 01, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of contingently redeemable noncontrolling interest in subsidiary			$ 0	$ 10,000
Issuance of contingently redeemable noncontrolling interest		$ 28,520
RealSweet LLC
Subsidiary, Sale of Stock [Line Items]
Ownership percentage by noncontrolling owners	31.00%
Ownership percentage	100.00%
Increase from sale of parent equity interest	$ 28,500
Proceeds from issuance of contingently redeemable noncontrolling interest in subsidiary	$ 10,000
Noncontrolling interest, ownership percentage threshold	8.40%
Issuance of contingently redeemable noncontrolling interest	$ 28,500
Purchase commitment			22,000
Amount funded			$ 100,000
RealSweet LLC | Forecast
Subsidiary, Sale of Stock [Line Items]
Purchase commitment					$ 130,000
RealSweet LLC | Amyris, Inc.
Subsidiary, Sale of Stock [Line Items]
Payments to noncontrolling interests	4,000
Intangible assets transferred	$ 14,500

XML

Mezzanine Equity - EcoFabulous Contingently Redeemable Noncontrolling Interest in Subsidiary (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 26, 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of contingently redeemable noncontrolling interest		$ 28,520,000
Loss (income) attributable to noncontrolling interest	$ (3,507,000)	$ 66,000	$ (6,435,000)	$ 1,266,000
EcoFab LLC
Subsidiary, Sale of Stock [Line Items]
Percentage of voting interests acquired					70.00%
Business acquisition, contingent revenue threshold					$ 100,000,000
Issuance of contingently redeemable noncontrolling interest			2,500,000
Noncontrolling interest recorded in connection with business combinations	$ 3,100,000		$ 3,100,000		$ 3,072,000
EcoFab LLC | No Planet B Investments, LLC
Subsidiary, Sale of Stock [Line Items]
Percentage of voting interests acquired	30.00%		30.00%		30.00%
Business acquisition, contingent percentage of voting interests to be acquired					30.00%
Loss (income) attributable to noncontrolling interest			$ 600,000

XML

Stockholders' (Deficit) Equity - Warrants and Rights Activity Summary (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Class of Warrant or Right [Roll Forward]
Number outstanding, beginning balance (in shares)	3,999,855
Exercises (in shares)	(2,296,335)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Number outstanding, ending balance (in shares)	1,703,520
Blackwell / Silverback warrants
Class of Warrant or Right [Roll Forward]
Number outstanding, beginning balance (in shares)	1,000,000
Exercises (in shares)	0
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 0
Number outstanding, ending balance (in shares)	1,000,000
Exercise price per share (in dollars per share) | $ / shares	$ 3.25
January 2020 warrant exercise right shares
Class of Warrant or Right [Roll Forward]
Number outstanding, beginning balance (in shares)	431,378
Exercises (in shares)	(431,378)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Number outstanding, ending balance (in shares)	0
Exercise price per share (in dollars per share) | $ / shares	$ 0
May 2019 6.50% Note Exchange warrants
Class of Warrant or Right [Roll Forward]
Number outstanding, beginning balance (in shares)	960,225
Exercises (in shares)	(960,225)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Number outstanding, ending balance (in shares)	0
Exercise price per share (in dollars per share) | $ / shares	$ 0
Interest rate	6.50%
May 2017 cash warrants
Class of Warrant or Right [Roll Forward]
Number outstanding, beginning balance (in shares)	1,492,652
Exercises (in shares)	(904,732)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Number outstanding, ending balance (in shares)	587,920
Exercise price per share (in dollars per share) | $ / shares	$ 2.87
May 2017 dilution warrants
Class of Warrant or Right [Roll Forward]
Number outstanding, beginning balance (in shares)	56,910
Exercises (in shares)	0
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 0
Number outstanding, ending balance (in shares)	56,910
Exercise price per share (in dollars per share) | $ / shares	$ 0
July 2015 related party debt exchange
Class of Warrant or Right [Roll Forward]
Number outstanding, beginning balance (in shares)	58,690
Exercises (in shares)	0
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 0
Number outstanding, ending balance (in shares)	58,690
Exercise price per share (in dollars per share) | $ / shares	$ 0.15

XML

Stockholders' (Deficit) Equity - Warrant Activity (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Equity [Abstract]
Exercises (in shares) | shares	2,296,335
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Proceeds from warrant exercise, including portion attributable to related party | $	$ 6.6

XML

Acquisitions - EcoFab LLC, Narrative (Details) - EcoFab LLC - USD ($) $ in Thousands	Jan. 26, 2022	Jun. 30, 2022
Business Acquisition, Contingent Consideration [Line Items]
Percentage of voting interests acquired	70.00%
Payments to acquire business	$ 1,700
Business acquisition, equity interest issued or issuable, shares (in shares)	1,292,776
Business acquisition, equity interest issued or issuable	$ 5,500
Noncontrolling interest recorded in connection with business combinations	$ 3,072	$ 3,100
No Planet B Investments, LLC
Business Acquisition, Contingent Consideration [Line Items]
Percentage of voting interests acquired	30.00%	30.00%

XML

Acquisitions - EcoLab LLC, Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 26, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Goodwill	$ 134,164		$ 131,259
EcoFab LLC
Business Acquisition, Contingent Consideration [Line Items]
Goodwill		$ 1,023
Less: noncontrolling interest	$ (3,100)	(3,072)
Total consideration		7,168
EcoFab LLC | Trademarks, trade names and other intellectual property
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		8,705
EcoFab LLC | Customer relationships
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		$ 512

XML

Acquisitions - MenoLabs LLC, Narrative (Details) - USD ($) $ in Thousands	Mar. 09, 2022	Jun. 30, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Principal		$ 740,996	$ 740,937
MenoLabs LLC
Business Acquisition, Contingent Consideration [Line Items]
Consideration transferred	$ 16,200
Payments to acquire business	11,300
Business combination, debt incurred	$ 500
Business acquisition, equity interest issued or issuable, shares (in shares)	852,234
Business acquisition, equity interest issued or issuable	$ 3,900
Business combination, consideration transferred, other	$ 400
Contingent consideration, earnout payment term	12 months
Acquisition-related contingent consideration	$ 400
MenoLabs LLC | Earnout Payment One
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration, earnout payments	10,000
MenoLabs LLC | Earnout Payment Two
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration, earnout payments	10,000
Bridge Loan | MenoLabs LLC
Business Acquisition, Contingent Consideration [Line Items]
Principal	$ 500

XML

Acquisitions - MenoLabs LLC, Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 09, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Goodwill	$ 134,164		$ 131,259
MenoLabs LLC
Business Acquisition, Contingent Consideration [Line Items]
Net tangible assets		$ 311
Goodwill		6,642
Total consideration		16,153
MenoLabs LLC | Branded products
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		5,600
MenoLabs LLC | Application (App)
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		$ 3,600

XML

Acquisitions - Onda Beauty, Narrative (Details) - Onda Beauty Inc $ in Millions	Apr. 11, 2022 USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Consideration transferred	$ 4.9
Payments to acquire business	1.0
Business acquisition, equity interest issued or issuable	3.5
Estimated net working capital adjustments	(0.1)
Contingent consideration, earnout payments	$ 0.5
Contingent consideration, earnout payment term	12 months

XML

Acquisitions - Onda Beauty, Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Apr. 11, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Goodwill	$ 134,164		$ 131,259
Onda Beauty Inc
Business Acquisition, Contingent Consideration [Line Items]
Net tangible liabilities		$ (164)
Goodwill		553
Total consideration		4,915
Onda Beauty Inc | Trademarks, trade names and other intellectual property
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		4,275
Onda Beauty Inc | Customer relationships
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		$ 251

XML

Acquisitions - Interfaces, Narrative (Details) - Interfaces $ in Millions	Apr. 29, 2022 USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Consideration transferred	$ 6.7
Payments to acquire business	3.4
Business combination, debt incurred	$ 3.3
Number of monthly and successive installments	24 months

XML

Acquisitions - Interfaces, Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Apr. 29, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Goodwill	$ 134,164		$ 131,259
Interfaces
Business Acquisition, Contingent Consideration [Line Items]
Net tangible assets		$ 1,474
Goodwill		5,219
Total consideration		$ 6,693

XML

Net Loss per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net (loss) income attributable to Amyris, Inc.	$ (110,013)	$ 15,381	$ (217,318)	$ (275,870)
Less: loss (income) allocated to participating securities	0	(13)	0	1,086
Net (loss) income attributable to Amyris, Inc. common stockholders, basic	(110,013)	15,368	(217,318)	(274,784)
Adjustment to earnings allocated to participating securities	0	13	0	0
Interest on convertible debt	759	902	1,216	0
Gain from change in fair value of debt	(35,114)	(71,067)	(47,764)	0
Gain from change in fair value of derivative instruments	(3,598)	0	(5,413)	0
Net loss attributable to Amyris, Inc. common stockholders, diluted	$ (147,966)	$ (54,784)	$ (269,279)	$ (274,784)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)	319,916,244	320,088,143	316,425,739	279,819,520
Net loss per share, basic (in dollars per share)	$ (0.34)	$ 0.05	$ (0.69)	$ (0.98)
Weighted-average shares of preferred stock outstanding (in shares)	0	277,666	0	0
Effect of dilutive convertible debt (in shares)	16,680,334	18,442,040	18,532,262	0
Effect of dilutive common stock warrants (in shares)	46,301	0	840,274	0
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)	336,642,879	338,807,849	335,798,275	279,819,520
Net loss per share, diluted (in dollars per share)	$ (0.44)	$ (0.16)	$ (0.80)	$ (0.98)

XML

Net Loss per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	113,896,921	24,588,418	113,896,921	41,268,752
Period-end common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	1,587,920	10,034,295	1,587,920	10,034,295
Convertible promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	86,683,389	0	86,683,389	16,680,334
Period-end stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	4,718,507	6,357,163	4,718,507	6,357,163
Period-end restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	17,313,912	8,196,960	17,313,912	8,196,960
Contingently issuable common shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	3,593,193	0	3,593,193	0

XML

Commitments and Contingencies (Details)	1 Months Ended	3 Months Ended
	Oct. 31, 2021 USD ($)	Oct. 01, 2019 complaint	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Product Liability Contingency [Line Items]
Liabilities recorded for agreements			$ 0	$ 0
Loss contingency, new claims filed, number | complaint		2
Renfield Manufacturing, LLC
Product Liability Contingency [Line Items]
Liabilities recorded for agreements			$ 0	$ 0
Guarantor arrangements, agreement term	10 years
Letter of Credit
Product Liability Contingency [Line Items]
Long-term, line of credit	$ 500,000

XML

Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 65,207	$ 52,316	$ 122,916	$ 229,175
Consumer
Disaggregation of Revenue [Line Items]
Revenue	42,973	20,695	77,524	36,347
Technology access
Disaggregation of Revenue [Line Items]
Revenue	22,234	31,621	45,392	192,828
North America
Disaggregation of Revenue [Line Items]
Revenue	41,207	41,123	76,072	61,425
Europe
Disaggregation of Revenue [Line Items]
Revenue	15,719	5,403	35,151	154,522
Asia
Disaggregation of Revenue [Line Items]
Revenue	5,363	5,170	7,043	11,858
South America
Disaggregation of Revenue [Line Items]
Revenue	2,094	332	3,113	789
Other
Disaggregation of Revenue [Line Items]
Revenue	824	288	1,537	581
Renewable Products
Disaggregation of Revenue [Line Items]
Revenue	54,390	37,172	97,855	65,351
Renewable Products | Consumer
Disaggregation of Revenue [Line Items]
Revenue	42,219	20,695	74,861	36,347
Renewable Products | Technology access
Disaggregation of Revenue [Line Items]
Revenue	12,171	16,477	22,994	29,004
Renewable Products | North America
Disaggregation of Revenue [Line Items]
Revenue	39,963	30,123	72,919	50,175
Renewable Products | Europe
Disaggregation of Revenue [Line Items]
Revenue	6,338	2,500	13,627	5,472
Renewable Products | Asia
Disaggregation of Revenue [Line Items]
Revenue	5,171	3,929	6,659	8,334
Renewable Products | South America
Disaggregation of Revenue [Line Items]
Revenue	2,094	332	3,113	789
Renewable Products | Other
Disaggregation of Revenue [Line Items]
Revenue	824	288	1,537	581
Licenses and Royalties
Disaggregation of Revenue [Line Items]
Revenue	6,454	11,000	15,767	154,800
Licenses and Royalties | Consumer
Disaggregation of Revenue [Line Items]
Revenue	5	0	438	0
Licenses and Royalties | Technology access
Disaggregation of Revenue [Line Items]
Revenue	6,449	11,000	15,329	154,800
Licenses and Royalties | North America
Disaggregation of Revenue [Line Items]
Revenue	0	11,000	433	11,000
Licenses and Royalties | Europe
Disaggregation of Revenue [Line Items]
Revenue	6,454	0	15,334	143,800
Licenses and Royalties | Asia
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Licenses and Royalties | South America
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Licenses and Royalties | Other
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	4,363	4,144	9,294	9,024
Collaborations, Grants and Other | Consumer
Disaggregation of Revenue [Line Items]
Revenue	749	0	2,225	0
Collaborations, Grants and Other | Technology access
Disaggregation of Revenue [Line Items]
Revenue	3,614	4,144	7,069	9,024
Collaborations, Grants and Other | North America
Disaggregation of Revenue [Line Items]
Revenue	1,244	0	2,720	250
Collaborations, Grants and Other | Europe
Disaggregation of Revenue [Line Items]
Revenue	2,927	2,903	6,190	5,250
Collaborations, Grants and Other | Asia
Disaggregation of Revenue [Line Items]
Revenue	192	1,241	384	3,524
Collaborations, Grants and Other | South America
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Collaborations, Grants and Other | Other
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ 0	$ 0	$ 0

XML

Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 65,207	$ 52,316	$ 122,916	$ 229,175
Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	22,708	26,951	47,120	178,665
Renewable Products
Disaggregation of Revenue [Line Items]
Revenue	54,390	37,172	97,855	65,351
Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	14,254	14,951	27,850	21,053
Licenses and Royalties
Disaggregation of Revenue [Line Items]
Revenue	6,454	11,000	15,767	154,800
Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	6,454	10,000	15,270	153,612
Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	4,363	4,144	9,294	9,024
Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	2,000	2,000	4,000	4,000
Sephora | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	10,092	8,078	17,725	12,519
Sephora | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	10,092	8,078	17,725	12,519
Sephora | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Sephora | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
DSM - related party | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	11,419	6,620	26,647	153,893
DSM - related party | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	2,965	4,620	7,377	6,281
DSM - related party | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	6,454	0	15,270	143,612
DSM - related party | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	2,000	2,000	4,000	4,000
Ingredion / PureCircle | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	1,197	12,253	2,748	12,253
Ingredion / PureCircle | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	1,197	2,253	2,748	2,253
Ingredion / PureCircle | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	10,000	0	10,000
Ingredion / PureCircle | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Revenue from all other customers | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	42,499	25,365	75,796	50,510
Revenue from all other customers | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	40,136	22,221	70,005	44,298
Revenue from all other customers | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	1,000	497	1,188
Revenue from all other customers | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	$ 2,363	$ 2,144	$ 5,294	$ 5,024

XML

Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 65,207	$ 52,316	$ 122,916	$ 229,175
Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	4,363	4,144	9,294	9,024
Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	22,708	26,951	47,120	178,665
Significant Revenue Agreement | Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	2,000	2,000	4,000	4,000
DSM - related party | DSM Ingredients Collaboration | Research and Development
Disaggregation of Revenue [Line Items]
Quarterly payments			2,000
DSM - related party | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	11,419	6,620	26,647	153,893
DSM - related party | Significant Revenue Agreement | Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	$ 2,000	$ 2,000	$ 4,000	$ 4,000

XML

Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Assignment (Details) - DSM - related party - DSM License Agreement $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($)
Disaggregation of Revenue [Line Items]
Estimated total unconstrained transaction price	$ 150.0
Maximum
Disaggregation of Revenue [Line Items]
Contingent consideration	235.0
License
Disaggregation of Revenue [Line Items]
Revenue	143.6
Intellectual Property License | License
Disaggregation of Revenue [Line Items]
Estimated total unconstrained transaction price	$ 143.6

XML

Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Accounts receivable, net	$ 41,125	$ 37,074
Accounts receivable - related party, net	5,001	5,667
Contract assets	3,946	4,227
Contract assets - related party	15,265	0
Contract liabilities	816	2,530
Contract liabilities, noncurrent	$ 0	$ 111

XML

Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1,098
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue, remaining performance obligation, amount	$ 526
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, remaining performance obligation, amount	$ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, remaining performance obligation, amount	$ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, remaining performance obligation, amount	$ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, remaining performance obligation, amount	$ 143

XML

Related Party Transactions - Related Party Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Principal	$ 740,996	$ 740,937
Change in Fair Value	1,475	57,386
Net	725,436	417,384
Foris Ventures LLC | Related Party Debt | Foris convertible note
Related Party Transaction [Line Items]
Principal	50,041	50,041
Unaccreted Debt Discount	0	0
Change in Fair Value	1,475	57,386
Net	$ 51,516	$ 107,427

XML

Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Accounts receivable - related party	$ 5,001	$ 5,667
Contract assets - related party	15,265	0
Accounts payable - related party	0	107,427
Accounts payable - related party
Related Party Transaction [Line Items]
Accounts payable - related party	$ 4,241	$ 5,011

XML

Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Quantity of Stock Options
Outstanding, beginning balance (in shares) | shares	3,087,225
Granted (in shares) | shares	1,916,237
Exercised (in shares) | shares	(36,021)
Forfeited or expired (in shares) | shares	(248,934)
Outstanding, ending balance (in shares) | shares	4,718,507	3,087,225
Vested or expected to vest (in shares) | shares	4,451,407
Exercisable (in shares) | shares	1,785,373
Weighted- average Exercise Price
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 9.91
Granted (in dollars per share) | $ / shares	3.03
Exercised (in dollars per share) | $ / shares	2.84
Forfeited or expired (in dollars per share) | $ / shares	11.55
Outstanding, ending balance (in dollars per share) | $ / shares	7.09	$ 9.91
Vested or expected to vest (in dollars per share) | $ / shares	7.24
Exercisable (in dollars per share) | $ / shares	$ 10.66
Weighted-average Remaining Contractual Life, in Years
Outstanding (years)	8 years	7 years 1 month 6 days
Vested or expected to vest (years)	7 years 10 months 24 days
Exercisable (years)	5 years 9 months 18 days
Aggregate Intrinsic Value, in Thousands
Outstanding | $	$ 1	$ 2,580
Vested or expected to vest | $	1
Exercisable | $	$ 0

XML

Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Quantity of Restricted Stock Units
Outstanding , beginning balance (in shares)	13,731,320
Awarded (in shares)	5,965,118
Released (in shares)	(1,726,412)
Forfeited (in shares)	(656,114)
Outstanding, ending balance (in shares)	17,313,912	13,731,320
Vested or expected to vest (in shares)	15,155,053
Weighted-average Grant-date Fair Value
Outstanding, beginning balance (in dollars per share)	$ 9.99
Awarded (in dollars per share)	3.60
Released (in dollars per share)	7.26
Forfeited (in dollars per share)	6.28
Outstanding, ending balance (in dollars per share)	8.20	$ 9.99
Vested or expected to vest (in dollars per share)	$ 8.06
Weighted-average Remaining Contractual Life, in Years
Outstanding (years)	2 years 4 months 24 days	2 years 9 months 18 days
Vested or expected to vest (years)	2 years 3 months 18 days

XML

Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 12,647	$ 8,746	$ 24,235	$ 13,028
Cost of products sold
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	81	73	159	137
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	1,784	1,318	3,401	2,380
Sales, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 10,782	$ 7,355	$ 20,675	$ 10,511

XML

Stock-based Compensation - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Share-Based Payment Arrangement [Abstract]
Compensation expense related to stock options and RSUs	$ 122.0
Weighted-average period	3 years 2 months 12 days